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Chapter 1 
BACKGROUND AND RATIONALE 
Every government is eager to control the increase of expenses by the implementation of central cost 
containment policies particularly in relation to pharmaceuticals. For the most part. those measures 
have relied on budgeting or price controls. including negotiated prospective budgets for hospitals. 
centralized negotiated budgets for ambulatory physicians including drug prescriptions, and limitations 
on payments for particular medications. Because those traditional central cost containment measures 
were only partially successfuL due to lack of incentives. the health authorities in Europe started to 
establish incentives for efficient healthcare delivery. Both traditional and recent containment measures 
focus especially on the pharmaceutical drugs sector in many countries. as these constitute a health 
technology that is relatively easy to introduce and implement compared to other forms of care. 
Financing prescription medicines in ambulatory care has been a central responsibility based on the 
traditional clinical trial outcomes (efficacy/safety parameters) used for registration. Although there is 
large variety betvveen the various countries. there are three related trends: decentralization of the 
healthcare decision-making process. prescription restrictions, and extra data requirements. One can 
distinguish various extra data requirements which all relate to the use of the drug in real daily practice. 
while the traditional clinical trial outcomes are only derived from randomised clinical trials. At a 
central level the demand for cost-effectiveness and budgetary impact data is increasing. The 
requirement for health economic data resulted to formal reporting requirements in some countries 
already (e.g. Canada, Australia. The Netherlands. UK. Portugal and Finland). Although the most 
evident impact of health economic studies is expected to be on central reimbursement audiences. 
evidence for the use of health economic studies by other audiences is expected to increase (e.g. 
patients, hospitals. insurers. formulary committees). This background information is described in more 
detail in Chapter 2. which is the introduction to this thesis. 
Pricing and reimbursement have been based. until recently, on the traditional clinical trial outcomes 
used for registration (efficacy. safety and quality parameters). which are called the first three hurdles. 
Consequently the growing burden on manufacturers to demonstrate the cost-effectiveness of their 
products is called the fourth hurdle in drug development. This fourth hurdle may have considerable 
consequences for all players involved. Health economic data (effectiveness and resource utilization) 
may be collected alongside a randomised clinical trial. (RCT).1 13 4 However. performing a RCT is not 
always ethical or feasible. For example, in a comparison of surgical techniques with drugs. 
randomisation can be performed. but blinding is impossible. Another example is that randomisation is 
not considered ethical in potential life saving interventions. Also the execution of a time consuming 
and costly RCT for every minor change in technology may not be justified or feasible. Considering the 
prospective approach. the concept of validity should be addressed: internal validity is the extent to 
which the analytic inference derived from the study sample is correct for the target population. 
External validity or generalisability is the extent to which a cost/effectiveness analysis found in the 
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study sample is also true in the external population. Clinical trials have a low external validity because 
they have strict inclusion and exclusion criteria and treatments are protocol driven. leading to 
overestimation of units ofhealthcare utilization. Therefore. both clinical and economic outcomes may 
not be typical and do not correspond to usual practice. Hence it should always be considered that, due 
to its restriction on external validity, the outcomes may not be representative of a target patient 
population who are going to usc the drug. Although randomisation is usually applied to balance 
confounding variables. inclusion criteria of patients and selection of investigators are fairly rigid, 
double blind and placebo control is often the rule. In addition treatment patterns are usually driven by 
the protocol.:! 5 Finally pharmacoeconomic analyses are usually interested in examining the discounted 
costs and benefits beyond the duration of patient follow-up, for example. when estimating the cost per 
life years saved in chronic diseases. 
An alternative design is the naturalistic economic trial. which is a randomised trial with the primary 
objective of gathering ··real world" or representative cost and effectiveness data. The naturalistic trial 
is an economic trial with the primary objective of gathering "real world" or representative cost and 
effectiveness data. The design is comparable with a traditional clinical randomised clinical. 
Naturalistic prospective studies usually share a number of features with clinical trials. such as parallel 
design and randomisation. However, they differ on other characteristics: population selection is based 
on representativeness. and clinical criteria are used instead of academic definitions for inclusions of 
patients. The protocol of a naturalistic study contains only a limited number of scheduled visits and 
procedures in order to minimise the impact on the treatment pattern corresponding with daily practice 
by protocol driven costs or protocol initiated changes in treatment patterns. Naturalistic studies have 
the additional advantage of providing valuable clinical data obtained in a more representative context 
(external validity). However since study drugs are usually not approved for registration at the time of 
performing of economic studies, the use of prospective naturalistic trials is limited. making submission 
of data on effectiveness and expected costs at the time of reimbursement not feasible. Finally the 
performing of a naturalistic economic trial may not always be ethical, for example randomisation may 
not be considered ethical. when clinical trial data show a substantial clinical advantage compared to 
standard therapy. 
Hence in practice it is not always possible to derive information from scientifically sound prospective 
studies. In these cases decision-analytic models may be used to provide the necessary cost-
effectiveness information using various existing data sources for clinical and economic information. 
Modelling studies are based on decision analysis. which is a well-recognized method for analysing the 
consequences of decisions that are made under uncertainty.6 It is an explicit. quantitative. prescriptive 
approach to healthcare decision-making and allows both clinical and economic consequences of 
medical actions and attitudes to be analysed under conditions of uncertainty. From treatment 
algorithms a model can be constructed which considers the timings of actions and their consequences 
over time. A decision-analytic model consists of a series of branches. each representing different 
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options (decisions or events), which arise at different points, referred to as nodes (e.g. decision node 
and chance nodes). In effect, a model shows the consequences and complications of different 
therapeutic interventions. and it should correspond as much as possible, to the real life situation of the 
disease. Models may take the form of simple decision-analytic trees or they may be very complex 
Markov models. \Vhile decision-tree models arc appropriate for acute episodes. Markov models are 
the first choice for pharmacoeconomic analysis of chronic diseases. 
Projections about a drug's effectiveness and expected costs can be modelled using realistic and 
explicit assumptions based on data from clinical studies. In addition modelling often helps overcome 
the practical limitations of prospective studies, particularly for chronic conditions like Parkinson's 
disease that may require longer-term extrapolations of drug effects and cost implications. Data sources 
for the variables being used in a model may be meta-analysis. databases. clinical trials and I or Delphi 
panels. 
In this thesis the focus is on the use of health economic models for reimbursement decisions, but 
models also may be a valuable tool to support the decision-making process in many areas and phases 
of development of a new drug from clinical program development to the design of a disease 
management program.7 ~ An example is the usc of a model for the assessment of the macro-economic 
consequences of reimbursement of a new drug on a nation-wide scale. which is included in this thesis 
(Chapter 11) and shows that one model can be developed for various purposes. 
In order to increase the scientific quality and integrity of pharmacoeconomic studies. national 
guidelines have been developed by various countries. The intent of the guidelines is to provide 
guidance to doers and users of studies. by laying out a general ·•state of the art" regarding methods. 
and by providing specific methodological advice on many matters. Although various groups have 
published recommendations on the good practice of economic evaluations 9 10 11 • those guidelines 
mainly focus on prospective studies and contain only a limited number of recommendations for the 
execution of modelling studies. This may partly explain why the acceptance of modelling studies has 
generally been lower than prospective studies. which is especially due to the level of uncertainty 
associated with modelling studies.12 In this thesis the role of modelling in economic evaluation is 
explored by discussing the concerns of models. which mainly relate to the trade-off bet\Veen internal 
and external validity: concerns about the inappropriate use of clinical data, concerns in observational 
data. concerns about the difficulties in extrapolation, concerns about the transparency or validity of the 
model. 
Over the next several years. most submissions for reimbursement in countries like the Netherlands will 
likely be based on modelling since pharmacoeconomic data were generally not required or included in 
the clinical research programs of products now approaching launch. If reimbursement of 
pharmaceuticals will be based predominantly on economic data derived from modelling studies. it is 
vital to scrutinise and refine the modelling approach carefully. especially the handling of uncertainty. 
Therefore the objective of this thesis is to identifY and explore various types of uncertainty in 
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modelling studies. Also methodologies were presented. which may reduce the level of uncertainty 
associated with modelling. and which may consequently increase the reliability of health economic 
outcomes of modelling studies. This may improve the acceptance of modelling studies. even in the 
absence of formal guidelines. The concepts are empirically illustrated using Markov models in chronic 
diseases: depression. Parkinson's disease and MS. Published real data were used. whenever possible. 
but extrapolation methods were used in absence of real data in order to illustrate the relevant issues. 
The thesis presents various methodologies. which are illustrated using a Markov modelling study in 
depression (Chapter 3). The primary objective of this study was to assess the appropriateness of the 
existing Dutch clinical treatment guidelines for GP's in depression from a health economic 
perspective. The assessment was based on a Markov model based on decision-analytic techniques. The 
primary perspective of the study was that of the third party payer. while the secondary perspective was 
that of the society in 1999. A scenario analysis was performed to test if an extension of the 
continuation treatment to maintenance treatment might result in a less or more favourable cost-
effectiveness outcome of the treatment guideline. 
UNCERTAINTY ASSOCIATED WITH THE DATA SOURCES YIELDING 
THE INPUT DATA FOR THE MODEL 
The reliability of the estimates depends on the choice of the data sources (selection criteria, external 
validity). The data may come from a variety of sources and are subject to varying degrees of 
uncertainty. The following issues relating to the selection of data sources are addressed in Chapter 4. 
• Classification of data being used in modelling studies 
• An assessment of the various data sources. including advantages and disadvantages 
• A general strategy on how to determine the appropriateness of a data source for a model 
• Recommendations on a strategy for data source selection and a transparent reporting format on 
data source selection. 
A main concern on the use of a modelling study is the use of a Delphi panel to gather data not 
available from actual existing data sources. There is no guarantee that the panel assessment of resource 
utilisation and utilities is an accurate reflection of reality. The use of a Delphi panel may particularly 
be controversial to estimate QAL Y s. which may become the primary final outcome for 
pharmacoeconomic studies. The existing Canadian. Australian and Dutch guidelines and the draft UK 
guidelines strongly recommend an estimate of the incremental cost per QAL Y gained. 13 14 15 16 
Chapter 5 presents a cross-sectional study as an alternative data source for a modelling study. It can 
be used to determine resource utilization and utilities for Markov health states. The overall design may 
be considered a hybrid between a naturalistic prospective study and a modelling study by ma.ximising 
the pros and minimising the cons of both types of design. This hybrid design was based on bridging 
the probabilities derived from literature and clinical trials with information on costs and utilities from 
a cross-sectional study. This design was illustrated using a Markov model for Parkinson· s disease. 
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Chapter 6 presents a health economic modelling study for multiple sclerosis (MS). which is an 
application of the two previous chapters on the handling of data from various secondary data sources. 
which allowed us to develop a life time Markov model for MS in order to estimate the cost-
effectiveness of interferons. The classification of disease severity in this study corresponds with semi-
Markov health states in our modeL The probabilities of clinical events were based on interferon beta 
clinical trial data in respectively relapse remitting and secondary progressive MS and observational 
data from the literature. The utilities and costs were derived from two separate cross-sectional studies. 
This study showed that a health economic model can be completely based on published data from 
various sources. 
UNCERTAINTY ABOUT CONFOUNDING VARIABLES 
The costs and utilities may be not only a function of the defined health states in a Markov model. but 
also of other variables. which may act as confounding variables when they arc not taken into account. 
In Chapter 7 a strategy is presented for the incorporation of a confounding variable in a Markov 
health states by means of health state specific relationships between the confounding variable and 
costs as well as time-dependent values of the confounding variable. The objective is to show whether 
the outcomes of a health economic model are severely biased, when a confounding variable is not 
taken into account. The concepts were illustrated using a hypothetical Markov model for Parkinson's 
disease. 
UNCERTAINTY REDUCTION THROUGH SENSITIVITY ANALYSIS 
Sensitivity analysis is currently the most widely used method to deal v.rith uncertainty in economic 
evaluations. A sensitivity analysis is based on modification of the basic clinical and economic 
estimates of parameters to judge the effect on study results of alternative assumptions for the range of 
potential values for uncertain paramctcrs. 17 Most recent pharmacoeconomic publications contain 
sensitivity analyses on only a limited number of variables. without justification of the choice of 
selected variables or the chosen range of each variable. In addition, the interpretation of the results of a 
sensitivity analysis remains subjective. as there is no scale for measurement of sensitivity and 
consequently there is no threshold value for discriminating between ··sensitive"' and ··non sensitive .. 
variables. 
In Chapter 8 a more objective method is presented for sensitivity analyses to minimize the amount of 
potential subjectivity. This new procedure, employing point-sensitivity and range-sensitivity, allows 
an objective judgment of the sensitivity of all variables of a model, pennitting the variables to be 
ranked according to the degree of sensitivity. However, a limitation of this method is that the 
sensitivity measurement is based on a uniform distribution of the variables. which may actually have 
different distributions. A second limitation is that the overall sensitivity measure is based on a 
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subjectively chosen range, which excludes the impact of values outside the range on the overall 
sensitivity. Chapter 9 presents a refinement of the method by the incorporation of probability 
distributions. which allow a more accurate assessment of the level of uncertainty in the modeL In 
addition, a bootstrap method is used to create probability distribution for fixed input variables based 
on a limited number of data points. 
A constraint of the above-mentioned and other methods for conducting sensitivity analyses is that 
those methods only show the sensitivity of the outcomes to a change through a range of potential 
values for one or more variables without taking into account the existing relationships between those 
variables. In Chapter 10 the concept of inter-variable uncertainty is introduced and explored. A 
methodology was presented considering this type of inter-variable uncertainty and showing the 
practical implications of it on the execution of sensitivity analysis. The initial method was based only 
on uniform distributions. and subsequently various methods were presented incorporating the real 
distributions. 
UNCERTAINTY ASSOCIATED WITH EPIDEMIOLOGY 
Chapter 11 presents a methodology for an appropriate assessment of the budgetary impact of a new 
drug. which simultaneously can be used for traditional cost-effectiveness analysis. A model was 
constructed for a new hypothetical drug in Parkinson's disease, which allowed us to determine the 
budgetary impact and the cost-effectiveness of this new anti-Parkinson drug (AP) from the perspective 
of the society in The Netherlands. The methodology consists of two steps: 1) a simple population 
model (Markov model) was constructed to validate the epidemiological data by proving the 
consistency betv.reen prevalence and incidence of Parkinson· s disease for the Dutch population: 2) this 
model was extended to a more complex model (semi-Markov model) by incorporation of disease 
progression for Parkinson's disease and all relevant economic and clinical measures. 
UNCERTAINTY ASSOCIATED WITH THE TRANSPARENCY OF THE 
MODEL 
The acceptance of modelling studies is generally lower than prospective studies not only because of 
the use of secondary data. but also because the reports of modelling studies do not always have 
sufficient transparency. Hence a standardised reporting format for modelling studies may improve the 
acceptance of those studies. Chapter 12 presents an example of a reporting format for economic 
evaluation based on a modelling design. Since, contrary to clinical trial data. there are no accepted 
methods for data collection and analysis for modelling studies. a more disaggregate reporting 
presentation is required for modelling studies. The report must address the various types of uncertainty 
in modelling studies and contain a justification of the choices in the selection of data sources. model 
design and its assumptions. managing confounding variables and execution and interpretation of 
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sensitivity analysis. The proposed format consists of a number of headings, which are followed by a 
brief recommendation on their content. 
In the discussion (Chapter 13) the use of health economic models for reimbursement purposes is 
addressed taking into consideration the levels of uncertainty. which were explored in this thesis. 
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Chapter 2 
Trends in Decision-making Process for 
Pharmaceuticals in Western European 
countries: 
A Focus on Emerging Hurdles for Obtaining 
Reimbursement and a Price 
SUMMARY 
Healthcare fmancing has become a topic on the political agenda in Western Europe in recent decades. 
For every government it has become a subject of continuous concern because the costs of health 
services and healthcare are an increasing important part of the collective burden of the economy. Most 
cost containment measures have relied on budgeting or price controls. Because those traditional 
central cost containment measures were only partially successful, due to lack of incentives. the health 
authorities in Europe started to establish incentives for efficient healthcare delivery by means of 
decentralisation of the healthcare decision-making process and the implementation of market 
mechanisms. Both traditional and recent containment measures focus especially on the pharmaceutical 
drugs sector in many countries. Recently there have been three parallel trends showing increasing data 
requirements at a central level, more decentralisation of the responsibilities and decision-making 
process and prescription restrictions. We address especially the increasing central data requirements 
and decentralisation of the pricing and/or reimbursement decision-making process. At a central level 
the demand is increasing for cost-effectiveness and budgetary impact data, which has already resulted 
in formal reporting requirements in some countries. The fmdings are based on the literature and expert 
opinion of local health policy experts in the various European Union countries. who co-authored this 
manuscript 
Chapter 2 
INTRODUCTION 
Healthcare financing has been a topic on the political agenda in Western Europe in recent decades. For 
every government it has become a subject of continuous concern because the costs of health services 
and healthcare are an increasing important part of the collective burden of the economy. There are a 
number of reasons. which may explain the increase in health care costs. The ageing of the population 
may be associated with an increase in morbidity and associated healthcare costs, although a recent 
study shows that population ageing may contribute much less to future growth of the healthcare sector 
than claimed by most observers. This study showed that costs may especially depend on remaining life 
time. 1 In addition to that health technology is also contributing to increases in health expenditures. In 
contrast to other economic sectors, new health technology scarcely reduces costs (e.g. personneL 
energy), at least in the short term. Another reason is that the patient has become more knowledgeable. 
The asymmetry of information ben.veen physician and patient has become much less pronounced, 
because the patient has become more knowledgeable than in the past by means of better education and 
media. In addition the patient has become aware more demanding and is claiming maximum quality of 
life regardless of the costs. Because insurance is generally compulsory in the European Union. the 
patient is usually insured, and because third party payers pay the majority of the costs there is 
generally no direct demand control for a patient. 
Every government is eager to control the increase in expenses by the implementation of central cost 
containment policies. which in particular relate to pharmaceuticals. For the most part these measures 
have relied on budgeting or price controls. including negotiated prospective budgets for hospitals. 
centralised negotiated budgets for ambulatory physicians including drug prescriptions, and limitations 
on payments for particular medications. Because traditional central cost containment measures were 
only partially successfuL due to lack of incentives. the health authorities in Europe started to establish 
incentives for efficient healthcare delivery by means of decentralisation of the healthcare decision-
making process and the implementation of market mechanisms. 
Decentralisation 
Most European healthcare systems, except that of Germany, have been based on the so-called 
Beveridge modeL a central system of care consisting of public institutions financed by state budget. 
Local authorities councils have recently obtained increasing authority to implement policies and 
freedom to structure local healthcare organisation (e.g. Italy. Sweden) 2 (in Italy: Decreto Legislative, 
19 June 1999, no. 229 3). In France in 1996 a reform created the Agence RCgionale d'Hospitalisation 
(ARB) and the Union RCgionale des Caisses d' Assurances Maladies (URCAM). Their main rules are 
to organise the hospital supply according to a fixed budget and regional healthcare needs. They must 
also implement locally healthcare priorities that are fixed at a national level and monitor the quality of 
healthcare delivery.4 While local health authorities in most countries usually receive funding from the 
central health authorities based on a per capita basis. in Italy and Sweden they can supplement this 
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funding with local taxes and health service charges. which may vary locally depending on local 
budgetary needs (Decreto Legislative. 19 June 1999. no. 229). 
In Germany the principle of statutory social insurance is called the .. Bismarck system··. Main features 
of the system are the financing via contributions by employees and employers and a mix of service 
supply by private and public services. Although in Germany there are no formal layers below the state 
level (Bundesliinder). statutory siclmess funds are trying to implement local healthcare organisations. 
such as practice networks including hospitals. 
Market Mechanisms 
A growing number of countries have recently adopted some form of purchaser-provider split. although 
the others have retained the more conventional budget setting structure. The basic idea is to create a 
demand side (purchasing agency) that is separate from the supply side (providers). The reforms split 
the system into purchasers and providers. For example. in the United Kingdom health authorities and 
general practitioner fundholders became purchasers. while the Trust hospitals and directly managed 
units became the providers. General practitioner fundholders are now grouped into primary care 
groups. which will become trusts (PCTs). Primary care trusts will control the whole budget (except for 
some specialist services): they will provide primary care and purchase hospital care and other services 
including drugs. Also in Sweden and Italy there are signals at local level of establishing purchaser-
provider split by local healthcare councils. As stated. for example. in the two Italian laws on the 
'"reordering of the National healthcare system" (Decreto Legislative 30 December 1992. no. 502: 
Decreto Legislative 7 December 1993. no. 517.5 6 In other countries. with the more conventional 
budget setting structure. market mechanisms may be limited to drugs only and especially hospital 
drugs. In France private (and also public) hospitals buy drugs through tenders. Private hospitals 
negotiate with the local sick fund payer according to their activities and receive a fixed budget per 
patients for drugs. 
Other Related Strategies 
The decentralisation of the healthcare decision-making process and the implementation of market 
mechanisms resulted in various other related strategies. 
Shift to Primary Care 
Throughout the 1980s and 1990s the trend has been away from hospital-based consultations and 
towards primary care. The function of the general practitioner has switched from a physician treating 
patients to a gatekeeper of the healthcare system. whose main responsibility is avoiding inappropriate 
optimal referring of patients to secondary care in order to save costs. For example. in Germany the so-
called Hausart=modelle. meaning that the family physician should navigate the patient through the 
system. emerged and to avoid hospitalisation out-patient surgery was encouraged through special 
contracts by sick funds together with statutory health insurance physicians associations to induce a 
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shift from in-patient to out-patient care. Further, health authorities have encouraged the development 
of practice net\vorks and integrated care models integrating in-patient and out-patient care. The 
respective legal requirements have been implemented into social security laws in recent years 
(http://'NWW.bmgesundheit.de/engl/healthcare.htm~ German social security law, SGB 140a-h).7 s Due 
to the legal framework of the German healthcare system these measures had only limited success up to 
date. On the other hand. a country such as France is still a pure fcc-for-service country, and there is 
almost no barrier to any health goods. French citizens can access either specialist or hospital directly 
without any inputs from the general practitioner. In Denmark, for instance, in the past decade it was 
considered an improvement in quality of health services that the patient was allowed to choose the 
type of care. primary or specialised. However. a co-payment was introduced for those patients using 
directly specialised care. After some years of follow-up the results show that the majority of patients 
keep attending the primary care services and only a lower than 10% uses specialised care. This might 
be considered a compromise betv.reen freedom to choose by the patient and respecting the principles of 
cost containment. 
Co-payment 
The health systems of the Western European economies have generally offered universal coverage 
with a comprehensive benefits package. Recent fmancial pressures have prompted most countries to 
look for ways to limit public sector fmancialliability by limiting benefits and influencing the demand 
side of the healthcare market. which resulted in an increase of co-payment by the patient. The bulk of 
co-payment is limited to the ambulatory healthcare setting. especially pharmaceuticals. although in 
Germany and France there exists also co-payments for in-patient care (German social security law. 
SGB 31:39 V). The objective of co-payment is to establish financial incentives for patient's demand 
control. which in many countries fail because of complementary insurance for co-payments. In France 
most French citizens have complementary private insurance, which is paid both by the employee and 
the employer. at least in large companies. This complementary insurance covers a significant part of 
the patient co-payment left by the SCcurite Sociale.9 
Clinical Guidelines/Disease Management 
Clinical guidelines outline the proper care of medical conditions and performance of clinical 
procedures. The intended goal of guidelines is to reduce inappropriate care and to improve patient 
outcomes. In addition. these guidelines are potential tools for reducing the costs of healthcare and for 
improving medical education. 10 
Pharmaceuticals 
Pharmaceuticals expenditures have risen in Europe and the United States during the 1990s. In most 
countries pharmaceutical spending has reached 10-15% of the total healthcare budget (in some 
countries, such as Greece. Portugal and Spain. this proportion is higher than 20%: OCDE health data 
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2000). Both traditional central containment measures and the cost containment measures resulting 
from the above strategies (decentralisation/free market regulation) focus especially on the 
pharmaceutical drugs sector in many countries. as these constitute a health technology that is relatively 
easy to introduce and implement compared to other forms of care. Recently there have been three 
parallel trends showing increasing data requirements at a central level, more decentralisation of the 
responsibilities and decision-making process and prescription restrictions. 
The objective of this manuscript is to give an overview of the current pricing and reimbursement 
environment for pharmaceuticals in Western European countries. We address especially the increasing 
central data requirements and decentralisation of the pricing and/or reimbursement decision-making 
process. The information was obtained from published literature. local published or available policy 
documents. A survey was conducted with local health policy experts in the key countries to validate 
the fmdings from the literature. add missing information and update the information. if necessary. The 
local health policy experts co-authored this manuscript and are involved in pricing and reimbursement 
issues in their domestic markets. We focussed on the key countries (United Kingdom. Germany. 
France. Italy and Spain). but also included relevant information from other countries (e.g. The 
Netherlands. Sweden and Denmark). 
TRADITIONAL CENTRAL MANAGED POLICIES 
Pricing and Reimbursement 
Registration and pricing/reimbursement decisions are currently distinct processes: registration of a 
new drug is based on quality of manufacturing and efficacy/safety data from randornised clinical 
(phase III) trials and a product has market approval after registration. The drug is available on the 
market but does not have reimbursement status, and consequently the patient must pay for the drug 
alone. Therefore registration is only the first entry barrier for a new drug. which is followed by hurdles 
due to pricing and reimbursement procedures. Although it is difficult to disentangle pricing and 
reimbursement decisions. a recent overview by our group for Europe clearly indicated that 
reimbursement and pricing may be considered as two separate procedures: decisions arc made by 
different bodies. different laws apply. different reporting data are required. and reimbursement and 
pricing are sequential decisions. 11 12 13 14 For example. in France the Transparency Commission 
decides on reimbursement. while the price is negotiated with the Comite Economique des Produits de 
Sante (CEPS). An exception is Italy. where pricing and reimbursement are strictly related to. the 
Commissione Unica del Farmaco (CUF). which is the Italian drug regulatory agency. in collaboration 
with the Comitato Intenninisteriale per la Programmazione Economica (CIPE: a body of the Ministry 
of the Treasury. 15 
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Cost Containment Measures 
Although there does not seem to be any systematic approach in selecting policies to curb the costs of 
pharmaceuticals. governments in general more and more have resorted to central demand and supply-
oriented policies to limit drugs expenditures. An example of a supply-oriented policy constitutes direct 
price control, whereas a demand-oriented policy would imply the introduction of a limited list of 
reimbursable drugs (i.e. a formulary). Hence governments have opted for limiting demand as well as 
supply of pharmaceuticals available under public reimbursement schemes. 
Drug Pricing 
Pricing of drugs is often limited by either price negotiation or price laws. which define an upper limit 
based on a reference price basket consisting of prices in neighbouring countries or a European average 
price. except for the United Kingdom, Germany and France. In the United Kingdom and Germany 
pharmaceutical companies are free to price their drugs that have received marketing authorisation. The 
only limitation is that medicines may only be sold at one price sold throughout the country. However, 
in the United Kingdom. pricing is constrained by pharmaceutical company's total profit in the 
domestic market. which can vary between 17% and 21% according to United Kingdom based research 
and development activity and exporting. France is a price state regulated country: unit price is 
negotiated with the ComitC Economique des Produits de Sante on the basis of ArmSlioration du Service 
MCdical Rendu (ASMR) and the drug budget impact (DCcret du CEPS. 2000). In Italy both pricing 
procedures apply. which depend on registration: (a) price negotiation. which applies to any innovative 
drug approved by European Agency for the Evaluation of Medicinal Products (EMEA) or introduced 
by a mutual recognition procedure and (b) directly calculated price. by means of the so-called 
'"European average". which applies when market drug authorisation is allowed directly from national 
government (Ministry of Health) instead of the European Agency for the Evaluation of Medicinal 
Products. 15 Pricing of in-patient drugs is less centrally regulated and corresponds more with a market 
model. Pharmaceutical companies are free to set drug prices. and drugs can be sold at different prices 
to various hospitals based on a negotiation process. The governments do not intervene in regards to the 
price that is negotiated. although the results of the tender are deeply influenced by an out-patient price. 
Discounts can widely vary and better discounts are obtained for widely used drugs. Competition 
between manufacturers has the strongest influence on drug price negotiations. followed by the volume 
of sales and package deals. Because in most countries in-patient drugs are within the hospital budget, 
hospitals may not always be able to finance premium priced drugs. Central authorities or local health 
insurers have recently taken over financing of those drugs. Drugs are excluded from the traditional 
hospital budget and prescriptions are often limited to selected centres in order to control the number of 
prescriptions. An example is Remicade, an expensive drug for the treatment of severe rheumatoid 
arthritis, which requires day-care because of the intravenous route of administration. The use of this 
drug results in an average annual costs of 30.000 euros per treatment. which exceeds the budget of 
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most hospitals. Dutch health authorities took over fmancial responsibility for this drug to guarantee it 
is available for the patients. especially because of shortage of Enbrel. an out-patient drug for the same 
indication. 
Reference Price System and Co-Payment 
Drugs are usually grouped according to chemical structure and the reimbursement level depends on 
necessity of a treatment. Essential drugs may be fully reimbursed. while complementary drugs may be 
partly reimbursed, and non-essential drugs may be fully paid by the patient. Often usually a number of 
categories. including chronically ilL and pensioners do not have to pay co-payment for drugs. This 
system is called the reference price system. which is applied usually only to drugs when there are 
several brands with the same compound available. 16 17 This system does not set drug prices; rather, it 
sets the reimbursement levels at which the sickness funds pay for each out-patient prescription drug 
(consumers pay the amount by which the product prices exceed the reimbursement levels). Drugs in 
each group are all reimbursed on a fixed amount. Reimbursement decisions regarding new innovative 
drugs will be based on judgement of a clinical benefit compared with standard therapy in the target 
patient population (indication). The judgement of the clinical benefit is based on traditional clinical 
outcomes derived from phase III clinical trials used for registration: efficacy, safety and quality. In 
addition other clinical criteria are taken into consideration: route of administration, or other relevant 
clinical information. When the evaluation of a drug is positive from a clinical point of view, the drug 
price has been the critical factor for final decisions on reimbursement until recently. The reference 
price system has t\vo primary functions: first. to lower the prices of drugs by inducing price 
competition. and. second. to encourage greater use of generic drugs by making consumers pay a 
greater share of the cost of higher-price brand-name drugs. Patients usually can have co-payment for 
drugs refunded through additional private insurance. Therefore this demand-oriented policy is usually 
not an effective cost containment measure. because patients remain relatively insensitive to the co-
payment system. when co-insurance is possible. There is usually no or limited co-payment for drugs 
supplied during hospitalisation. It is important to note that while we describe general mechanisms. that 
there is a wide variation across EU. 
Posdive and Negative Lists 
There is an increasing trend to the development of positive and negative lists. which aim at reducing 
the number of reimbursement drugs as well as total spending on pharmaceuticals. The selection of 
drugs for a list is mainly on the basis of efficacy/safety parameters. At central level a positive list 
contains drugs which will be reimbursed. while drugs on a negative list (e.g. Black List in the United 
Kingdom and the former List lB in The Netherlands) must be paid fully by the patient. The Black List 
contains drugs. which are not reimbursed. although licensed. These are mainly old and ineffective 
products for which better and cheaper alternatives are available. In the United Kingdom there is also a 
grey list of drugs for use in limited circumstances. for example, Viagra. In Germany there is an 
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established negative list [social security law. SGB 34(3) V] which is technically updated by a federal 
committee (Bundesausschuss Arzte!Krankenkassen). Further. the first draft of a positive slist is due for 
submission on 30 June 2001. which is set up by a special committee (German social security law. SGB 
33a V). 18 The increase in pharmaceuticals expenditures in Europe up to 10-15% of the total healthcare 
budget 9. shows that the traditional central cost containment measures were not sufficient to control the 
drug costs leading to drug policy reform. which is described below. 
CURRENT RESTRUCTURING OF DRUG POLICIES 
Recently there have been three parallel trends showing increasing data requirements at a central level, 
more decentralisation of the responsibilities and decision-making process and prescription restrictions. 
Data Requirements 
Pricing and reimbursement have been based until recently on the traditional clinical trial outcomes 
(efficacy. safety and quality parameters) used for registration. We can distinguish various data 
requirements which all relate to the use of the drug in real daily practice. while the traditional clinical 
trial outcomes are only derived from randomised clinical trials. 
Effectiveness 
There is an increasing demand for effectiveness data. Efficacy and effectiveness are two different 
concepts. Both. however. have an impact on the effect of a drug. In the case of efficacy. the effect is 
examined under ideal conditions in a homogeneous group of patients. and usually with the assistance 
of intermediate (surrogate) end-points. Effectiveness data. on the other hand. offer a clearer picture of 
the actual value of a drug because the effect is examined under more realistic conditions using a more 
heterogeneous group of patients. This information about use in common practice also provides more 
insight into whether the aim of the treatment v..r:ill ultimately be achieved. Effectiveness research is 
therefore oriented towards defmitive outcomes such as a reduction in morbidity and mortality. A 
recent Italian law allows phase III clinical experimentation (both randomized controlled trials and 
uncontrolled. observational studies) at present conducted only in hospitals and/or specialty clinics. to 
be conducted also in an out-patient setting. This kind of experimentation provides data from a large 
sample of population in a "naturalistic setting". therefore providing good insight into the 
"'effectiveness'" of the pharmaceutical technologies (SOLE 24 Ore Sanita. no. 3. 23-29 January 
2001).19 In France the Transparency Commission considers the public health value of the drug, which 
is called an Amelioration du Service Medicale Rendu (ASMR). which may be considered as a 
comprehensive effectiveness measure. 
Cost-Effectiveness Data by a Health Economic Analysis 
The fourth hurdle in drug development is the growing burden on manufacturers to demonstrate the 
cost-effectiveness of their products before acceptance for reimbursement or.less relevant, pricing, may 
have considerable consequences for all players involved. Health economic data should permit reliable, 
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reproducible and verifiable insight into the effectiveness of a drug, the costs that will result from its 
use. and the possible savings that will be made compared with other drugs and/or treatments. Health 
economic studies are already being used for the reimbursement of new drugs in Australia and Canada. 
Those countries have official requirements for submission of health economic data since the early 
l990s.:o 21 There is currently a trend towards an increasing demand for health economic data in the 
decision-making process information in Europe and in several countries to formal reporting 
requirements now (the United Kingdom, Finland and Portugal) or in the near future (The Netherlands 
and Non:vay). 11 21 This is also true in Italy. In fact a recent provision (February 20001) by the 
Comitate Interministeriale per la Programmazione Economica (CIPE: the Ministry's Board of 
Economic Planning) claims that a new drug is admitted to reimbursement when its cost-effectiveness 
ratio is favourable in comparison to other drugs already admitted for the same indication. or it is useful 
to prevent and treat symptoms and pathologies not already treatable by others drugs (Delibera CIPE I 
February 2001. no. 3/2001).22 In France health economic data help at supporting premium price. as 
part of the negotiation process. 
Budgetary Impact Data by a Financial Analysis 
In addition to the cost-effectiveness of a new drug. reimbursement decisions will also be based on the 
budgetary impact of a new drug on the annual national healthcare budget. especially the impact of a 
new drug on the drug budget. Therefore the authorities are requiring an assessment of the impact of a 
new drug on the annual drug budget. For the financial analysis, data on the following subjects will be 
required: descriptive epidemiology (data on incidence and prevalence). The patient group that is 
indicated for the drug and the anticipated substitution effects (i.e. the extent to which the existing 
treatment will be replaced): the use of the drug (e.g., posology. length of the treatment), the price of 
the drug: the expected market share plus the variables that would facilitate or slow down the drug sales 
and the total treatment costs. On the basis of the cost-effectiveness analysis and financial analysis an 
advice can then be drawn up as to whether the drug should be reimbursed; examples include The 
Netherlands, United Kingdom and Italy 13 (in Italy: Delibera CIPE I February 2001 00), For example, 
in Italy the recent Comitate Interministeriale per la Programmazione Economica (CIPE) provision (see 
above) specifies that the drug price is negotiated also on the basis of appropriate economic evaluations 
of the drug in its market and competition context. However, the budgetary impact analysis is not 
clearly defmed and no formal guidelines exist. for example, it is not clear yet what is taken into 
account. drugs costs only or also other medical costs. In France the price is negotiated with the Comite 
Economique des Produits de Sante (CEPS) on the basis of the Amelioration du Senrice Medical Rendu 
(ASMR), but also incidence/prevalence of the disease. public health concern and drug budget in order 
to assess the budgetary impact (Decret du CEPS. 2000).24 In Spain the budget impact is also 
considered during the price and reimbursing negotiation. The royal decree 27111990. which regulates 
these processes. requires a forecast of the sales as an e1ement for the final decision. 
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Decentralisation and/or Prescription Guidelines 
Financing prescription medicines in ambulatory care has been a central responsibility. The central 
authorities have recently begun often to shift the responsibility for development of prescription lists to 
the local authorities. 
OecentraNsation 
The responsibility for financing prescription medicines in ambulatory care is moving from the central 
to local level (e.g. Sweden. The Netherlands. United Kingdom). For example, the Dutch government 
considers giving the local health insurers the responsibility for the purchasing process for drugs. which 
means that they will directly bargain and negotiate with pharmaceutical companies. In the United 
Kingdom drug financing is no longer a central funding mechanism. Primary care trusts now have 
··devolved"' budgets and can set their own drug budgets. In Sweden from the beginning of 1998. the 
responsibility for financing prescription medicines in ambulatory care was transferred from the 
National Social Insurance Board (RFV) to the county councils over a 3-year period. Under the new 
structures local consumption patterns and total cost of medicines are more transparent to regional 
administrators and prescribers. As a result. treatment should be more responsive to local needs and 
cost containment measures should become more effective. Although the local authorities are becoming 
more involved in influencing the prescribers to reduce volumes and switch to cheaper drugs (supply 
side). decisions on a reimbursement status level and reimbursement price in general is still the 
responsibility of the central authorities. 
Drug Formularies 
There is a tendency to shift the development of lists to local authorities leading to local lists. 
Formularies have been used already by hospitals for in-patient drugs. but key actors in local healthcare 
(e.g. specialists. general practitioners. pharmacists and insurers) are now developing formularies for 
ambulatory drugs. In general drugs are added to the formulary when there are no similar drugs 
available. Drugs are substituted mainly when major clinical improvements and/or drug cost savings 
are expected. The use of expensive drugs is usually rationed by means of prescription guidelines or 
delivery restriction. 
Prescription Restrictions 
\¥bile traditionally reimbursement decisions applied to the officially registered indication. which was 
usually a broad indication. authorities have recently been imposing restrictions on the claim made for 
the drug. These restrictions usually relate to follow a treatment protocol. to limit the prescribers or to 
limit the range of indications (United Kingdom. Germany and France). In Germany prescriptions are 
more and more restricted by the prescribing guidelines given by the federal committee of physicians 
and sickness funds (Ar.:neimittelrichtlinien). For example. these prescribing guidelines restrict drug 
therapy to the approved indications from clinical trials. The Bundesinstitut filr Arzneimittel und 
Medizinprodukte (Federal Institute for Drugs and Medical Devices) tends to approve drugs only for 
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indications which were part of the clinical trials. Specific to Italy is the issue of the so-called "Note 
CUF". This set of criteria for reimbursement of some selected active principles are specifically meant 
at reducing drug availability by identifying specific drug indications for which the drug is reimbursed. 
For example, ondansetron. granisetron and all 5-hydroxytryptamine type 3 antagonists are limited by 
Nota 57 to "prevention and treatment of nausea and vomiting in patients undergoing emetogenic 
chemotherapy'". thus excluding all other potentially emetogenic indications (Decreto Ministero della 
Sanita.. 22. December 2000).:5 The narrowing of the indication especially depends on the efficacy. but 
also the results of the above health economic analysis and financial analysis may be taken into 
consideration. which may suggest that within the registered range of indications a further limitation of 
the field of application must be made from the point of view of cost-effectiveness and budgetary 
impact. In the United Kingdom the National Institute for Clinical Excellence (NICE) is producing 
clinical guidelines incorporating technology and economic results. which include specific advice on 
targeting drugs. although it is not legally binding. 
Financial Liability 
Prescription guidelines may be also used to audit physicians in terms of quality assurance to determine 
whether these guidelines are being correctly followed. Financial sanctions may be imposed if the 
recommendations are not followed. Prescription behaviour (or prescriptions patterns) of physicians 
may be also be directly linked with financial liability. We may distinguish between budget and 
envelop responsibility. budget being individual and envelop being collective responsibility. In 
Germany physicians have a target budget for phannaceutical expenditure and exceeding the budget 
may result in financial sanctions. This target budget is calculated by applying the so-called 
RichtgrbjJen per member or RichtgrOjJen per retiree multiplied by the number of treated members or 
retirees per quarter. The sum per quarter times four results in the yearly target budget. The 
RichtgrOjJen take criteria such as physician specialty and status (member. retiree) into account. In 
addition. some products and some indications are considered as ·essential' and exempted from these 
guidelines (Praxisbesonderheiten. Wirkstoffausnahmen). which means that they arc not included in the 
total prescribing bill of the physician. In Germany the Kasseniirztliche Bundesvereinigung (National 
Association of Statutory Health Physicians) and the leading Krankenkassen associations fonn a federal 
framework. the Bundesausschuss Arzte!Krankenkassen. which is responsible for setting up and 
updating prescribing guidelines (Ar::neimittelrichtlinien) which should guide the physicians 
prescribing behaviour with regard to economic viability. The introduction of these guidelines means 
that the physicians are individually liable for mal-compliance with these guidelines. and that this mal-
compliance may result in financial sanctions. Through the creation of these guidelines for certain 
drugs. the Bundesausschuss can exercise control over physicians prescribing. In general. there seems 
to be a mix between prescribing guidelines (Ar::neimittelrichtlinien) and physicians individual budgets 
based on RichtgrOjJen. In the United Kingdom the individual prescriber is monitored by hospitals and 
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primary care trusts. ""Overprescribing" is a problem only if budget constraints are broken. 
''Underprescribing" can become a political issue. for example. not following the National Institute for 
Clinical Excellence (NICE) guideline. Each trust must decide on prescribing policy: peer pressure is 
used to make individuals conform. In France groups ofhealthcare provider have their own envelop. In 
case they exceed the value of the "key-letter" might be reduced or its increase may be lower than 
inflation. In Spain during the past decade the position of primary care pharmacist has been created in 
several regions. This person is committed to develop recommended lists of save. effective and cheap 
drugs that are mailed to physicians. and also to advice prescribers. The pharmacist is also performing 
an ex post control of the type and budget impact of prescriptions and interviewing physicians to keep 
the expenditure in the established limits. 
Clinical Guidelines/Disease Management 
There is a trend to development and implementation of clinical guidelines. which usually are only 
prescription guidelines for physicians. These guidelines usually contain a recommendation for 
prescribing generic drugs and encourage the optimal usc of drugs. Through the creation of guidelines 
for certain conditions. the healthcare authorities can exercise control over physicians· prescribing. 
These recommendations are seen as an extension of the non-reimbursement list. However. as 
described above. most of the prescribing guidelines enforce the usc of drugs in the approved indication 
instead of the optimal use of drugs. These prescribing guidelines should strictly be distinguished from 
clinical guidelines or treatment recommendations from specialty associations or opinion leader. In 
France the Agcnce Nationalc d' Accreditation et Evaluation en SantC (ANAES) issues clinical 
guidelines. The Reference Medical Opposable (RMO) is the official prescription guidelines for 
physicians (http://w\VW.anaes.fr!). The French guidelines are determined by a scientific committee 
who consider general themes (prescription. diagnostic tests. biology. surgery) and/or different 
pathologies. Included in these guidelines are regulations indicating what the physicians should or 
should not prescribe following a certain diagnosis. All drugs were revisited by the Transparency 
Commission to check again their public health value. The development of guidelines is usually a 
deccntralised local process with involvement of representatives of physicians and local insurers. 
Another example is the United Kingdom; one of the objectives of the National Health Service is to 
promote rational prescribing amongst general practitioners. The Department of Health pays for general 
practitioners· subscription to the Drug and Therapeutic Bulletin. an independent publication from the 
Consumers· Association. which contains evaluations of treatments and pharmaceutical products. 
However. this is not always in line with the official guideline. for example Relenza. 
In summary. we have three recent parallel trends showing additional data requirements at a central 
leveL more decentralisation of the responsibilities and decision-making process and prescription 
restrictions. 
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DISCUSSION 
The objective of this contribution was to present an overview of the current pricing and reimbursement 
environment for pharmaceuticals. Financing prescription medicines in ambulatory care has been a 
central responsibility. which was based on the traditional clinical trial outcomes (efficacy/safety 
parameters) used for registration. Although there is large variety between the various countries. there 
are three related trends: decentralisation of the healthcare decision-making process. prescription 
restrictions. and additional data requirements. Decentralisation and prescription limitations are not 
independent processes: Central authorities often shift the responsibility for development of 
prescription lists to the local authorities. At a central level the demand for cost-effectiveness and 
budgetary impact data is increasing. which has already resulted in formal reporting requirements in 
some countries (e.g. The Netherlands). Although the most evident impact of health economic studies is 
expected for central reimbursement audiences. evidence for the use of health economic studies by 
other audiences is expected to increase (e.g. patients. hospitals, insurers. formulary committees).::!6 We 
already notice that this recent decentralisation process is adopting some of the economic criterion to 
better inform medical decisions on prescription. For instance, in Spain that probably is the most 
decentralised EU country. a new type of staff has been incorporated, in some regions, for primary care: 
the primary care pharmacists. These are committed to report on safety, efficacy and effectiveness of 
drugs as well as on the prices and rough cost-effectiveness values. Their recommendations are 
published and handed out to primary care physicians. A close follow-up of the prescriptions is carried 
out and an evaluation of the outcomes after the pharmacists reports are implemented. This approach to 
prescription has contained costs where applied. and it is observed by other Spanish regions with 
interest. 
Below we address first general potential limitations of decentralisation and market mechanisms in the 
healthcare market and then focus on drug-specific issues. 
We distinguish tv.ro potential limitations of deccntraEsation and market mechanisms in the healthcare 
market limitation. Firstly. in the current free market developments healthcare remains free at the point 
of delivery or is paid for indirectly through insurance premiums. Although there is an increase in co-
payment. private health insurance is taken out for those services that are not provided free of charge. 
Hence customers will not shop around for the lowest price. and consequently there is still little 
pressure on producers to keep prices down. Instead. they may compete with one another by providing 
more attractive services. which may in fact lead to price increases rather than reductions~ this is 
referred to as non-price competition. Secondly. the decentralisation of the healthcare decision-making 
process by broadening the role of health insurers from fmancial controllers to purchasers increased 
competition by increasing the number of buyers from one central body to more potential buyers. There 
are two recent developments which may inhibit the favourable consequences of this competition. 
Firstly. the increasing opportunities of administrative databases may lead to mergers between 
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purchasers: The use of databases allows management at a larger scale (e.g. larger number of patients) 
and may be beneficial only when benefitting from economies of scales. As a consequence mergers 
may lead to an oligopoly inhibiting the intended efficiency of purchaser-provider split. 
On the other hand, the use of clinical guidelines outlining proper care will increase the homogeneity of 
the healthcare services. and therefore the products can compete on price and be comparable with one 
another. The increasing information technology (e.g. decision support tools for physicians) may 
facilitate implementation of more standardised treatment from prescription guidelines to more 
comprehensive disease management. The use of evidence based medicine will increase the consensus 
in clinical decision-making. increase the homogeneity and improve the assessment of appropriateness 
and quality. The increasing information technology (e.g. databases) may contribute to data collection 
of evidence-based data associated with different treatments. 
In addition to the above general trends. there are other drug-specific developments. which need to be 
considered. \Vhile registration procedures for Europe are becoming centralised with central European 
decision-making by the European Agency for the Evaluation of Medicinal Products (EMEA). pricing 
and reimbursement decisions are still national affairs. Although opponents argue that drug registration 
and reimbursement must be kept strictly separate. there are signs that economic evaluation may 
become part of the registration dossier in the near future. Secondly. harmonisation of guidelines and 
further moves towards Europe-wide decisions on drug pricing and reimbursement are likely. given the 
increasing interdependency of European markets and regulatory authorities. A consequence is that the 
role of the central authorities will further decrease. On the one hand. centralisation of 
pricing/reimbursement decisions shifts to the European level. and. on the other hand. decentralisation 
of the other healthcare decisions (e.g. prescription restrictions. local formularies. clinical guidelines) 
shifts to the local level. However. the second part of this conclusion needs to be considered with 
prudence because the local sickness funds are financed differently in the various European countries. 
which will affect the option of the decentralised decision process in each country. 
Another consideration is how cost-effectiveness data could be used at a central European level for 
pricing and reimbursement decisions. A key principle in health economics is that cost-effectiveness is 
based on the country-specific healthcare setting: local treatments patterns and local financing system 
determine the clinical and economic outcomes. Consequently a European cost-effectiveness ratio (e.g. 
10.000 EURO per quality-adjusted life year) cannot be determined or is meaningless. Hence the use of 
health economic data at a central European level needs an in-depth examination. Some other important 
difficulties for European pricing and reimbursement are drug price differences between countries and 
parallel import. Furthermore, cost-effectiveness needs to be a particularised not only at the country 
level but also at the regional level. The reason is that once there are decentralised budgets, regions 
have political power to adopt decisions that consider more efficient given their health policy. costs (for 
instance. salaries are not equal across Spanish regions). patient management and epidemiological 
conditions. Trying to foresee the future. due to international trade and patent agreements. similar 
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pricing Vvill become a more and more common policy throughout EU countries. but reimbursement 
policies - and hence adaptation of cost-effectiveness studies to inform on reimbursement and 
prescription practices -will have to be tailored more specifically to a difficult range of medical 
decisions. 
Finally, we address the option of temporary reimbursement. which is being considered by Dutch and 
French authorities. Health economic evaluations consider efficacy and especially effectiveness. 
However. effectiveness data are usually not available at time of reimbursement procedures. Therefore 
temporary acceptance of an innovative drug to the reimbursement package might be considered. A 
conditional acceptance would permit initial decision-making on reimbursement based on the cost-
effectiveness ofthc new drug derived from modelling data. followed by validation through subsequent 
prospective data collection. This would minimise the logistical and methodological concerns related to 
current policy. It would also reduce the concern of industry that health economic evaluation guidelines 
would delay product launch, shortening the period of useful patent life and the return on research and 
development investment. New drugs would be made available more quickly if prospectively data 
collection were not required prior to reimbursement. On the other hand, removal of a drug from a 
reimbursement package after additional prospective data were evaluated might have ethical concerns 
and lead to some social unrest. Regardless of the issue of temporary reimbursement there will surely 
be a need for collection of real-life data after the introduction of a new expensive drug, which accords 
perfectly with the concept of evidence-based medicine. The principle of evidence-based medicine is 
that clinical encounters should be supported by scientific conclusions based on data as much as 
possible. 
Although the objective of this manuscript is to address the increasing central data requirements in the 
pricing and/or reimbursement decision-making process. the decision will be at least partially political. 
First, guidelines prescribe proper execution of health economic evaluations but not cut-off points for 
approving reimbursement. The decision about how much society will pay for increased effectiveness 
is political. Second. the weight of all data (e.g. data of the health economic evaluation and the 
financial impact analysis) in the decision-making process is currently not defined. Therefore we may 
conclude that the decision-making must become more transparent for a successful implementation of 
the new drug policies. 
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Assessment of Clinical Guidelines for 
Continuation Treatment in Major Depression 
from a Health Economic Perspective 
SUMMARY 
OBJECTIVE: The primary objective of this study was to assess the appropriateness of the existing 
Dutch clinical guidelines for the treatment of depression from a health-economic perspective. The 
existing guidelines recommend continuation treatment for a period up to 9 months. METHODS: The 
assessment was based on a Markov model using decision-analytic techniques. For this analysis we 
defined six mutually exclusive states defined by the existence of depression and type of treatment. The 
outcomes for the model were defmed as: time without depression (TWD). quality-adjusted life years 
(QAL Ys). direct medical costs, and cost of lost productivity. The primary perspective of the study was 
that of the third-party payer. while the secondary perspective was that of the society in 1999. The 
probabilities of clinical events and therapeutic choices as well as the utilities were based on published 
literature. The medical resource use related to each state was abstracted from published literature and 
expert opinion. The associated 1999 unit costs of the used medical resources were derived from 
official Dutch tariff lists of allowable reimbursements. Indirect costs in this model were based on lost 
productivity only. RESULTS: The results of the primary analysis showed that the usc of the 
guidelines is not cost-effective. Continuation treatment for a period of 9 months increases the total 
direct medical costs (NLG 1276 vs. NLG 474). decreases the costs resulting from lost productivity 
(NLG 304 vs. NLG 909). increases total costs (NLG 1580 vs. NLG 1383) and increases TWD (96.9% 
vs. 86.4%). However. continuation treatment does not change the utility outcomes (0.60 vs. 0.61 
QAL Ys) for both treatment strategies. Hence continuation treatment is not cost-effective from either a 
third-party payer perspective or a societal perspective. A scenario analysis showed that an extension 
of the continuation treatment to maintenance treatment might result in a favorable cost-effectiveness 
outcome of the treatment guideline. CONCLUSION: In conclusion. based on the assumptions used in 
the model. the current Dutch treatment guidelines for depression are only appropriate from a health-
economic perspective if continuation treatment is extended to maintenance treatment. 
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INTRODUCTION 
Epidemiology 
Depression is a common debilitating illness that exerts a large sociaL medical and economic impact on 
society. Epidemiological studies show a prevalence varying between 1% and 4% in women and 
between 2% and 3% in men.1 ::! 3 The highest prevalence of the disease appears to be in adults between 
the ages of 18 and 44.4 5 A study by Ormel yields a prevalence of6.7% for persons older than 18 years 
in the Netherlands, which is the study country in this manuscript.6 
Economic Impact of Depression 
Although there is some variation due to the diversity ofhealthcare systems. as a rule of thumb most of 
the developed countries spend about 10% of their national income on healthcare.7 About 10% of total 
health care expenditures is spent on mental disorders treatment. 8 Several important findings have 
emerged with regard to mental disorders. Most recent studies point out that the economic burden of 
depression consists ofhealthcare expenditures (direct costs) and costs related to loss ofproductivity.9 
10 There are a number of other factors that may explain. why depression is such a significant problem 
of public health. leading to long-term morbidity and costs: 1) depression has a high risk of recurrence 
and chronicity~ 2) the fact that depression is mainly prevalent among young adults (between 18 and 44 
years) means that the patients involved represent the active population, increasing the costs to society 
through productivity losses due to work days lost 3: 3) severe depression can lead to frequent and 
lengthy hospitalisations, which have an enormous impact in economic terms 11 and; 4) major 
depression is associated with significant social morbidity. decreases in health status and well being. 
and impacts dramatically on the ability of patients to function normally in the work place.c 13 14 
Treatment of Depression 
The drugs most often used in current treatment patterns for depression include the tricyclic 
antidepressants (TCAs) and the newer selective serotonin reuptake inhibitors (SSRis). which arc 
associated with fewer side effects.15 .1 6 Depressive episodes usually respond well to short-term 
treatment: studies have shown that approximately 65% to 80% of depressive patients can be treated 
effectively with anti-depressant drugs. while placebo response rates have often been in the range of 
20% to 40%.17 The treatment of the acutely depressed patient is referred to as short-term or episodic 
treatment. Although patients usually responded well to short term treatment. relapse and recurrence 
are common problems in clinical practice. 18 19 ::!o A new episode may be either a relapse or recurrence, 
which are now recognised as two distinct events. the former being a re-emergence of the original 
depressive episode and the latter the emergence of a new episode. unrelated to the originaL IS A 
relapse has been loosely defined as a depressive event that takes place within 4 to 6 of the original 
event. whereas a recurrence occurs after this period.15 Patients who achieve a stable asymptomatic 
state with full restoration of psychosocial function and who are symptom free for six months or more 
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following an episode of depression are said to have recovered? 22 A review of studies with a follow-
up of more than 1 year has shown consistently high rates of recurrence: all patients experienced at 
least 2 episodes in Perris' and Angst's study~ respectively 96% in Carlson's and 78% in Lehman's.23 24 
25 26 Studies indicate that 50% to 85% of patients with a diagnosis of major depression will experience 
at least one more episode of depression in their lifetime.27 28 and individuals with a history of two or 
more depressive episodes have almost a 90% chance of experiencing a third.29 
Several studies have indicated that long-term treatment of depression may be beneficial for patients 
with major depression. 30 31 3::: The findings of those studies resulted in recommendations for 
prolongation of the antidepressant medication. Accordingly. the WHO (WHO Organisation Mental 
Health Collaborating Centers. 1989) 33• the Agency for Health Care Policy and Research (AHCPR) 34 
in the US and numerous other consensus groups (Paykel and Priest 35, Montgomery et al. 1993 36, 
American Psychiatric Association 37• Commission de Transparence 1994 38, Swedish Board of 
Health 39) have established depression treatment guidelines recommending at least 4 to 9 months of 
antidepressant therapy beyond initial symptom resolution for an initial depressive episode, with longer 
antidepressant treatment for subsequent episodes. The clinical treatment guidelines for Dutch GPs 
I"NHG-standaard" by the Dutch association of GP's (""Nederlands Huisartsgenootschap"1)] 
recommend a period of continuation treatment up to 9 months after response to medication:.to 
As mentioned above. a distinction should be made between relapse and recurrence. The decision 
whether to continue treatment after a positive response and for how long should therefore take into 
consideration both the risk of relapse and the risk of recurrence. Hence. prolongation treatment may 
be considered to consist of two components. one aimed at preventing a relapse. and one aimed at 
preventing recurrence. Those components have been labelled continuation and maintenance treatment, 
respectively. and for the rest of this article we will use this terminology. 
Although the clinical efficacy of the SSRis is comparable to that of the TCAs 41 • their major 
advantage in clinical practice is the lower incidence of side effects and increased patient compliance. 15 
42 43 The use of antidepressive medication in The Netherlands has been studied using a local database 
ofGPs over the period 1994 to 1995. This smdy showed that nearly all patients using SSRis. received 
the minimal effective dosage versus only 61% of the patients using TCAs.44 Hence the increased 
patient tolerability of SSRis clearly makes them ideal agents for the long-term maintenance phase of 
treatment. which has been confirmed by a number of studies.20 32 45 46 In those studies. responders to 
an acute treatment 'Nith an SSRI were randomised to continuation of the treatment or switched to 
placebo. and relapse and/or recurrence were assessed during the continuation and/or maintenance 
period. 
1 NHG-standaard: guideline by the Dutch Association of GPs ("'N ederlands Huisartsgcnootschap "). 
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Assessment of Clinical Guidelines from a Health-Economic Perspective 
A growing number of organisations have issued clinical guidelines for prolongation of antidepressant 
medication following response to an initial antidepressant medication.34 35 37 36 38 39 40 Clinical 
guidelines outline the proper care of medical conditions and performance of clinical procedures. The 
intended goal of guidelines is to reduce inappropriate care and to improve patient outcomes. In 
addition. these guidelines are potential tools for reducing the costs of hcalthcare. and for improving 
medical education.47 While the principal goal of clinical guidelines is to define what is best for the 
individual patient. an assessment of those guidelines from a health economic perspective is performed 
from the broader society perspective. This approach consists of relating cumulative measures of costs 
over time v.rith cumulative measures of clinical benefit. Economic measures such as direct medical 
costs and cost of lost productivity must be considered. while costs play a minor role in the decision-
making for clinical guidelines.48 49 Another difference is that the majority of clinical guidelines have 
been based on efficacy outcomes of randomised clinical trials - relapse and recurrence rates for 
continuation and maintenance treatment. respectively. Ideally. health-economic studies should not be 
based on efficacy. but on effectiveness in terms of morbidity and mortality: [e.g. quality-adjusted life 
years (QAL Y)]. If no effectiveness data are available. then appropriate modelling techniques may be 
used to model efficacy data into what is expected in practice (effectiveness). All assumptions behind 
such modelling techniques should be evaluated with the help of sensitivity analysis. 
Economic evaluation is a valuable tool allowing strategic choices to be made in the context of 
healthcare policy. This approach appears to be particularly relevant for chronic disorders that are 
common and make use of many healthcare resources. A health-economic assessment of clinical 
guidelines is especially relevant when the disease leads to a high burden on society in terms of costs 
and social morbidity (quality of life). Consequently the necessity for a health-economic assessment of 
clinical guidelines may be based on following criteria: 1) prevalence or incidence and 2) cost-of-
illness. According to both criteria and considering the epidemiological and economic data presented 
on depression. it is obvious that a health-economic assessment of clinical guidelines for treatment in 
depression is justified. 
The primary objective of this cost-effectiveness study was to determine the appropriateness of the 
Dutch .. NHG-standard'" recommending continuation treatment from a health economic perspective~ a 
secondary objective was to determine the optimal period of prolongation of an antidepressant 
medication. 
The underlying hypothesis of this study was that a prolongation of an antidepressant treatment v.rill 
lead to a favourable health-economic outcome compared with short-term treatment only. A reduction 
of relapse and/or recurrence v.rill result in: 1) an increase of Time without depression (TWD). in 
quality oflife. and consequently. in QAL Ys; and 2) a reduction of total costs (direct medical costs and 
costs oflost productivity). which will lead to a favourable incremental cost-effectiveness outcome. 
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DESIGN AND METHODS 
Decision analytic techniques were used to specify the potential health-economic benefits of the 
clinical guidelines. This application of decision analytic techniques to the development of guidelines 
is relatively new, and thus there is limited experience. 5° 51 In that sense, this study is exploratory in 
nature. Its main aim is to show how health-economic analysis can be used alongside clinical guideline 
development. This cost-effectiveness analysis compared prolongation of antidepressant medication 
versus no prolongation after response to an initial treatment with an antidepressant in the Dutch 
healthcare setting. The Netherlands was chosen for the purpose of illustration, because this country 
was the first European country to have developed phannacoeconomic research guidelines. 52 Hence. 
this offered the opportunity of conducting a health-economic analysis according to these standardised 
research guidelines. The primary perspective of the study was that of the third party payer. while the 
secondary perspective was that of the society in 1999. 
Figure 1. Markov states and possible transition used in the model. 
Markov Models 
Health-economic modelling studies are based on decision analysis. which allows for the analysis of 
both clinical and economic consequences of medical actions and attitudes.53 From treatment 
algorithms a model can be constructed which considers the timings of actions and their consequences 
over time. In effect. a model shows the consequences and complications of different therapeutic 
interventions. and it should correspond as much as possible, to the real life situation of the disease. 
Models may take the form of simple decision analytic trees or they may be very complex Markov 
models. Whereas decision tree models are appropriate for acute episodes, Markov models are the first 
choice for phannacoeconomic analysis of chronic diseases. like depression. The data being used in a 
modelling study can be categorised into transition probabilities (e.g. response. relapse and recurrence). 
healthcare utilisation (e.g. drugs. consultations). prices and tariffs. and utilities. 54 The data may come 
from a variety of sources and is subject to varying degrees of uncertainty. Data sources for the 
variables being used in a model may be clinical trials. literature (e.g. meta-analysis). databases. 
medical records. and official tariff lists of allowable- reimbursements. These data sources will yield. 
for each variable. a fixed input value and a range. The standard analysis will be based on the fixed 
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input value for all variables. The range of each variable is then used to determine the sensitivity of the 
outcome to the analysis, when the input value is varied within its range. 
Description of the Markov Model 
A Markov process represents a convenient way of modelling the long-term evolution of health states 
over successive time periods.55 A Markov process model describes several discrete states of health in 
which a person can be at time t=n as well as the states of health into which the person may move at 
time t=n+ 1. The progression from t=n to t=n+ 1 is called a cycle. Probabilities are associated with 
each change from one health state to another~ these are termed transition probabilities (P). Each 
transition probability is a function of the health and of the time spent in each health state. The 
Markov model used in this study is shown in Figure I: each Markov state is assigned a utility, and the 
overall contribution of this utility depend on the length of time spent in the state. A utility can be a 
clinical as well as an economic parameter. 
For this analysis we defined s:Lx mutually exclusive states based on the existence of depression and 
the type of treatment applied: 
• no depression and no prolongation of treatment (ND) 
• no depression and prolongation with SSRI (ND-SSRI) 
• no depression and prolongation with TCA (ND-TCA) 
• depression in ambulatory setting treated with SSRI (AD-SSRI) 
• depression in ambulatory setting treated with TCA (AD-TCA) 
• treatment failure in severe depression requiring hospitalisation (DH). 
Patient progression through these states was divided into cycles of 2 months. A 2-month cycle time 
was chosen, because this interval closely approximates the time of the sequential therapeutic stages: 
e.g. the initial 2-month trial of anti-depressant medication is followed by a continuation treatment for 
another 6 months in case the patient responded positively. 
Description of the Transitions 
In the model all patients begin in the state identified above as ··no depression", either with or without 
medication, and during each subsequent cycle they either remain in the same state or progress to 
another state depending on the allowed transitions and their associated probabilities. The transition 
probabilities between the states are based on relapse and recurrence rates for responders with or 
without prolonged treatment and subsequent response rates to treatment. 
The model is based on the following assumptions: 
No Prolongation and prolongation of treatment: 
• The low patient compliance with TCAs makes them less than ideal agents for prolongation 
treatment. Therefore the health-economic assessment was based on prolongation of first-line 
treatment of depression with an SSRI. 
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• A patient will be hospitalised after three subsequent treatment failures with antidepressants. 
including increase of dosage of antidepressants. 
• An increase of dosage of antidepressant medication (SSRJ or TCA) was not been included in the 
model. The assumption is that an increase of the dosage of an antidepressant will occur within the 
cycle time of2 months. 
• We have excluded the possibility of suicide in the model. Although patients with depression may 
have a significant risk for suicide over the long-term. previous studies showed that the incidence 
of suicide over a period of 18 months was negligible. being less than 1%.56 For the same reason. 
suicide was not included in a previous publication by our group nor was it included in the study 
by Jonsson. as the cost associated with suicide is minimal due to the low incidence and the 
relatively low impact on cost. 57 ss 
No prolongation of treatment: 
• Patients not currently on prolongation treatment will be treated again with an SSRI after a relapse 
or recurrence. In the event of no response to this treatment. the patient will be switched to a TCA. 
• Patients who do not respond to a TCA will be switched to another type (class) ofTCA. 
• Responders to a SSRI or a TCA will discontinue this treatment after the short-term period. 
Prolongation of treatment: 
• Patients receiving prolonged treatment with a SSRL who experience a relapse or recurrence. will 
be switched to a TCA. The probability of a response will correspond to the probability of response 
to a first-line antidepressant treatment. 
• Responders to a SSRI will continue this treatment as prolongation treatment after the short-term 
period. 
• Responders to a TCA will. in the base case analysis. terminate this treatment as prolongation 
treatment after the short-term period because of the low level of compliance with TCAs~ in a 
scenario analysis. they will continue this treatment according to the Dutch clinical guidelines. 
• Patients, who do not respond to a TCA. will be switched to another type (class) of TCA. 
• The patients who experience a relapse or recurrence after termination of an antidepressant 
treatment. consist of two subpopulations: l) patients who would also have experienced a relapse 
or recurrence on prolonged treatment; and 2) patients who would have not experienced a relapse 
or recurrence on prolonged treatment. Both groups of patients will be treated with the initial 
antidepressant that resulted in the response. The first group of patients will not respond to this 
medication; the second group of patients will have a probability of response corresponding to an 
initial antidepressant treatment. 
• Patients receiving prolonged treatment with the first TCA who experience a relapse or recurrence 
will be switched to another TCA. The probability of a response will correspond to the probability 
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of response to a first-line antidepressant treatment. Patients receiving prolonged treatment with the 
second class ofTCA who experience a relapse or recurrence will be hospitalised. 
Table I. Clinical data and sources. 
Clinical data 
SSRI 
Response to 1-line treatment 
Response to 2-linc treatment 
Relapse during continuation treatment 
Moon 
Recurrence during maintenance treatment 
Mean 
TCA 
Relapse during continuation treatment 
Recurrence during maintenance treatment 
Relaps.e after termination of medication 
Mean 
Recurrence aftcrtcrminntion 
Mo<m 
Response to hospitalization 
TCA 
SSRI 
TCA 
SSRI 
Moan 
Transition probability 
0.600 
0.300 
0.016 
0.040 
0.028 
0.036 
0.049 
0.042 
0,092 
0.018 
0.112 
0.100 
0.106 
0.084 
0.131 
0.108 
0.581 
0.643 
0.612 
0.627 
0.616 
Clinical and Economic Outcomes 
Reference 
Nuljten, 1995 
Nuljten. 1995 
Montgomery, Dunbar 1993 
Montgomery. Rasmussen 1993 
Montgomery. Dunbar 1993 
Momgomery 1988 
Nuljten 1998 
Frank 1993 
Montgomery 1993 
Montgomery, Rasmussen 1993 
Montgomery. Dunbar 1993 
Montgomery 1988 
Gcrctscggcr 1995 
Gcrctscggcr 1995 
Gershon 198 J 
Clerc 1994 
The clinical outcomes for the model were defined as Time without depression (TWD) and QAL Ys; 
the economic outcomes were the direct medical costs and costs resulting from lost productivity. 
The primary perspective of the study was that of the third-party payer, while the secondary 
perspective was that of the society in 1999. From a scientific point of view. the society perspective 
should include all indirect costs. including the costs of time spent. However. the Dutch 
pharmacoeconomic research guidelines state that .. the focus is on production losses, when including 
indirect costs".52 The costs were determined from the perspective of the Dutch society in 1999. 
Utilities and costs were discounted at 4% according to the Dutch pharmacocconomic research 
guidelines. 
The cost assessment was based on the assignment of costs to defmed health states associated with a 
cycle time of 2 months. The direct medical cost of each health state was determined by the healthcare 
utilisation associated with each health state, including medication. consultations, procedures and 
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number of days of hospitalization. The cost resulting from lost productivity was based on working 
days lost over a period of2 months. 
Table H. Utilities for the health states. 
Health state 
Tre:1nncnt depression: SSRI 
Trcanncnt depression TCA 
In remission SSRL prolongation 
In remission TCA. prolongation 
In remission. off drug therapy 
Severe depression 
Data Sources 
Utility 
0.70 
0.64 
0.80 
0.72 
0.86 
0.30 
Different types of data can be distinguished in modelling studies: 
• probabilities of clinical events. generally arc beyond the control of the physician (e.g. probability 
of relapse. recurrence and response): 
• probability of therapeutic choices (e.g. therapy after a relapse or during continuation 
treatment or maintenance treatment). 
• utilities of different Markov health states; and 
• direct medical costs. consisting of the units of healthcare utilisation and their prices/tariffs. 
Costing of direct medical costs involves estimating the number of units of healthcare utilisation 
and multiplying this by the corresponding prices/tariffs. Costing for lost productivity involves 
estimating the number of working days lost and the opportunity cost to society. 
The probability of clinical events and therapeutic events was based on published literature (Table I). 
The response to first- and second-line antidepressant medication was derived from a study by 
Nuijten.ss The percentage of patients relapsing during continuation treatment with an SSRI was based 
on the average percentages of patients relapsing in two randomised double-blind clinical trials by 
Montgomery and Dunbar 32 and Montgomery and Rasmussen:~5 The percentage of patients not on 
continuation treatment who relapsed was based on the percentage of patients receiving placebo who 
relapsed in those clinical studies. 
The percentage of recurrence during a maintenance treatment with an SSRI was based on the 
percentage of recurrence in the two clinical studies published by Montgomery in 1988 46 and 1993.32 
The percentage of recurrence among patients not on maintenance treatment was based on the 
percentage of recurrence among placebo-treated patients in these clinical studies. The relapse rate for 
patients treated with TCAs was derived from a literature review by Nuijten56 which was based on data 
from various studies. 59 60 61 
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Table III. Cost data and sources. 
Costs 
Direct costs (NLG) Costs"' Range Reference 
SSRis 2.60 Ta'Xe Nov. 1999 
TCA- amytripti1ine 0.25 Ta'Xe Nov. 1999 
TCA- :mafranil, clomipramine 0.94 
Consultation 40.00 COTG '99 
Per diem 289.00 280-295 COTG "99 
Cost of lost productivity Reference 
Working days lost (days) 5.2 Broadhead 
(over two months) 
GDP per capita (NLG) 42729 CBS.1999 
GDP per capita per working day 244 CBS, 1999 
"':drugs: daily treatment cost>. 
The Actuarial Method was used to adjust all relapse and recurrence percentages to transition 
probabilities corresponding to a cycle time of 2 months.6z It was remarkable that the transition 
probabilities for relapse and recurrence for patients on placebo were similar in both studies. 
The utilities for the different health states were derived from a study by Revicki (Table II).63 All 
utilities were determined for ambulatory treatment. We assumed that the utility for the health state 
corresponding to hospitalisation was equal to the utility for severe depression, as an assumption was 
validated by expert opinion (DA Revicki. MEDTAP International. Bethesda. Washington. USA). 
The medical resource use for each state was abstracted from published literature (Table III).&+ The 
treatment patterns and resource utilisation were adjusted for 1999 values and validated by expert 
opinion. The associated 1999 unit costs of medical resources used (e.g .. professional services. 
healthcare services) were derived from official Dutch tariff lists of allowable reimbursements (Taxe: 
November 1999) and other sources [College Tarieven Gezondheidszorg (CTG, 1999). central tariffs in 
healthcare for consultations and procedures. Utrecht.]. The daily treatment cost (DTC) of a treatment 
with an SSRI was an average of the DTCs of the four most prescribed SSRis in The Netherlands 
(IMS). Dosages of drugs were derived directly from the official Dutch Formulary 
(Farmacotherapeutisch Kompas) (Table III). The base-case analysis was based on the cheapest TCA. 
amytriptiline. 
Costs due to lost productivity in this model were based on the value of working days lost, according to 
the gross domestic product (GDP) per-capita figure. Because lost productivity is frequently excluded 
from pharmacoeconomic analyses. it was difficult to fmd sources directly applicable to The 
Netherlands for this study. and so we used data from the study by Broadhead et aJ.14 We assumed that 
lost productivity for depressed patients is consistent. whether they are treated with an SSRI or a TCA. 
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When the results of this study were adjusted to our cycle time of 2 months. depression was found to 
increase the number working days lost to 5.8 days over a period of 2 months. The cost of lost 
productivity resulting from hospitalisation was calculated by assuming 100% productivity losses. 
Assessment of lost productivity was based on the friction method: the Dutch pharmaco-research 
guidelines recommend the use of the Friction Cost Method over the more traditional Human Capital 
Approach (HCA).52 The use of an appropriate method of assessment is especially relevant for chronic 
disease like depression. where the use ofHCA would have lead to an overestimation of the cost oflost 
productivity. 
Sensitivity analyses were performed on the relevant variables in our model. Sensitivity analyses were 
performed on relapse and recurrence probabilities under prolongation treatment because both figures 
were derived from a limited number of clinical trials with limited external validity. The response rate 
to hospitalisation was based on the average of the response rates reported in studies that assessed the 
efficacy of intramural administration of antidepressants.65 66 67 The lower and upper ranges were based 
on the minimum and maximum values that we found in the literature (Table I). In addition. we 
performed sensitivity analyses on the DTC for a TCA and the per diem. The DTC for TCA was varied 
bet\Veen minimum and maximum values: the per diem was varied bet\Veen plus and minus 10%. 
Sensitivity analysis is based on the modification of the basic clinical and economic estimates of input 
variables over a plausible range of values to evaluate the effect on study results of alternative 
assumptions for uncertain variables.6s In contrast. scenario analysis is based on the modification of the 
underlying therapeutic strategies of the model. In this study. a scenario analysis was performed on the 
prolongation of a treatment with a TCA assuming full compliance. Another scenario analysis was 
performed on an extension of the continuation treatment as recommended by the guidelines to an extra 
year of maintenance treatment. Finally a scenario analysis was performed on compliance during 
prolonged antidepressant treatment with an SSRI. 
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Table IV. Results: discontinuation ofTCAs. 
Outcome Costs Time without 
(l'LG) depression 
Direct Cost of lost Total % 
Costs productivity Costs 
Base case: 9 months 
-Prolongation 1276 304 1580 96.9% 
-Termination 474 909 1383 86.4% 
- Difference 803 -606 197 10.4% 
- ICR (Cost/month) 854 210 
- ICR (Cost/QAL Y) Termination Termination 
Dominant Dominant 
Scenario: 2Imonths* 
- Prolongation 3831 1512 5343 94.9% 
-Termination 4681 4282 8963 82.9% 
- Difference 
-850 -2770 -3620 12.0% 
- ICR (Cost/month) Prolongation Prolongation 
Dominant Dominant 
- ICR (Cost/QAL Y) Prolongation Prolongation 
Dominant Dominant 
*:discounting at 4%. 
Table V. Cost distribution of direct medical costs: discontinuation ofT CAs. 
Outcome Costs (NLG) 
Base case: 9 months 
- Prolongation 
-Termination 
- Difference 
Scenario: 21 months* 
- Prolongation 
-Termination 
- Difference 
36 
Drugs 
736 
75 
661 
1514 
178 
1336 
Consultations 
309 
53 
255 
642 
129 
513 
Hospitalisation 
232 
346 
-114 
1675 
4374 
-2698 
Total 
1276 
474 
803 
3831 
4681 
-850 
QALY 
Months Years 
8.72 0.60 
7.78 0.61 
0.94 -0.01 
17.09 1.31 
14.92 1.31 
2.17 0.00 
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RESULTS 
The Markov model was built using the decision-tree software (DATA™ 3.5 by TreeAge Software, 
Williamstown. MA. 1996). The model was run to giver an expected value for TWD. QAL Ys and cost 
per patient. Sensitivity analyses were performed on the main clinical and economic input variables in 
order to ascertain the robustness of the conclusions. The key results of the analysis are shown in Table 
IV. and show that the use of guidelines (prolongation treatment) increases the total direct medical 
costs substantially from NLG 474 to NLG 1276. while it reduces substantially the cost of lost 
productivity from NLG 909 to NLG 304. 
Table VI: Results: continuation of TCAs. 
Outcome Costs Time without QALY 
Base case: 9 months 
~ Prolongation 
~Termination 
~ Difference 
- ICR (Cost/month) 
~ ICR (Cost!QAL Y) 
Scenario: 21 months* 
~Prolongation 
~Termination 
~ Difference 
~ ICR (Cost/month) 
- ICR (CostiQAL Y) 
*:discounting at 4%. 
(l<LG) 
Direct 
Costs 
1278 
474 
804 
852 
Termination 
Dominant 
3801 
4681 
-SSO 
Prolongation 
Dominant 
Termination 
Dominant 
Cost oflost 
productivity 
302 
909 
~607 
1415 
4282 
-.2867 
Total 
Costs 
1580 
1383 
197 
209 
Termination 
Dominant 
5216 
8963 
-3747 
Prolongation 
Dominant 
Termination 
Dominant 
Table V1I: Cost distribution of direct medical costs: continuation ofTCAs. 
Outcome 
Base case: 9 months 
~ Prolongation 
~Termination 
~ Difference 
Scenario: 21 months* 
~ Prolongation 
-Termination 
~ Difference 
Costs (NLG) 
Drugs 
736 
75 
662 
1539 
178 
1361 
Consultations. 
309 
53 
256 
663 
1.29 
534 
Hospitalisation 
346 
-114 
1599 
4374 
~.2775 
depression 
% 
96.9% 
86.4% 
10.5% 
95.2% 
82.9% 
1.2.3% 
Total 
1.276 
474 
803 
3801 
4681 
~880 
Months Years 
8.72 0.59 
7.78 0.61 
0.94 ~0.02 
17.13 1.27 
14.92 1.31 
.2..2.2 -0.04 
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Table 'VIII. Sensitivitv analysis: base case analysis (continuation treatment). 
Sensitivity Range tCRw ICR~Tqtal cOJJts 
AnalysiJJ ~1cdical coSts 
Relo.pse 0.0160 Termination- Terminntion-
dominunt domimnt 
0.04 Termination- Termination-
dominant dominant 
Response hospitalisation 0.518 Termination- Termination-
dominant dominunt 
0.643 Termination- Termination-
dominant dominunt 
Per diem (NLG) 260 Tcnnination- Termination-
dominant dominant 
318 Termination- Termination-
dominant dominant 
DTC-TCA (NLG) 0.94 Termination- Termination-
dominant dominant 
No discounting 0% T crmination- Termination-
dominant dominant 
"': discowning at 4%. 
Table LX. Sensitivity analysis: scenario analysis (maintenance treatment). 
Sensitivity Range ICR:- lCR .. Total Costs 
Analysis Medical co~ts 
Relapse 0.0160 Prolongation- Prolongation-
dominant dominant 
0.04 Termination- Termination-
dominant dominant 
Recurrence 0.036 Prolongation- Prolongation-
dominant dominant 
0.04 Prolongation- Prolongation-
dominant dominant 
Response hospitalisation 0.518 Prolongation- Prolongation-
dominant dominant 
0.643 Prolongation- Prolongation-
dominant domim.nt 
Per diem (NLG) 260 Prolongation- Prolongation-
dominant dominant 
318 Prolongation- Prolongation-
dominant dominant 
DTC-TCA (NLG) 0.94 Prolongation- Prolongation-
dominant dominant 
No discounting 0% Prolongation- Prolongation-
dominant dominant 
"': discounting at 4%. 
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The use of the guideline increases TWD substantially from 86.4% to 96.9%, while it does not increase 
the number of QALYs (0.60 versus 0.61). This first incremental cost-effectiveness analysis 
( costiQAL Y) shows that the use of the guidelines is not cost-effective either from the third-party 
payer (medical costs). or from the societal perspective; termination of treatment is dominant versus 
prolongation. because prolongation increases the costs without an increase in QAL Y s. The results of 
the incremental cost-effectiveness analysis on TVVD are expressed in extra costs per extra month 
without symptoms of depression; the results vary from NLG 854 to NLG 474 for the third-party payer 
and society perspective. respectively. 
Prolonged treatment until 21 months (continuation treatment followed by maintenance treatment) 
reduces the medical costs from NLG 4.681 to NLG 3.831when compared with termination of 
treatment. Maintenance treatment increases TWD from 82.9% to 94.9%, while it does not increase the 
number of QALYs (1.31). Hence. maintenance treatment is cost-effective from both the third-party 
payer and societal perspective because prolongation decreases the costs without a decrease in QAL Ys. 
Table V provides a breakdown of direct costs by components: drugs. consultations and 
hospitalisations. As would be expected. the costs of drug therapy and associated extra consultations 
were higher for prolongation treatment. whereas the cost of hospitalisation is lower due to fewer 
relapses. Only an extension to a maintenance treatment is cost saving, since the higher drug and 
consultation costs are offset by the reduction in hospitalisation costs. 
Table X. Com2liance with SSRis: base case of9 months. 
Outcome Costs Time without QALY 
(1\'LG) depression 
Direct Cost of lost Total % Months Years 
Costs productivity Costs 
20% 
- Prolongation 634 788 1422 88.5% 7.96 0.61 
-Termination 474 909 1383 86.4% 7.78 0.61 
- Difference 161 -121 39 2.1% 0.19 0.00 
- ICR (Cost/month) 854 210 
- ICR (Cost!QAL Y) Tennination Termination 
Dominant Dominant 
80%* 
- Prolongation 1116 425 1541 94.8% 8.53 0.60 
- Tcnnination 474 909 1383 86.4% 7.78 0.61 
- Difference 642 -484 158 8.4% 0.75 -0.01 
- ICR (Cost/month) 854 210 
- ICR (Cost!QAL Y) Tcnnination Termination 
Dominant Dominant 
*:discounting at 4%. 
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Table VI and Table VII show the results of the scenario analysis, which assumes that treatment with 
TCAs will be continued after a response. The analysis shows that the 9-month results are still similar 
to the base-case analysis. Prolonged treatment until 21 months (continuation treatment followed by 
maintenance treatment) reduces the total costs slightly more than the base case analysis (NLG 3,747 
versus NLG 3.620). Table VII shows that cost savings result from a further reduction in 
hospitalisation costs (NLG 2,775 versus NLG 2.698). As would be expected, continuation of TCA 
treatment will lead to higher costs for drug therapy and associated extra consultations compared with 
discontinuation, but continuation will also reduce relapses and recurrences in responders to TCAs. 
which will lead to further reductions in hospitalisations and lost productivity and an increase in TWD. 
On the other hand, continuation with TCAs will not lead to a higher number of QAL Ys: Table II 
shows that the unfavourable side effect profile of TCAs is associated with lower QAL Ys for patients 
using TCAs either for acute treatment or prolongation treatment. 
Table VIII and Table IX show the results of the sensitivity analyses for respectively the base-case 
analysis (9-month treatment) and scenario analysis (maintenance treatment). respectively. The 
sensitivity analyses for the base-case analysis show that varying the variables within their range docs 
not change the outcome of our model, whereas sensitivity analyses for maintenance treatment show 
that the outcome of our model is not sensitive to most of the variables other than the relapse rate 
during prolongation of treatment. When the analysis is based on the maximum values, termination of 
treatment becomes more favourable than maintenance treatment. 
Tables X and XI show the relationship between the expected outcomes and compliance with SSRI 
treatment when TCAs are discontinued after a response (base-case analysis) and compliance is varied 
between 20% and 80%. These results show that the lower compliance substantially reduces potential 
cost-savings of prolongation treatment. especially in the maintenance-treatment scenario. Although 
compliance does not have an impact on QAL Ys. lower compliance substantially reduces TWD. 
DISCUSSION 
This study examined the cost-effectiveness of continuation treatment with SSRis compared to no 
preventive treatment in order to assess the appropriateness of clinical guidelines for continuation 
treatment. In our model, the use of the NHG guideline recommending a continuation treatment for 
9 months was not cost-effective. when compared to no prolongation. in responders to an initial 
treatment. A scenario analysis revealed that only continuation of treatment followed by maintenance 
treatment with SSRis was favourable. both in terms of cost and effect. in the treatment of patients with 
depressive disorders in a Dutch setting. This scenario analysis showed that an extension of the 
continuation treatment will decrease the medical costs and the costs of lost productivity compared 
with no prolonged treatment. while it will increase the TWD. Sensitivity analyses showed the 
robustness of our conclusion. Although continuation of TCA treatment will lead to cost-savings, the 
use of TCAs will have a negative impact on QAL Ys due to their unfavourable side-effect profile of 
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TCAs. In addition, published data show that compliance with TCAs is low in real practice. which 
justifies our base-case analysis in which only continuation with SSRls is considered. 
Table XI. ComE:liance with SSRis: maintenance of 12 months. 
Outcome Costs Time QALY 
(NLG) without 
depression 
Direct Cost of lost Total % Months Years 
Costs productivity Costs 
20% 
-Prolongation 3670 1227 4789 84.0% 17.64 
-Termination 4681 4282 8963 82.9% 14.92 
- Difference 
-I Oil -3055 -4175 15.1% 2.72 
- ICR (Costfmonth) Prolongation Prolongation 
Dominant Dominant 
- ICR (Cost/QAL Y) Prolongation Prolongation 
Dominant Dominant 
80%* 
-Prolongation 3277 664 3506 91.1% 19.13 
- T crmination 4681 4282 8963 82.9% 14.92 
- Difference 
-1404 -3618 -5457 23.3% 4.21 
- ICR (Cost/month) Prolongation Prolongation 
Dominant Dominant 
- ICR (Cost/QAL Y) Prolongation Prolongation 
Dominant Dominant 
*: discounting at 4%. 
Although the use of the guideline increases TWD substantially, it does not increase the number of 
QAL Ys. The values for utilities (Table II) explain this outcome: the use of an antidepressant reduces 
the QAL Ys of health states in patients v.rithout depression because of side-effects. Although 
prolongation treatment reduces relapses and recurrences. and consequently overcomes the reduction in 
QALYs resulting from depression, this gain is apparently not sufficient to offset the lower utilities in 
treatment in responders. 
The results of any modelling exercise need to be treated with some degree of caution. It is worthwhile 
to keep in mind that the purpose of pharmacoeconomic studies is to inform or aid in decision-making 
and not to usurp the relationship between patient and physician or to interfere with the physician's 
treatment decision based on his assessment of the patient's clinical status. This model adheres to this 
tenet. Decision-analytic teclmiques. upon which our Markov model is based, have several wealmesses. 
Among them is the fact that the results of our literature review do not necessarily represent real 
clinical practice, since much of the literature examined was based on data from clinical trials. Data 
from clinical trials does not necessarily have a high degree of external validity because the results are 
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often contingent upon protocol adherence, which is not representative of treatment modalities outside 
the trial setting. 
We analysed lost productivity in our model. The use of lost productivity in pharmacoeconomic 
studies remains controversial. The Australian Guidelines did not see them as central to 
pharmacoeconomic analyses and recommended that they be reported only in rare instances.69 
However. more recently the Canadian guidelines seem willing to accept estimates of lost productivity 
from the societal perspective as long as the source of the cost data is documented and a sensitivity 
analysis has been performed.70 The recent Dutch pharmaco-economic research guideline also 
recommends the inclusion of costs of lost productivity associated with working days lost 52, but based 
on the so-called friction method: the period over which the production losses are calculated is limited 
to the friction period. which is the period between the start of absence and the actual moment of 
replacement. This period is currently estimated at 3 months on the average. We used the Friction Cost 
Method in order to avoid any overestimation of the impact of costs of lost productivity caused by 
prolonged treatment. We only included indirect costs due to lost productivity. The inclusion of all 
indirect costs would make results less credible. There is no consensus yet. among scientists on how to 
deal with time spent on unpaid activities and time spent by caregiver among scientists. In addition. the 
healthcare decision maker tends to be only interested in medical costs, while general policy makers 
may also be interested in indirect costs caused by productivity losses. Therefore. the current analysis 
can be considered an underestimation of the true benefits to society of prolongation of antidepressant 
medication. 
The results of this study confirm that the use of maintenance therapy with SSRls in the treatment of 
depressive disorders is justified. A number of studies. which vary from modelling studies to 
retrospective database analysis. all have shov.rn that the higher drug costs of a maintenance treatment 
with SSRis are offset by savings in other medical costs. mainly hospitalisation. In a study by 
Hatziandreu. a model was constructed that followed two cohorts of 35-year-old women at high risk for 
recurrent depression over their lifetimes.27 The authors conclude that a long term maintenance 
treatment with sertraline appears to be a clinically and economically justified choice for patients at 
high risk of recurrent depression, which corresponds with findings of studies by Boyer 71 and 
Kamlet.29 In addition Nuijten,5S using a Markov process analysis, showed that total costs associated 
with a 1-year period of maintenance therapy for depression in Germany were 33% lower with the 
SSRI citalopram than with TCAs, and again, relapse rates had a large impact on the model outcomes. 
However. most of those studies compared initial treatment with SSRI and initial treatment with TCA. 
assuming continuation of SSRI and discontinuation ofTCA. Hence, those studies compared both type 
of drug and duration of treatment. In our study we compared prolongation and termination in 
responders to an initial treatment with SSRis. This approach allowed us to evaluate the cost-
effectiveness of a prolonged treatment alone. which is a sounder scientific design. 
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The increased patient tolerability of SSRls clearly makes them ideal agents for the long-term 
maintenance phase oftreatment.2° Nevertheless. a study by Quik and K.leintjens n showed that Dutch 
patients in the GP setting do not receive insufficiently long antidepressant therapy, including with 
SSRis. Another Dutch study by De Waal, which showed that all patients using SSRis, received the 
minimal effective dosage. may indicate that the insufficient treatment period may not be a result of the 
unfavourable safety profile of SSRls, but of other reasons. For example. physicians may not always 
communicate the importance of continuing antidepressant treatment to symptom-free patients, who 
may consider themselves as completely recovered. Hence. practice guidelines based on research may 
not be applicable to real-world practice. Important feasibility issues such as constraints faced by 
practitioners, the concerns of patients, and the limitations of the healthcare system need to be 
considered. In a supplementary analysis we showed that compliance is a main feasibility constraint 
from a health-economic perspective. The validity of practice guidelines ranks as the most critical 
attribute. even though it may be the hardest to define and measure. Conceptually, practice guidelines 
are valid if they lead to the health and cost outcomes projected for them while other parameters remain 
equal. A prospective collection of health economic data and utilities in a naturalistic setting may 
validate the projected health-economic outcomes of our model and identify and assess the critical real-
life issues such as non-compliance. 
CONCLUSION 
The results of this cost-effectiveness study show that clinical guidelines for continuation treatment are 
not justified from a health-economic perspective. A scenario analysis showed that extension of the 
continuation treatment to a maintenance treatment might substantially increase the cost-effectiveness 
of the treatment guideline. The increased costs for antidepressant medication are offset by the 
increased effectiveness and the reduction of total costs. Sensitivity analyses confirmed the robustness 
of these findings. 
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The Selection of Data Sources for Use in 
Modelling Studies 
SUMMARY 
Economic analysis has become increasingly important in hcalthcarc in general, and particularly with 
respect to pharmaceuticals. Therefore, it is vital that the methods used in such evaluations are carefully 
scrutinised and refined. However. guidelines contain only a limited number of recommendations for 
the use of secondary data in modelling studies. In this manuscript. the selection of data sources in 
modelling studies will be addressed. The objectives of this manuscript are as follows: (i) to present a 
general strategy on how to determine the appropriateness of a data source for a model and (ii to 
present recommendations on a transparent reporting format for the selection of data sources. 
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INTRODUCTION 
Economic analysis has become increasingly important in healthcare in general, and particularly with 
respect to phannaceuticals. In future. decisions over the reimbursement of phannaceuticals are likely 
to require information on cost-effectiveness in addition to registration requirements. Because 
economic evaluation will play a fundamental role in healthcare decision-making. it is vital that the 
methods used in such evaluations are carefully scrutinised and refined. If economic analysis is to play 
an important and useful role in the allocation of scarce healthcare resources. then such analyses must 
be performed properly and with care. 
In order to increase the scientific quality and integrity of pharmacoeconomic studies. national 
guidelines have been developed by various countries. The intent of the guidelines is to provide 
guidance to those conducting studies. and those using them. by laying out a general "'state of the art" 
regarding methods, and by providing specific methodological advice on many matters. Australia was 
the first country to develop and implement guidelines for the economic evaluation of pharmaceuticals. 
Draft guidelines were released in 1990. and these were revised and implemented in 1992 and 1995.1 2 
Canada became the second country to release national guidelines in 1994.3 
\Vhile these guidelines extensively describe issues like comparator. perspective and type of analysis. 
they contain only a limited number of recommendations for data management. The Ontario 4 and 
Australian guidelines are the most prescriptive on the issue of data capture. The Ontario guidelines 
recommend the use of databases and meta-analysis of randomised clinical trials. The Australian 
guidelines recommend the use of results from randomised clinical trials. supplemented by additional 
information. The Canadian guidelines do not specifically address this issue, but appear to favour data 
from clinical trials. 
In practice. it is not always possible to derive information from scientifically sound prospective 
studies. In the absence of clinical trial data, there are no generally accepted methods describing how to 
collect data and validate data for local practice patterns. Because the guidelines were written mainly 
for studies based on primary data derived from Phase III trials. requirements for data management, 
especially data sources. may indeed seem redundant. 
Although the revised Australian guidelines recognise the need to model an economic evaluation under 
certain circumstances. the principal focus is still on the quality and reporting of randomised clinical 
trials, without recommendations for data management in modelling studies.2 Data management is a 
straightfo!VIard process. based on usual clinical trial procedures: the data on effectiveness and costs 
will be collected alongside a clinical trial. These guidelines may also be applied to naturalistic studies. 
which are also based on primary data. However. there are no recommendations on how to collect data 
when an analysis necessitates the use of secondary data. Even a phannacoeconomic analysis based on 
a standard Phase III trial may have to rely on secondary data in order to incorporate patients with 
treatment failures, who in a clinical trial are usually lost to follow up. but may be the main cost drivers 
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from an economic viewpoint. 
In most clinical trials. economic data are not collected alongside the study. Even when they are. the 
data may need to be projected to populations. time periods. or settings that were not observed in the 
clinical study. In these cases. decision-analytic models may provide some of the missing information. 
Decision analysis is an explicit. quantitative, prescriptive approach to medical decision-making and 
allows both clinical and economic consequences of medical actions and attitudes to be analysed under 
conditions of uncertainty.5 The model resulting from the decision analysis must correspond. as much 
as possible. to the real life situation of the disease and should reflect actual treatment patterns with 
input values (probabilities and items of healthcare utilization) deviating as little as possible from 
population values. Models may take the fonn of simple decision-analytic trees or they may be very 
complex Markov models of underlying disease processes and treatments. 
The subject of this manuscript is the selection of data sources, and issues relating to this subject. Those 
issues are: 
• classification of data being used in modelling studies 
• the various types of data sources 
• a general strategy on how to determine the appropriateness of a data source for a model 
• recommendations. 
THE SELECTION OF DATA SOURCES 
Data management can be categorised into the selection of data sources and methods of data 
processing. The reliability of the estimates depends on the choice of the data sources (selection 
criteria, external validity) and data processing (calculation of mean or median. Mantcl-Haenszel 
method. actuarial method). Hence, there may be a potential bias. both in the choice of the data sources 
and the methods of data processing. 
Classification of Data 
The data may come from a variety of sources and are subject to varying degrees of uncertainty. Data 
sources for the variables being used in a model may be clinical trials. literature (e.g. meta-analysis). 
databases. medical records, Delphi panels and/or official tariff lists for healthcare use. These data 
sources will yield. for each variable. a fixed input value and a range. The standard analysis will be 
based on the fixed input value for all variables. The range of each variable is then used to determine 
the sensitivity of the outcome to the analysis. when the input value is varied within its range. The costs 
are based on units of healthcare utilisation and tariffs/prices. Effectiveness is based on clinical 
outcomes (mortality), the time without symptoms/toxicity (TWiST concept) or utilities. 
Three different types of data can be distinguished in modelling studies: 
1. Transition probabilities. These are out of the control of the physician and are derived from 
clinical measures. Examples of transition probabilities are response to a treatment, relapse 
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after a previous response, and mortality. 
2. Treatment patterns. In addition to standard therapy being the first choice of therapy for the 
total cohort entering the modeL the following decisions on the choice of therapy may occur in 
the model: (i) therapy after a response (termination of treatment or continuation of treatment) 
(ii) therapy after a treatment failure in response to the initial treatment: and (iii) therapy after a 
treatment failure, for example, a change to second-choice therapy. 
3. Costing infonnation. Costing involves estimating the units of healthcare utilisation used and 
their prices/tariffs {product of unit and price). 
Assessment of Data Sources 
This section discusses the advantages and disadvantages of the different data sources. 
Clinical Trials 
Because a clinical trial is designed for registration purposes. the objective of a clinical trial is to show 
a statistical difference between the study drug and the comparator, which requires a high internal 
validity in order reduce the impact of confounding variables. Therefore. clinical trials have strict 
inclusion and exclusion criteria, and treatments arc protocol driven. which may lead to the 
overestimation of units of healthcare used. Consequently, clinical trials have a low external validity. 
which means both clinical and econon:ric outcomes may not be typical and do not correspond to usual 
practice. Hence it should always be considered that, because of its restriction on external validity, the 
outcomes may not be representative of a target patient population who are going to usc the drug. 
In addition. a clinical trial is not designed for pharmacocconomic purposes and the units of healthcare 
that are used and collected may not be complete when using these data retrospectively. Additional 
limitations for the collection of units of healthcare utilisation arc the fact that: (i) since clinical trials 
are only driven to prove differences in efficacy, it is difficult to measure significant differences in 
healthcare resources used: (ii) the units of healthcare used are country specific and the duration of 
follow-up of clinical trials is too limited for pharmacocconomic purposes. Phannacoeconomic 
analyses are usually concerned v.rith examining the discounted costs and benefits beyond the duration 
of patient follow-up, for example, when estimating the cost per life-year saved. 
Meta-Analysis 
A meta-analysis may be used, in particular, in the determination of transition probabilities (based on 
efficacy measures for initial treatment), when the comparator in a phannacoeconomic analysis is not 
the same as the comparator in a clinical trial or when clinical trials consist only of 1 ann (e.g. 
oncological trials). For treatment failures, a meta-analysis may be the preferred first-choice option. If 
we assume that clinical outcomes are not country-specific. a meta-analysis need not be limited to trials 
running in the study country. 
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The risk of meta-analyses is that they might be subject to publication and inclusion bias. particularly if 
criteria are chosen in order to produce the intended results. Although various tests for bias can be 
carried out. there is no guarantee that a meta-analysis has not been performed to give more scientific 
weight to what amounts to selective reporting of clinical trials. This problem is further complicated by 
the fact that there may be selective publication of the result of clinical trials. A meta-analysis based on 
a small number of trials should be interpreted with caution.6 "When there is too much heterogeneity. 
because of to differences in design or study population. studies may not be combined. The use of 
meta-analysis depends on the existence of relevant literature on treatment failure after the initial 
treatment. 
Finally. because a meta-analysis is only a form of quantitive review of individual trials, it has the same 
limitations mentioned in the section on ''"Clinical Trials". 
Databases 
A database may not be a suitable source for guiding decisions in healthcare since so much of the data 
it contains are not scientifically valid. Although databases may contain a lot of detailed information on 
both clinical and economic outcomes. the format of this information has to fit the structure of the 
model. However, the majority of the existing databases have not been developed for economic 
evaluations. 
The 2 different databases that can be distinguished are claim databases and clinical outcomes 
databases. In the case of claim databases. the objective is to collect. for administrative purposes, all 
data on healthcare resources used: in clinical databases. the objective is to measure clinical outcomes 
for medical or scientific purposes. 
1) Claim Databases 
Claim databases have the advantages of a large number of patients and a high external validity. 
However, these databases usually have little or no information on clinical outcomes. Clinical tests may 
have been recorded for reasons of reimbursement, while the outcomes of these tests are usually not 
registered. The amount of healthcare resources used may be recorded. but often it is limited to the 
outpatient setting only. whereas hospitalisation is usually the main cost driver. In contrast. hospital 
management information systems only contain information limited to inpatient care. 
Studies based on databases that are designed to compare different treatments. are rarely sufficient to 
draw defmitive conclusions about the relative effectiveness of treatments because. like other non-
randomised studies. the estimates are susceptible to unrecognised underlying biases that can render the 
conclusions invalid. Because of the retrospective nature of the review, patients may have been 
nonrandomly assigned to a treatment and it is possible that some differences observed resulted from 
differences between patient groups. A related limitation is the absence of a control group to which 
people were randomly assigned (i.e. those who did not receive the centre's programme). In the 
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absence of a control group. we cannot rule out the possibility that the observed improvements were the 
result of chance or statistical regression to the mean. 
Another potential source of bias is the "clinic patient bias""7 • which is a variant of prevalence-incidence 
variance.~ This bias occurs when only patients who had at least 2 measurement points (e.g. clinical 
visits) during the follow-up period arc included in the analysis. This type of database abstraction will 
miss any cases in which. for instance. adverse drug reactions resulted in the death of the patient or 
discontinuation of therapy after only a single visit. 
The patients in databases usually are labelled according to existing medical classification systems. 
such as the International Classification of Disease-91h revision-Clinical Modification (ICD-9-IM) or 
diagnosis-related groups (DRGs) for inpatient care. Because of financial incentives. patients may be 
labelled with a different ICD-9 code or more severe DRGs. Another problem associated with diagnosis 
is the lack of consensus on defining criteria for a pathology. and the overlap of symptoms. For 
example in psychiatric disorders patients with depression and patients with generalised an.'Xiety 
disorder frequently have overlapping characteristics. which makes it difficult for a physician to 
clinically distinguish among these disorders. Hence. a subpopulation of patients with ICD-9-IM code 
for depression may include patients with generalised an.'Xiety disorder because of inaccurate diagnosis. 
The population in a claims database may not be representative of the overall population and may 
contain a biased sample of patients~ for example. in the US. Medicare databases will only consist of 
the elderly. while Medicaid databases will only contain patients with a low sociodcmographic status. 
2) Clinical Databa~es 
Clinical databases contain mainly clinical outcomes. but usually no. or incomplete. information on 
healthcare use. The external validity may be limited because of bias resulting from the site(s) of the 
data collection. the speciality of the physicians and the primary objective of the database 
implementation. which may vary between a prospective clinical study and evaluation of a healthcare 
programme. Prospective studies have the same limitations as clinical trials (section on .. Clinical 
Trials""). while for a healthcare programme. the limited choice of therapy will reduce the external 
validity. 
The clinical outcomes should have enough external validity in order to be used as an effectiveness 
measure or to be extrapolated to effectiveness measures Direct relevant outcomes (TWIST. QUAL Y s 
or Quality of Life) for pharmacoeconomic studies are usually not included. The sample size in a 
clinical database is generally lower than in a claims database. Hence. the measurement of statistical 
significance will be more difficult. 
Medical Records 
There are a number of shortcomings and limitations to the use of medical records: when switching 
between inpatient and outpatient care. different medical records have to be used. For instance. medical 
records of general practitioners (GPs) can be used until a patient is hospitalised. Although after 
52 
The selection of data sources 
hospitalisation, a report of the main events will be sent to the GP, medical hospital records still need to 
be accessed. \Vhilc databases yield information that can be directly entered into statistical data 
processing sofuvare, information from medical records cannot be entered directly and, as a result, data 
entry can be time consuming. Access to medical records may be complicated in many countries 
because oflcgislation associated with privacy protection. 
Delphi Panel Techniques 
The usc of expert opinion is appropriate in situations in which there is little or no published material in 
a particular area. or in which the results of a thorough literature review or meta-analysis are considered 
unreliable,9 conflicting,10 or insufficient to cover the requirements of a study. Delphi panels operate in 
stages or rounds, in an effort to obtain a convergence of opinion in a particular area. Conventional 
Delphi panels must go through at least 2 rounds, and typically go through three to four stages of data 
collcction.11 
The second distinct feature is that in the classic Delphi there is no face-to-face contact between the 
respondents. although there may be face-to-face contact between the investigator and the respondents. 
That is, all responses by panellists are anonymous to other panellists. The rationale for this is that 
respondents will not be intimidated or dominated by other respondents. This is a particular concern in 
the healthcare profession, 11 where there is a hierarchical structure in healthcare delivery and seniority 
dominates most hcalthcare activities. Along with the questionnaire, experts may be provided with a 
literature review or seed algorithm in an effort to frame their responses. 
There are several methodological weaknesses inherent in the process described above. As the 
techniques seek to quantify qualitative information, compromises have been made between scientific 
rigor and the need for structured information in certain areas. The main areas of weakness are as 
follows. 
l. A problem related to the iterative process in Delphi method is the potential for experts to drop out 
following the first round. This behaviour may lead to a response bias if the attrition rate is 
substantial. 
2. Expert opinion can be used as a structured way to include expert opinion about cost-effectiveness 
of treatments. However, there is variability in the way this is carried out and the results can be 
strongly influenced by unduly favourable or negative estimates being included. 
3. In the pharmacoeconomic studies reviewed there were no explicit criteria for the selection of 
experts for participation in the studies. 13 Several of the studies did not fully justify the selection of 
experts or even indicate the number of panel members. In section on "Recommendations", a 
number of selection criteria for the members of a Delphi panel will be presented. 
4. The impact of outliers is relatively high when using 10 members. which is considered as an 
appropriate sample size. 13 The statistical error resulting from the low sample size may lead to a 
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high standard deviation and the impact of an outlier on the fixed input value may be significant. 
leading to a large difference with the real population mean. 
5. The use of a "physician-expert panel" to estimate resource use, while common. carries the risk that 
respondents may give inaccurate estimates or specify the resources required for ideal care, rather 
than that provided in practice. Physicians may adjust estimations based on other estimations. 
because they do not want be outliers. In addition. physicians may overestimate variables related to 
the success of their treatment (for example. response rates. mortality, complications. adverse 
events). and also underestimate variables related to healthcare use, in order be more efficient. 
Other Data Sources 
Drug textbooks may yield information on dosages of drugs. drug prices and reimbursement 
percentages. Official tariff lists from health insurance companies contain information on tariffs for 
other medical costs (procedures. consultations and hospitalisation). Financial departments of particular 
institutions may yield information on costs from the provider's perspective. 
GENERAL STRATEGY 
To illustrate the application of a general strategy. a Markov model is used and applied to the economic 
outcomes of maintenance treatment with selective serotinin reuptake inhibitors (SSRis) as the first-
choice therapy for depression over a 1-year follow-up period. The general structural details of the 
Markov depression model have already been described in a previous paper. 14 and the specific details of 
the model with respect to depression are shown in figure 1. This model defines 4 mutually exclusive 
states: 
• no depression 
• mild depression 
• severe depression 
• chronic depression . 
The patients' progression through these states is divided into 6 cycles of 2 months each. which closely 
approximates the time of the sequential therapeutic stages. Chronic depression represents an 
absorption state and after entering this state a patient remains there. The transition probabilities 
between the states arc based on response rates to treatment and relapse rates after termination of 
treatment. This information was obtained from published literature values and current clinical practice. 
The cost assessment was based on the assignment of a fixed cost to each health state. which depends 
on the choice of therapy. Further details of the sources for the clinical and economic data. with respect 
to depression. are given in a previous paper.l4 
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Initial Medication 
Transition Probabilities 
The probabilities for the initial transitions in a model usually correspond with the efficacy measures 
derived from a clinical trial comparing treatment with the new drug versus placebo or another drug 
therapy. In the model. the transition probabilities for the comparative treatment may be derived from 
the clinical trial if the chosen comparator for the phannacoeconomic study corresponds to the 
comparator in the clinical trial of the new drug. \XIhen the comparator in the clinical trial is another 
drug or placebo, the transition probabilities for the phannacocconomic comparator need to be derived 
from published literature. 
Figure 1. Markov model for depression used in the present study. 
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Because, in this case. the transition probabilities for the comparator are derived from a different data 
source. any dissimilarity in patient populations and protocol procedures that lead to a bias has to be 
controlled. For example. in the antidepressant model. the first option was to base the transition 
probabilities to the health state "no depression'" on the response rates for citalopram and tricyclic 
antidepressant (TCA) recorded in a clinical trial. Because the clinical trial of citalopram was not based 
on comparison with a TCA, the response rate for a TCA was derived from a large meta-analysis.15 
This meta-analysis was a weighted average of the response rates of the 4 most widely used 
antidepressants in Germany, according to the proportion of their volume market shares (IMS). 
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In this study, we deviated from the general rule to derive the response rate of the new drug from the 
clinical trial. The response rate for citalopram was assumed to be equal to that of standard therapy, 
although in a multi-centre study by Rosenberg et at 16 superior response rates for citalopram were 
found. Since this superior response rate for citalopram was based on data from a limited number of 
trials, and there is no evidence that the response rate for citalopram is higher than the response rate for 
other SSRis, the higher response rate found in the clinical trial may be a result of statistical variance. 
Because SSRis and TCAs have a similar clinical efficacy, the response rate for citalopram was 
assumed to be equal to the response rate for TCAs. 
Healthcare Resource Use 
The healthcare resources used, associated with the period before the initial transitions may be derived 
from a clinical triaL but this information may be of limited usc because of its low external validity: 
consequently, it may lead to an overestimation of the healthcare resources used. 
Other potential data sources are databases and published pharmacoeconomic literature. These data 
sources may. only in a few cases yield. information of sufficient quality corresponding to the 
following study characteristics: 
• study country 
• perspective 
• initial study population and different subpopulations (patients with treatment failures). 
Another option is the use of expert opinion. which is often used in pharrnacoeconomic studies. 
According to the guidelines the use of expert opinion is only allowed in situations in which no other 
data source is available. 
Finally. dosages of drugs may be derived directly from drug textbooks, when their use in the model 
corresponds with indications in these books. The advantage of this approach is that it is time saving, 
and consequently cost savings, when compared with other methods of collecting this information. 
For example, in the depression model described here. the units of healthcare usc could not be derived 
from the clinical trial or other published country-specific literature. Hence this information was based 
on a Delphi panel. except for the drug dosages. which were based on standard prescription guidelines 
according to the official German drug textbooks (Rote Liste ).17 The Rote Listc also gave the 
reimbursement percentages and daily treatment costs for the antidepressant drugs, while for other 
medical resources. this information was based on prices and/or tariffs from official health insurance 
tariff lists. The associated 1993 unit costs of the medical resources used (e.g. various professional 
services. health services facilities and tests carried out) were derived from official German tariff lists 
BewcrtungsmaBstab fur kassenartzliche Leisumgen (BMA)18] and other sources [Deutsche Ort 
Krankenkasse (DOK 819]. Since citalopram was not registered in Germany yet. we used the weighted 
average daily treatment cost (DTC) of SSRis in Germany as a proxy in our calculations [2.58 
Deutschmarks (DM)]. 
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Treatment Failure 
Information on patients with a treatment failure usually cannot be derived from a clinical trial for t\vo 
reasons: (i) the majority of clinical trials arc not based on an intent-to-treat design and, consequently. 
these trials do not yield information on patients withdrawing as a result of treatment failure (e.g. 
adverse events. noncompliance); (ii) the treatment pattern for a patient completing the clinical trial. but 
showing no response. cannot be determined because of the end of the follow-up period. 
While the follow-up of treatment failures may not be relevant for registration purposes. from a 
pharmacoeconomic perspective. patients who have failed treatment arc a critical subpopulation in a 
model. and phannacoeconomic studies show that treatment failures may account for the majority of 
costs (e.g. hospitalisation. For instance in depression the main cost driver was hospitalisation for 
treatment of resistant depression: a minority of the patients accounted for the majority of the costs. 14 
Therefore in any pharmacocconomic study the impact of the costs associated with treatment failure 
need to be assessed. If a new product is more efficacious. leading. for example. to a higher response 
rate (derived from a trial). the lower number of treatment failures will often lead to cost savings. 
The impact of the cost-effectiveness has to be determined qualitatively by describing the disease 
progression of these patients in the modeL for which information on treatment pattern. healthcare 
resource use and transition probabilities is required. 
The treatment patterns after a treatment failure has to be based on the usual local practice in a study 
county. which may be based on local guidelines that need validation. because real practice may differ 
from the guidelines. Expert opinion is currently the most suitable method for this confirmation. 
When there are no guidelines, databases or expert opinion have to be used to determine standard 
therapy for second and subsequent treatment failures. These standard therapies may consist of 
different treatments. For instance. treatment failure because of an adverse event will lead to switching 
to another therapy. while treatment failure resulting from poor efficacy of the product may lead to 
increase in dosage. 
The pathways for all causes of treatment failure have to be incorporated into the structure of the 
model. In case there is no consensus on the first-choice therapy for a type of treatment failure. the 
subsequent usual care niay be a weighted mix of existing therapies (e.g. 50% switch medication: 50% 
increase medication). 
For the transition probabilities and for the units ofhealthcare use associated with treatment failures. an 
assessment of databases and epidemiological data in the literature has to precede the use of expert 
opinion. As a result. expert opinion may need to be used for only transition probabilities. healthcare 
resource use. or both. However. the extrapolation of data derived from literature and databases is only 
possible if these data sources deal with a similar study population (e.g. patients with a treatment failure 
after previous therapy). For subsequent treatment failures after the first treannent failure. the 
abovementioned strategy can be used. 
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Because study populations in data sources must have a similar medical history of treatment failures, 
the chances of finding data sources dealing with the appropriate study population, or of finding an 
appropriate secondary hard data source will decrease after each treatment failure. An option for these 
patients with multiple treatment failures is to assume that their transition probabilities and/or 
healthcare resource use will be similar to patients with an initial or second treatment failure. These 
assumptions have to be validated by expert opinion. If these assumptions cannot be justified expert 
opinion has to be used for the data collection. 
Generally it is more difficult to fmd appropriate hard data sources for the transition probabilities that 
may be derived from published clinical trials. than for the healthcare resource use. Databases will be 
the most relevant hard data sources for the determination of healthcare resource use. The prices and 
tariffs will be based on the same data sources as discussed in previous section on ··Initial Medication". 
For example. in the modeL the treatment pattern after an initial treatment failure. while receiving 
antidepressant therapy. was derived from the clinical guidelines defmed in the US Clinical Practice 
Guidelines. 15 The choice of third-line therapy was also derived from the same source. but the response 
rate to this therapy. which determined the subsequent transition probabilities. could not be derived 
from the literature. The assumption was made that these transition probabilities were similar to 
second-line therapy. an assumption that was validated by an expert. The units ofhealthcare use could 
not be derived from a country-specific database. and were consequently derived from expert opinion. 
Responders 
In most clinical trials. the response of patients is assessed after a short term study period. For treatment 
of acute diseases, such as community-acquired pneumonia. the response corresponds to a complete 
recovery without a higher risk for a new episode than the average population; here. there is no need to 
follow responders for a longer period of time. In the modeL the responders will not lead to costs and 
remain in perfect health. 
In the case of chronic diseases or increased risk of a new episode, the trial may only follow the patient 
to a response after a short term therapy. For instance in depression the objective of most trials is to 
prove a better response rate to short term treatment with the new antidepressant versus placebo and/or 
another antidepressant. Hence, the study duration of most clinical trials in this indication is only 6 to 8 
weeks. which corresponds to the acute short term treatment period. In situations in which a long term 
effect is expected after treatment termination, or the continuation of a successful treatment is 
evaluated. patients need to be followed for a longer period of time. For instance. there have been a 
number of clinical trials assessing the long term effect of continuation treatment with antidepressants 
versus short term treatment only. In case patients are followed after response. the data collection 
method described for "initial treatment" may be applied. In case patients are not followed. the data 
collection method described for "treatment failure"' may be applied. 
The prices and tariffs will be based on the same data sources discussed in section on .. Initial 
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Medication"'. For example, the "initial treatmenC strategy was used; relapse rates were derived from 
the citalopram clinical trial and transformed into transition probabilities. zo The relapse rates after 
successful episodic treatment with a TCA were based on the responders to an initial treatment v.rith an 
SSRI. who were sv.ritched to placebo; hence, the assumption was that responders to an SSRI and a 
TCA will have similar relapse rates. Finally. healthcare resource consumption used was based on 
expert opinion. 
RECOMMENDATIONS 
The follov.ring guidelines are proposed for the use of secondary data sources in phannacoeconomic 
studies. 
Readers should be able to understand the methods used for the selection and use of data sources in 
modelling studies. The sources of study data should be recommended and explained in sufficient 
detail. The reader should be able to evaluate the strengths. weaknesses and possible sources of bias 
that may be inherent in the data used in the analysis. Selection criteria for studies and databases should 
be described and authors should explicitly note the direction and magnitude of potential bias in the 
data sources used. When clinical and/or economic (in case of a ''piggy back" trial) data are derived 
from a clinical trial. details of the design. and results of the study should be given [e.g. study 
population. follow-up period of patients, follow-up of patients who v.rithdraw and treatment failures 
(intention-to-treat). method of randomisation and primary and secondary clinical outcomes with 
confidence intervals]. 
The general applicability of the study population is important in assessing the results of clinical trials 
for suitability for economic evaluations. This level of uncertainty may be dealt with using a sensitivity 
analysis. Factors that can limit the application of the results include differences across countries or 
healthcare systems. and benefits that result only from a clinical trial protocol, but that would not arise 
in real practice, such as unrealistically high compliance rates. 
For clinical outcomes. the general rule may be to assume that data are not country-specific. Hence, 
data may be derived from studies performed in other countries and pooled results of international 
studies may also be used. For each study. this assumption has to be controlled. In some indications. 
clinical outcomes are country-specific. An example is the response rate to treatment with antibiotics in 
pneumonia. which will vary from country to country because of differences in resistance patterns. 
When data are derived from a synthesis of a number of articles. details should be given as to the 
method of synthesis. or meta-analysis of material (e.g. search strategy and criteria for inclusion of 
studies in the overview). For each study. the clinical outcomes should be presented. with information 
on the study population and the number of patients. Clinical outcome measures derived from 
overviews have the advantage that the confidence interval is usually narrower than that from an 
individual triaL and the results may be more generally applicable. Typically. the point estimate would 
be used in economic studies as the best case value and the confidence interval would be used as the 
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relevant range for sensitivity analysis. For economic measures and information on therapeutic choices. 
the general rule may be that country-specific data sources have to be used. while clinical measures 
usually do not need to be derived from country-specific literature. 
At each location in the model (e.g. Markov state). the patient subpopulation has to correspond as much 
a possible with the population in the data source (s) being used. Both the similarities as well as the 
differences should be mentioned. The first step is to describe the subpopulation in the model (e.g. 
population after I failure to initial therapy). The second step is to list the transition probabilities. 
costing and therapeutic choices from the available data sources. The next step is to describe. for each 
data source: type (e.g. database. medical record). number of patients. study population (inclusion and 
exclusion criteria). countries. date of data collection. cost of access to database and data abstraction. A 
justification for the final ''YES"' or "'NO'" decision to usc a data source should be presented. based on 
the advantages and disadvantages of the specific source. 
Finally the following criteria for the selection of members for a Delphi have to be considered. First, 
the members of the Delphi panel have to be a representative sample of the population of physicians 
treating the defined patient population under investigation. Second. the type or types of physician(s) 
involved (GP. hospital-based specialist. office-based specialist) must be decided on. It is possible that 
different types of physicians need to be included: for example. patients with depression may be treated 
by either a GP or psychiatrist while a patient experiencing treatment failure (e.g. resistant depression) 
may be referred to hospital for a treatment by a hospital-based psychiatrist. Third. the physician should 
have enough experience in treating the defined patients, which may be assessed by the number of 
treated patients who have the disorder that is under investigation. Fourth. the physician should not 
only have experience with the disorder. but also with the defined ""usual care" as initial treatment. 
Finally. the selection of a physician should correspond with the perspective of the study [e.g. in the 
US. a physician's contract may be either with the health maintenance organisation (HMO) or another 
managed care organisation]. 
DISCUSSION 
With the growing increases use and growing importance of modelling studies for economic 
evaluations. a new area for research has been created. In order to obtain objective and reproducible 
results from those studies it is imponant to have standardised methods of evaluation. contained in 
accepted guidelines on methodology. Although various groups have published recommendations on 
the good practice of economic evaluations:!'::!::! ::!3• those guidelines mainly focus on prospective studies 
that rely on primary data. and consequently, contain no recommendations for the handling of 
secondary data. which are closely related to the appropriate execution of a modelling study and the 
credibility of the results from a modelling study. 
From the perspective that results from modelling studies are of interest to many parties with different 
responsibilities and diverging interests. it is obvious that besides guidelines for the selection of data 
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sources, transparent and unambiguous presentation of the data sources is required for a proper 
understanding. 
A standardised strategy for data source selection and a transparent reporting format on data source 
selection has been presented in this article, which may improve the acceptance of such data and thus 
stimulate further research. even in the absence of formal guidelines. 
References 
Australia Commonwealth Department of Health, Housing and Community Services. Guidelines for the 
pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee. 
Canberra: Commonwealth Department. 1992 
2 Commonwealth Department of Australia Department of Hwnan Services and Health. Guidelines for the 
pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee. 
Canberra: Australian Government Publishing Service. 1995 
3 Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic 
evaluation of pharmaceuticals: Canada. 1st ed. Ottawa: CCOHT A. 1994 
4 Ontario Guidelines for Economic Analysis of Pharmaceutical Products. Ontario: Canadian Ministry of 
Health. Drug Progr:rms Branch. 1993 
5 Weinstein MC. Fineberg HV. Clinical decision analysis. Philadelphia (PA): WB Saunders Co .. 19SO: 22S-65 
6 Egger M. Davey-Smith G. Misleading meta-analysis. British Medical JournaL 1995: 310: 752-754 
7 Detsky AS. O'Rourke KO. Corey PN, Johnston N. Fenton S. The hazards of using active clinic patients as a 
source of subjects for clinical studies. J Gen Intern Mcd. 1988; 32: 260-66 
S Sacket DL Bias in analytical research. J Chronic Dis. 1979:32:51-63 
9 Jariath N. Weinstein J. The Delphi methodology (part two): a useful administrative approach. CJONA 1994; 
7(4): 7-20 
10 Jones J. Hunter D. Consensus methods for medical and health services research. BMJ 1995: 311: 376-80 
11 Barr J. Schumacher G. Using decision analysis to conduct pharmacocconomic studies. pp. 1197-1214, 
Quality of life and pharmacoeconomics in clinical trials (2nd edition). cd by B. Spilker 1996: Philadelphia: 
Lippincott-Raven Publishers 
12 Willi:rms P. Webb C. The Delphi technique: a methodological discussion. Journal of Advanced Nursing 
1994: 19: 180-186 
13 Evans C. The usc of consensus methods and expert panels in pharmacocconomic studies: practical 
applications and methodological shortcomings. Pharmacoeconomics. 1997; 12 (2Pt 1): 121-9 
14 A Markov Process Analysis Comparing the Cost-Effectiveness of Maintenance Therapy with Citalopram 
versus Standard Therapy in Major Depression. Nuijten M. Hardens M. Souctre E. Pharmacocconomics. 
1995: 8 (2): 159-168 
15 Clinical practice guideline. Depression in primary care: treatment of major depression (AHCPR publication 
no. 93-0551). Rockville (MD): Public Health Service. Agency for Health Care Policy and Research, 1993 
16 Rosenberg C. Damsbo N. Fuglum E. et al. Citalopram and imipramine in the treatment of depressive patients 
in general practice: a Nordic multicentrc clinical study. Int Clin Psychopharmacol 1994: 9 Suppl. I: 41-8 
17 Rote Listc 1993. Arzncimittclvcrzeichnis des BPI. Aulcndor£1\Vfutemberg: Edition Cantor Verlag fiir 
Mcdizin und Naturwisscnschaftcn GmbH. 1993 
1 S BMA. Bewertungsmass-stab fiir kassenartzliche Leistungen. Cologne: Deutscher Artzc-V crlag GmbH. 1993 
19 DOK-8: AOK-Bundcsverband. 1994 Apr 15:256 
20 Montgomery SA. Rasmussen JGC. Tanghoi P. A 24-wcek study of 20 mg citalopram and placebo in the 
prevention of relapse of major depression. lnt Clin Psychopharmacol1993: 9: ISI-S 
21 Clemens K. Townsend R. Luscombe F. Mauskopf J. Osterhaus P. Babula J. Methodological and conduct 
principles forpharmacoeconomic research. Pharmacoeconomics 1995; 8 (2): 169-74 
22 Drummond MF. Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the 
BMJ. BMJ 1996:313:275-83 
23 Jefferson T. Dcmichclli V. Are guidelines for peer-reviewing economic evaluation necessary'? A survey of 
current editorial practice. Health Econ 1995:4: 383-8 
61 

Chapter 5 
Bridging Decision-Analytic Modelling with a 
Cross-Sectional Study: 
Application to Parkinson's disease 
SUMMARY 
The ideal design for demonstrating the possible health outcomes and costs associated with a new drug 
would be a naturalistic prospective study. However, it is often not feasible to derive the required 
information from scientifically sound prospective studies. In these cases, decision-analytic models 
may provide some of the missing information. However, the use of a Delphi panel to gather data for 
these models is a major concern because of potential bias and data accuracy. Because reimbursement 
of pharmaceuticals is often based on economic data derived from modelling studies. it is obvious that 
potential bias due to the use of Delphi panels should be minimised. 
In this manuscript we will present an alternative data source for a modelling study: the cross-sectional 
study. Data from such studies can be used to yield costs and utilities for Markov health states. The 
overall combined design may be considered a hybrid between a naturalistic prospective study and a 
modelling study by maximising the pros and minimising the cons of both types of design, including an 
increase of external validity. This hybrid design is based on bridging the probabilities derived from the 
literature and clinical trials with information on costs and utilities from a cross-sectional study. This 
design has also logistical advantages. namely a shorter required study duration compared with 
prospective naturalistic studies for chronic diseases. This combined design was illustrated using a 
Markov model for Parkinson· s disease. 
Chapter 5 
INTRODUCTION 
Most countries are, and have been during the last 2 decades. confronted with the problem of increasing 
costs for healthcare and how to fmance these expenditures. In The Netherlands. the main response to 
rising costs has been the introduction of an impressive number of cost containment policies over the 
last decade. This resulted in the Drug Reimbursement System, which is based on the classification of 
drugs into groups of interchangeable drugs (Geneesmiddelen Vergoedingssysteem: GVS). In this 
system. there is a fixed refund price being based on the average list price for ''therapeutically 
interchangeable drugs" belonging to the same group (cluster). Any new drug, which cannot be 
clustered.. is not reimbursed. unless there is no treatment for the relevant pathology. Currently, the 
Dutch government is investigating making the submission of health economic data an official 
requirement when applying for reimbursement of a new innovative drug. as in Australia and Canada. 1 
Because there were no requirements for phamacoeconomic data when most of the current phase III 
clinical trials were started. pharmacoeconomics was. in general. not included in the clinical 
programmes of products now approaching launch. Therefore. it is expected that for most of the 
submissions for reimbursement in countries such as The Netherlands in which the use of 
phannacoeconomic data will become an official requirement. data will be based on a modelling 
design. 
If reimbursement of pharmaceuticals is going to be based mainly on economic data derived from 
modelling studies, it is especially vital to carefully scrutinise and refine this type design. A main 
concern about the use of modelling studies is the use of a Delphi panel to gather data which could not 
be derived from actual existing data sources. The use of a Delphi panel may particularly controversial 
in estimating quality-adjusted life-years (QALYs). which may become the primary final outcome for 
phannacoeconomic studies. The existing Canadian and Australian guidelines and the draft UK 
guidelines strongly recommend an estimate of the incremental cost per QAL Y gained.1 2 3 
The objective of this manuscript is to present a strategy to improve the quality of the data for use in 
phannacoeconomic modelling studies by using an add-on cross-sectional study as an additional data 
source i.e. combining a modelling study with an add-on cross-sectional study. 
MODELLING STUDIES 
The ideal design to demonstrate the possible health outcome and costs associated with a new drug is a 
naturalistic prospective study. However. in practice. it is not always possible to derive all required 
information from scientifically sound prospective studies. A modelling design may chosen because of 
practical limitations of prospective studies. This is especially the case in chronic conditions like 
Parkinson's disease: required study durations may vary from 5 to 10 years. In these cases. models can 
be used to extrapolate clinical outcomes beyond the duration of the trial. Furthermore. the forthcoming 
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legislation requiring phannacoeconomic data for reimbursement decisions which need to be made 
'Nithin a limited time frame 'Nill expand the indication for modelling studies to other conditions (e.g. 
acute phases of a disease such as community-acquired pneumonia). Modelling is an attractive 
alternative for the generation of pharmacoeconomic data 'Nithin short periods e.g. for products which 
are nearing launch, as is the case in The Netherlands (see Introduction). 
Modelling studies arc based on decision analysis, which allows both clinical and economic 
consequences of medical actions and attitudes to be analysed.4 From treatment algorithms a model can 
be constructed which considers the timings of actions and their consequences over time. In effect. a 
model shows the consequences and complications of different therapeutic interventions. It should 
correspond as much as possible to the change to the course of the disease. Models may take the form 
of simple decision-analytic trees or they may be very complex Markov models. While decision tree 
models are appropriate for acute episodes. Markov models are the first choice for pharmacoeconomic 
analysis of chronic diseases. 
Data Sources 
The data used in a modelling study can be categorised into transition probabilities. treatment patterns 
(or therapeutic choices), health care utilisation and utilities and prices and tariffs. The data may come 
from a variety of sources and are subject to varying degrees of uncertainty. Data sources for the 
variables used in a model may be clinical trial reports, literature (e.g. meta-analysis), claim or clinical 
databases. medical records. and official tariff lists. These data sources yield. for each variable. a fixed 
input value and a range. Standard analyses are based on the fixed input value for all variables. The 
range of each variable is then used to determine the sensitivity of the outcome to the analysis when the 
input value is varied within its range. 
The limitations of the various types of data sources have been extensively discussed previously.5 It is 
usually not possible to derive all data from actual existing data sources. because of lack of available 
data sources or unreliable data. The main drawback of all existing data sources is that they have not 
been developed for economic evaluations but for either administrative or medical/scientific purposes. 
Hence they may suffer from incompleteness (e.g. no information on either healthcare utilisation or 
clinical outcomes. especially QAL Y s), insufficient external validity and an inappropriate fonnat of the 
information (i.e. one that does not fit the structure of the modeL 
When there are no reliable data available. the use of Delphi expert opinion is considered appropriate.6 
Delphi panels operate in rounds, in an effort to reduce variance in estimations by the experts in a 
particular area. The first round consists of individual interviews 'Nith the participating experts. The 
first round consists of individual interviews 'Nith the participating experts. The experts are provided 
with a description of the model and are asked to provide infonnation based on their clinical experience 
and their knowledge of the literature. The interviewer asks the expert to provide infonnation of the 
following items: probabilities. healthcare utilisation and therapeutic choices. All information on these 
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items has to match the basic characteristics of the model (time horizon, cycle time. health states). All 
responses by panellists arc anonymous to other panellists. The rationale for this is that respondents 
will not be intimidated or dominated by other respondents. This is a particular concern in the 
hcalthcare profession7 where there is a hierarchical structure in healthcare delivery and seniority 
dominates most care activities. In the second round the experts arc asked to re-estimate the estimation 
provided in the first round. The second round is performed by having each expert fill in a 
questionnaire. which is sent by emaiL phone or fax. 
There are a number of methodological weaknesses inherent in the Delphi process (see Nuijten5). 
Briefly. these are the potential for experts to drop out following the frrst round, the potential for 
outliers related to sample size. and the potential for adjustments of the estimations to ideal care 
(overestimation of variables related to the success of treatment, or underestimation of variables related 
to hcalthcare utilisation). The main methodological weakness of the Delphi panel process is that the 
data arc based on estimations, whereas data from other data sources arc based on real measurements 
i.e. the perceived values of the physicians may differ from real values. 
Transition Probabilities 
For clinical outcomes. the general rule is to assume that transition probabilities are not country 
specific. Hence. data may be derived from studies performed in other countries and pooled results of 
international studies may also be used. Probabilities for clinical outcomes associated with treatment 
following the initial treatment (e.g. second-line therapy) may often be derived from the literature. 
However, clinical trial data for determining probabilities of clinical outcomes associated with 
subsequent treatments (e.g. third-line therapy) will be scarce. In this case. epidemiological studies may 
yield data on disease progression, which may be used to determine transition probabilities for those 
patients. The Delphi panel technique may need to be used to yield all remaining probabilities. Because 
a model is usually only marginally sensitive to probabilities associated with treatment failures after 
second-line treatment. the impact of uncertainty associated with the methodological weaknesses of 
Delphi panel technique in this case would be low. 5 
Treatment Pattern 
Data on treatment patterns or therapeutic choices may be based on local guidelines or sometimes claim 
or clinical databases. which are validated by expert opinion. However. for the majority of modelling 
studies, there will be no actual existing data and the use of expert opinion is the only option for 
determining treatment pathways. The first step is to obtain a quantitative description of treatment 
pathways by consulting 2 experts. The next step is to use a Delphi panel to determine the probabilities 
for each treatment option. when several treatment strategies exist. Determination of these probabilities 
by using a Delphi panel technique may be appropriate when the sample of Delphi panel members is 
representative for usual care (i.e. they treat their patients according to the most widely used treatment 
in the study country). and the sample size of the Delphi panel is sufficient. 
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Healthcare Utilisation and Utilities 
Data on healthcare utilisation and utilities usually needs to be completely derived from a Delphi 
paneP Hence. a model v.ill be especially sensitive for effectiveness (QAL Y s) and cost outcomes 
Other Data Sources 
Other data sources for modelling studies may include; 
• drug textbooks that contain information on dosages of drugs. drug prices and reimbursement 
percentages. 
• official tariff lists from health insurance companies contain information on tariffs for other 
medical costs (procedures, consultations and hospitalisation). 
• and financial departments of particular institutions. which may yield information on costs from the 
provider's perspective. 
STRATEGY 
In this section, a strategy is described for substantially reducing the amount of data which need to be 
derived from a Delphi panel- a strategy which may substantially improve the quality of the input data 
in a model. and consequently, the cost and effectiveness outcomes. The strategy is illustrated by using 
a hypothetical Markov model for Parkinson's disease which was used to model the cost-effectiveness 
of a hypothetical new antiparkinsonian drug (AP) from a German health insurance (Krankenkassen) 
perspective in Germany. This ·new drug" is modelled as add-on therapy to usual care (fig. 1). Our 
model is based on the following assumptions: 
• the Markov health states in the model correspond with severity levels according to the existence of 
motor fluctuations ("'no fluctuations" and "fluctuations"). 
• the follow-up period is 5 years: the cycle time is 1 year, which is based on the follow-up period of 
the clinical trials for the AP. 
• there is no mortality during the study period. 
• beyond the actual follow-up period of the clinical trial for the AP, the delay in disease progression 
due to treatment with the AP will be modelled using the same rate beyond the clinical trial period. 
• disease progression corresponds with the development of fluctuations. 
• a hypothetical cohort of persons with no fluctuations will receive the AP or usual care. After the 
first cycle, patients may have remained without fluctuations or have become ··fluctuators ". Patients 
v..rill continue the treatment with the AP for the remainder of the study period irrespectively or 
whether they are fluctuators or not. 
• the AP will reduce disease progression annually by 25%. 
The assumptions. related to hypothetical product AP, are purely hypothetical: they are not based on 
any published or unpublished clinical trial data. The definition of the Markov health states according 
to the existence of motor fluctuations was based on clinicalliterature.8 
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Figure 1. Markov model for Parkinson's disease. 
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Utility is a general concept for measuring the value individuals attach to the consequences of various 
actions (consequences of several treatment options in our example).9 The goal of this measurement 
technique is to obtain a numerical value that represents the strength of the individual's preferences for 
a particular outcome. 10 Utilities can be used in a cost-utility analysis, v.rith results presented as costs 
11 1: 13 14 
per QALY for each of the treatment alternatives. 
The assessment of utility was based on the following formula: 
" 
utility= It_,. x u_,. 
s-l 
Vv'bere: n is the total number of cycles spent in a particular health state: s is the health state: t is the 
number of cycles spent in a particular health state: and u is the utility of the particular health state ("no 
fluctuations"' or "fluctuations .. ). The latter is used to relate each health state to an average QAL Y. 
Various health state classification systems are available (e.g. Torrance Index 11 and EuroQol.15 
In our modeL utilities were derived from the patients by using the Torrance Index. 
Cost Assessment 
The cost assessment was based on the assignment of a total fixed cost to each health state 
corresponding with a cycle time of 1 year. The costs of each health state was determined by the 
healthcare utilisation associated with a health state i.e. medication. consultations. procedures, tests and 
number of days of hospitalisation. Each health state is associated with a mix of healthcare utilisation: 
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treatment costs for all patients arc included as well as costs associated with supportive care (weighted 
according to the proportion of patients). 
In our model, costs were determined from the perspective of the Krankenkassen. The costs were 
derived from the following sources: drug costs- official German price lists of drugs16 1;: hospital costs 
- mean cost per day of inpatient care1s: visit costs for GPs and office-based specialists - official tariff 
list 19 ::o: diagnostic costs- official tarifflists_l9 zo 
Clinical Trials 
Transition probabilities between the different health states may generally be derived from clinical 
trials and epidemiological or observational studies. In our example, we derived the annual transition 
probability from ''no fluctuations" to 'l:luctuations'' for usual care from a study by Dodel et al. 
(Table 1).::1 The average duration of disease since the onset of symptoms was determined for each 
patient at inclusion. The average duration of disease since onset of symptoms was 7.1 and 13.9 years 
for patients without fluctuations and with fluctuations, respectively. Hence, the average duration to 
progression to fluctuations is 6.8 years. which can be transformed into an annual probability of0.147 
by taking the reciprocal of 6.8 years. This calculation is based on a method by Beck to determine 
annual mortality by taking the reciprocal of life expectancy.::. Disease progression with the AP in our 
model was derived from a hypothetical clinical trial showing that the AP reduces disease progression 
by25%. 
Cross-Sectional Cost-of-Care Study 
Our strategy includes a cost-of-care study based on a cross-sectional study design, which was 
performed for our model. The defining characteristic of a cross-sectional study is that the basic health 
state of each person in the evaluation is examined essentially once. QAL Y s and costs during a period 
of time are determined at one point in time for each patient (fig. 2). These measures of utility (QAL Ys) 
and resource utilisation can be determined for each severity level and subsequently the relationship 
between utility markers of clinical status and costs can be established. A cross-sectional study consists 
of the following steps. which have been adjusted to Parkinson's disease. 
• Selection of sites. These sites have to be a representative sample of providers that are treating the 
patient population under investigation is being treated. It is possible that different types of sites 
need to be included. In our example, the majority of patients without fluctuations may be treated 
by a GP. whereas the majority of patients with fluctuations may be treated by a neurologist. In 
addition. the sites should have adequate experience in treating the defined patients; this may be 
assessed by the annual number of patients treated with the pathology under investigation. 
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Figure 2. Flow chart for a retrospective cross-sectional study. 
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• Selection of patients. In our model, a defmed number of patients with Parkinson's disease was 
selected from the registries of the participating sites corresponding with the defmed study 
population in the model. In this case. the primary diagnosis was idiopathic Parkinson's disease 
(clinically characterised by bradykinesia. resting tremor. cogv.rheel rigidity, and postural reflex 
impainnent)8. This definition excludes all parkinsonism ofkno\Vll aetiology and any disorder with 
multiple system involvement or significant lesions of the striatum, such as progressive 
supranuclear palsy. olivopontocerebellar atrophy. multiple system atrophy, striatonigral 
degeneration. 
• Screening for eligibility criteria. Subsequently, all selected patients with idiopathic Parkinson's 
disease were screened for the inclusion and exclusion criteria. Inclusion criteria may be: (i) 
presence of a caregiver able to give valid information; (ii) patients insured vvith the 
K.rank.enkassen: and (iii) patients who have consented to participate. Exclusion criteria may be: (i) 
patients with nonidiopathic parkinsonism: (ii) patients with severe neurological or psychiatric 
disorders, particularly dementia; (iii) patients vvith severe organic pathologies (e.g. neoplastic 
disease. severe cardiovascular disease): and (iv) patients currently involved in a clinical trial. The 
initial screening was based on the medical records. The patient was then invited to participate in 
the study (direct phone calls could be made). The study investigator arranged an interview with 
each patient and.. if necessary. the caregiver. At the time of the visit. each patient was evaluated for 
inclusion using the study criteria and, if proven eligible. would be included. In case of inclusion. 
the patient and his/her related caregiver were interviewed to complete the socio-demographic. 
medical. and economic section of the Case Record Form (CRF). To confirm and/or add 
information to be recorded in the CRF"s, the study investigator was allowed to contact other 
sources. typically the patient's GP or a hospital in the case of previous in patient care. 
70 
Bridging decision-anal_vtic modelling with a cross-sectional stud_v 
• Detennination of health state utilities. At the end of the interview, health state utilities were 
determined (e.g. Torrance Index or EuroQol). If necessary, the patient was instructed on how to 
use the questionnaire. 
• Patient stratification. The selected patient population was stratified into groups of disease severity 
according to existence of fluctuations i.e. "no fluctuations'" and "fluctuations. 
• Data collection. All relevant units of resource utilisation in the 3 months preceding the study visit 
were collected for each patient. 
• Detennination of input values. The mean and distribution of all units of costs and utility were 
determined for each severity level: these were incorporated into the corresponding Markov health 
states in the modeL 
• Statistical anal_v'Ses. Statistical analyses were performed to identify any confounding variables 
(e.g. the type of Parkinson's disease). 
The cost-care study in this example yielded relationships betv.rcen severity level and costs for 
Germany. which are specific for Germany. The function betv.reen severity and utility may be 
extrapolated to other countries, if we assume that clinical outcomes are not country specific.5 Table I 
shows for the relationship between costs and utility according to the existence of fluctuations. 
Table I. The fixed input values for the Markov model. 
Stage Costs (DM) Costs (DM) Utility 
(3 months) per year 
Mean 
No fluctuations 1.020 
Fluctuations 2.050 
Markov Model 
4.080 
8,200 
Mean 
0.73 
0.49 
Duration of disease Differ- Transition 
since onset of encc Probabilit 
svm toms (v) v 
mean 
7.1 
13.9 6.80 P~O.I47 
Subsequently, a Markov model can be used to simulate the disease progression and accrual of costs 
and compare the cost-effectiveness of the AP versus usual care by combining data derived from the 
literature and clinical trial (AP transition probabilities) with data derived from the cross-sectional 
study (costs. utilities). This approach has similarities with the concept of a "longitudinal prevalence 
analysis". which is used in epidemiology. The costs in this analysis were discounted at 5%: no 
discounting was applied to the utilities. The results of the analysis are shown in Table II. The results of 
the baseline analysis show that the use of the AP [daily treatment cost (DTC) is DM2 ($US1.5)] is 
more costly than usual care. with direct medical costs DM25,265 (SUS18.254) versus DM22,967 
($US16.594). respectively. A secondary analysis was performed in order to assess the impact of AP on 
current costs associated with usual care, by excluding the drug costs of the AP. This analysis showed 
that the use of the AP would reduce the current costs for usual care from DM22,967 ($US 16,594) to 
DM21.962 ($US15,868). The AP was associated with only a 2% increase of effectiveness: 3.41 
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QAL Ys versus 3.35 QAL Ys. Consequently. the use of AP would lead to an incremental cost-
effectiveness ratio ofDM34.294 ($US24J77) per QALY. 
Table II. Results of the cost-effectiveness analvsis. 
AP 
Costs (DM)* 25.265 
QALY 3.41 
*: Discounting at 5%. 
Usual care 
22.967 
3.35 
Incremental cost-
effectiveness (ICER) 
!J.C = CF-C<f 
f:£ E,--E,., 
34.294 
The results of a sensitivity analysis performed for percentage reduction in disease progression by the 
AP. are shown in Table III. Results show that the model is rather sensitive to a change in the 
percentage reduction of disease progression: at least 50% reduction in disease progression may justify 
the use of AP in patients with Parkinson·s disease. 
Table III. Results of the sensitivitv to reduction of disease progression. 
Usual AP 
care 
Reduction 0% 25% 50% 75% 100% 
QALY 3.35 3.35 3.41 3.48 3.57 3.65 
Costs (DM)* 22967 26270 25265 24182 23016 21762 
ICER usual care 38300 9346 223 AP 
dominant dominant 
*: Discounting at 5%. 
DISCUSSION 
Because study drugs are usually not approved for registration at the time economic studies are 
conducted. prospective naturalistic trials and the submission of data on effectiveness and expected 
costs at the time of reimbursement are usually not feasible. The execution of a prospective naturalistic 
study would substantially delay the product launch. shortening the period of useful patent life and 
reducing the return on research and development investment. 
The use of a hybrid design (combining a modelling study with an add-on cross-sectional study) has 
logistical advantages compared v.rith a prospective naturalistic study. The model development and the 
execution of the cross-sectional study can be performed within 6 months, which compares favourable 
with the optimal duration of prospective naturalistic studies for chronic diseases (which varies betv.reen 
1 year and a life-time follow-up). Aside from this practical convenience of data availability. 
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observational data derived from a cross-sectional study may well have higher external validity than the 
data derived from randomised prospective trials. 
A hybrid design may also have other methodological advantages compared with the use of data from a 
naturalistic study. Instead of data collection being retrospective, data from a hybrid design may be 
collected prospectively during, for example. a 3-month period following inclusion. Both the 
prospective and retrospective approach may have pros and cons. The risk of the retrospective approach 
is that data collection on resource use may be incomplete. For instance, in the case of switching 
between in- and outpatient care, different medical records may need to be accessed. The risk of the 
prospective approach is the introduction of a potential bias on both part of the patient and the 
physician. For example. physicians may adjust their treatment patterns to those of ideal care, which 
may reduce the external validity of the prospectively collected data (e.g. resource use may be 
underestimated). Hence. an advantage of the retrospective approach to data collection is the high 
external validity of the data. An advantage of the prospective approach is that the data collection form 
(CRF) will be primarily developed for the cross-sectional study. Consequently. the type of data 
(clinical and economic) collected will be pre-defined and will correspond with the characteristics of 
the model. 
A further methodological advantage of a hybrid design is that economic measures will be determined 
over a fixed period of time (3 months in our model for Parkinson's disease). A requirement for the 
cross-sectional approach is that patients do not switch between health states over the study period; the 
costs associated with each health state need to be determined. In our modeL we assumed that patients 
with Parkinson's disease will not have disease progression during a 3-month study period. 
Consequently, another advantage of the prospective approach is that clinical assessments may be 
repeated at the end of the study period in order to confirm the stability of the disease over the chosen 
study period. The risk of disease progression may be reduced by minimising the follow-up period. 
which will increase the statistical error. Consequently, a larger sample size may be required. 
In our modeL resource utilisation, excluding the AP. and utilities, were derived from a cross-sectional 
study based on usual care practises i.e. without the usc of the new hypothetical product. The resource 
utilisation and utility of a health state are functions of both the underlying disease and adverse events 
associated with treatment. In our modeL we valued the health states with the use of the AP according 
to the resource utilisation and utilities of health states with usual care (without the AP). Hence, the 
assumption in our model was that the AP was not associated with any adverse events which affected 
the resource utilisation and utilities of the health states. 
In our Markov modeL the transition probabilities only depended on the impact of the AP and usual 
care on moving from the health state ''no fluctuations" to "fluctuations". However. disease 
progression in Parkinson's disease may also depend on co-variables such as past clinical history and 
co-morbidity. Therefore, the extension of a Markov model to a so-called semi-Markov modeL would 
have allowed a more realistic simulation of the disease, incorporating all relevant variables in real life. 
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CONCLUSION 
The ideal design to demonstrate the possible health outcomes and costs associated with a new drug 
would be a naturalistic prospective study. However. a prospective naturalistic study cannot always be 
performed for logistical and budgetary reasons. In addition. study drug are usually not approved for 
registration at the time of the economic studies are performed, which limits the use of a prospective 
naturalistic triaL .. Piggy-back trials .. have limited external validity, because they have strict inclusion 
and exclusion criteria and treatments are protocol driven, leading to overestimation of units of 
healthcare utilisation: on the other hand, the units of utilisation collected may not be complete. In 
addition, the units of healthcare utilisation are country specific and the time to follow-up of clinical 
trials is too limited for pharmacoeconomic purposes. 
In these cases. decision-analytic models may provide some of the missing information. However. a 
main concern with modelling studies is the use of a panel of experts to gather data which can not be 
derived from the literature. There is no guarantee that their assessment of resource utilisation and 
utilities is an accurate reflection of reality. From the perspective that results from modelling studies are 
of interest to many parties with different responsibilities and diverging interests. it is obvious that 
potential bias due to the use of a Delphi panel should be minimised. 
In this article. we presented the cross-sectional study as an alternative data source for a modelling 
study: data from such a study can be used to determine costs and utilities for Markov health states. The 
overall design may be considered a hybrid between a naturalistic prospective study and a modelling 
study by maximising the pros and minimising the cons of both types of design. This hybrid design is 
based on bridging probabilities derived from literature and clinical trials with information on costs and 
utilities from a cross-sectional study. This design was illustrated using a Markov model for 
Parkinson· s disease. 
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Chapter 6 
Cost-Effectiveness Analysis of Interferon Beta 
in Multiple Sclerosis: a Markov Process 
Analysis 
SUMMARY 
OBJECTIVE: The objective of this study was to examine the cost-effectiveness of preventive 
treatment v.rith interferon beta (IFNB) versus no preventive treatment in patients with multiple 
sclerosis. METHODS: The setting for this study was the United Kingdom. A lifetime Markov process 
model was constructed to model the average quality-adjusted life years (QAL Y s) and the costs of both 
treatment strategies. Data for the construction of the model came from published literanrre. including 
large multicenter randomised clinical trials in relapsing-remitting and secondary progressive multiple 
sclerosis. Costs were obtained from published sources. RESULTS: The results of the baseline analysis 
from the National Health Service (NBS) perspective showed that the use of interferon beta as 
preventive treatment forMS increased the total average discounted cost from £51.214 to £221.436 per 
patient. The undiscounted effectiveness increased from 24.9 QAL Ys to 28.2 QAL Ys, resulting in an 
incremental cost-effectiveness ratio of£51,582 per QAL Y. Sensitivity analyses showed the robustness 
of this model for other interferons. CONCLUSION: The study showed that preventive treatment with 
interferon beta in patients with multiple sclerosis may not be fully justified from a health-economic 
perspective, although interferon beta is associated with an improved effectiveness compared with no 
preventive treatment. 
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INTRODUCTION 
Epidemiology 
Multiple sclerosis (MS) is the second most common cause of neurological disability in young and 
middle-aged adults. 12 Females are more susceptible by a factor that approaches 2:1 in population 
studies, but this varies among surveys.1 Males are more likely to have progressive disease from onset.3 
4 The mean age of onset of MS is during the third and fourth decades of life with a peak incidence 
during the late 20's- early 30's.s 6 
Most patients initially have the relapsing-remitting form (RRMS) with a variable frequency of 
exacerbations (mean 1-2 per year). At onset, 65% of patients fall into the RRMS category.3 6 
Eventually most RRMS patients "Will develop the secondary progressive form (SP). In this stage. fewer 
exacerbations occur. and recovery from them is always incomplete. Eventually no recovery is 
possible. In addition. a chronic and slow increase in neurological deficits takes place. Thus. the patient 
suffers from increasingly severe disability.7-IO 
Quality of life 
It is generally recognized that MS can dramatically affect the quality of life (QoL) experienced by an 
afflicted patient and/or his/her family. Many MS patients have a normal life span and have to live with 
some degree of disability over a prolonged time period. Family life. economic status and social 
interaction may be affected by somatic symptoms of the disease.1 ' Cognitive dysfunction affects 43% 
to 65% of MS patients and also has a major negative influence on QoL in MS patients. Cognitively 
impaired patients are less likely to be professionally active. are more dependent, report more sexual 
dysfunction and tend to be less socially engaged than cognitively intact MS patients.12 
Economic Impact of Multiple Sclerosis 
The full economic cost of MS to society and to the individuals concerned is uncertain. but is most 
likely to be substantial. bearing in mind that: (i) MS patients experience a major perturbation in their 
daily activities: (ii) MS affects mainly young productive people between the ages of 25 and 40 1 who 
are obliged to interrupt their professional activities either temporarily or permanently. 13 
A positive correlation bet\veen total health-care costs and the Expanded Disability Status Scale 
(EDSS) has been demonstrated among MS patients. Above an EDSS scores of 5.5 (needs aid to walk), 
costs increased particularly quickly .13 
Few economic studies ofMS have been published. A prevalence-based cost of illness study in the UK 
(1995) estimated the annual burden ofMS at £1.199 million.14 The largest share was carried by the 
state. and the total cost included the following: state benefits. £287 million (23.9%): NHS costs 
(hospitalization. other treatment and support). £153 million-12.8%): lost tax revenue £148 million 
(12.3%). Annual NHS costs range from £336 to at least £4.275 per patient depending on their level of 
mobility which influences the number of hospital in-patients visits. The costs for drugs were 
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insignificant (£23/patient, (<2%) interferon not included). Lost earnings (33%). private expenses 
(11.7%) and employers· expenses (6.3%) were higher. The authors suspected that this total cost value 
was an underestimation in that diagnostic costs were not completely assessed and the use of average 
(general population) values for consultation time may not have been accurate for MS patients. In an 
earlier study conducted in England and Wales, the annual costs of the disease were estimated at £125.4 
million (1986/87 prices). In this study. the largest component (20%) was the lost earnings of MS 
sufferer. although the cost burden of the family was not considered_ IS A more recent cross-sectional 
cost of care study was performed to assess the economic burden of multiple sclerosis (MS) in the UK 
France and Germany. 16 Patients were stratified into three severity groups according to the EDSS: 
stages I. II and III. corresponding to mild (EDSS l.0-3.5). moderate (EDSS 4.0-6.0) and severe (EDSS 
6.5-8.0) MS respectively. From the societal perspective, the total cost of MS for three months was 
estimated at£ 3500, £ 4612 and£ 9989 per patient for stages I. II and ill patients respectively in the 
UK. From the health-insurance perspective, the cost for three months was estimated at£ 535. £ 616 
and£ 2020 in the UK per patient with stage I, II and III MS respectively. 
Indirect costs tend to be the largest contributors to the overall cost burden. Taking into account 
employment history, medical insurance. amount and source of family income and disease progression. 
MS can cost an individual 40% of their lifetime earnings. 13 17 18 Recent studies have indicated that 
fifty to eighty percent of MS patients are unemployed within 10 years of disease onset. 19 20 21 As 
mentioned for the UK study, indirect costs related to lost earnings represented £395 million per annum 
or 33.0% of the total burden. Of this. 26.3% was attributed to lost earnings of non-professional 
caregivers. It has also been reported that 39% of men and 19% of women with MS retire early due to 
disability, with one of the most frequently cited reasons being MS-related fatigue.22 Cognitive 
impairment. spasticity. perturbation of co-ordination and disturbances of bladder and bowel functions. 
non-remittent disease course, heavy physical work and age over thirty may be factors contributing to 
early retirement or unemployment.20 23 24 
A previous cost-effectiveness study was performed for preventive treatment with interferon beta in 
patients with initial RRMS.25 This study was based on a modelling design following patients over a 
period of five and ten years. The study showed that the additional cost of INFB of£ 43.400 is offset 
by gains in QAL Ys of0.13. indicating a cost-utility ratio of£ 328,300 per QAL Y gained. The 10-year 
analysis produced a slightly more favorable cost-effectiveness ratio of£ 228,300. This study could not 
take into account the potential reduction in disease progression associated with usc of interferon beta 
in patients who had already progressed to SP because clinical data documenting the favorable effect of 
interferons in SP were not yet available. 
Treatment of Multiple Sclerosis 
We will focus on the prevention of disease activity by interferons. The rationale for such therapy is 
that MS is generally thought of as an autoimmune disease. Interferons have. by definition. antiviral 
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properties. but they also have irnmunomodulating and antiproliferative properties. The classification of 
interferons as IFNcx., IFN]3, and IFNy, is based on their antigenicity and the similarities of their 
nucleotide sequences. Two types of recombinant IFN~ exist. IFN~-la and 1FN~-lb. IFNa and IFN~ 
are used in the treatment ofMS because of their immunomodulatory capacity to suppress the activated 
immune system. A major effect is thought to occur through the blocking of IFNy effects. which 
activate the immune system.26 29 A major breakthrough in the treatment ofRRMS patients is evident 
in the recent results of clinical trials in which recombinant IFN beta (IFN]3-l b or IFNJ3-la) was shown 
to significantly reduce the relapse rate. 20 30 3! IFN]3-1 b was the first of the interferons tested in a large-
scale clinical trial in RRMS and SP. 
The IFN]3-1 b results in RRMS were based on pooled results from three-year, multicenter, randomized. 
double blind. placebo-controlled clinical trials each with three parallel treatment groups (placebo vs. 
1.6 MIU vs. 8 MIU IFN]3-1b).30 All patients in the study were given the option of continuing 
treatment in a double-blind fashion, extending the total treatment period to 5.5 years for a proportion 
of patients. Subsequently. tv.ro studies with IFN]3-1 a were performed in RRMS patients. 20 32 
1. The results of all interferon beta trials are comparable. 3D 32 All of the IFN]3"s reduce the relapses in 
MS. 
2. The IFN]3"s have a positive effect on delaying progression in disability over the t'W'O to three year 
trial period. 
3. These effects of IFN]3"s are dose related. Debate over dosage exists, and although the approved 
dosage should be given: the highest tolerable dose is preferred. 
The IFN]3-lb results in SP were based on a three-year. multicenter. randomized. double blind, placebo 
controlled clinical trial with patients receiving either 8 MIU interferon or placebo.3 1 This was the first 
clinical study that showed that interferons might delay disease progression in patients with SP. 
In the event that the favorable effect of interferons on the frequency of acute exacerbations and disease 
activity may have an impact on cost-effectiveness. the present study uses a modelling technique to 
compare the cost-effectiveness of interferon beta with no preventive treatment in patients with MS in 
the UK. The hypothesis is that interferons \Viii lead to a long-term reduction in disease activity. 
including acute exacerbations and disease progression (change in disability over time defmed as 
change in EDSS). and a decrease in morbidity leading to an increased Quality of Life. which will 
offset the expected increased drug costs. 
METHODS 
To estimate the costs and effectiveness of preventive treatment with interferon beta in patients with 
MS versus usual care in the health-care setting of the UK. a lifetime model was constructed using 
decision analysis techniques.33 34 The main analytical plan for the study was an incremental cost-
effectiveness analysis. This approach consists of combining cumulative measures of costs over time 
so 
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with a cumulative measure of effectiveness, resulting in incremental costs per clinical benefit gained 
(e.g .. cost per life year gained). The analysis was performed for a hypothetical cohort of 30-year old 
female patients with initial RRMS. i.e .. patients whose clinical picture was characterized by periods of 
exacerbation (relapse) from which recovery was complete or partial with subsequent mild disability. 
For a more specific measure of impairment.. the Expanded Disability Status Scale (EDSS) was used.35 
In generaL the inclusion criteria used in the clinical trials of interferon beta were used. Effectiveness 
was expressed as Quality Adjusted Life Years (QALYs). The model also included all relevant 
economic measures such as resource utilization patterns associated with outpatient and inpatient care 
for the treatment of MS. indirect costs (working days lost) and direct. non-medical costs. 
The setting of the study was that of the UK health-care system of 1998. The primary perspective of the 
study was that of the NHS according to the NICE guidelines 36. while the secondary perspective was 
that of the society in 1998. Costs used in the model were expressed in 1998 sterling pounds (£). and 
study costs were adjusted to 1998 costs from 1996 costs by using a 4.3% inflation correction.37 The 
cost valuation was based on the direct health-care costs. direct nonmedical costs and indirect costs. 
The costs were discounted by 6% from the second year onwards. and no discounting was applied in 
the first year. The data sources were literature. including clinical trials of interferon beta and other 
interferons, and official price and tariff lists. An external opinion leader validated the methodology 
(model structure and assumptions). 
Description of the Model 
Markov-process analysis techniques were used to model the clinical and economic outcomes accrued 
over a lifetime with or without preventive treatment. An advantage of the Markov process model is 
that it allows modelling ofMS disease progression beyond the follow-up of the clinical trials. 
Figure 1 shows the structure of the Markov model for MS. The model structure for the usual-care 
treatment arm is identical. The first branch point on a tree is called a decision node because it 
corresponds to a choice of treatment - interferon beta or usual care. A decision node is represented as 
a small square (0). Subsequent to the decision node. the structure of the semi-Markov process model 
is shovm. and is identical for both treatment options. The other branch points indicate allowed 
transitions. The cycle time chosen for the model was three years. which closely approximates the 
follow-up period for the interferon beta clinical trials in RRMS and in secondary progressive MS. 
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Figure 1. Simplified version of the semi-Markov model for the base case scenario. Only the sub-tree after 
interferon beta is shown for feasibility purposes. 
82 
"r-N"rAGJ;.I-:>..!>-2 
'--'ST0:0"""-----~~.!-~::1 NT-STAG!; 1-2.,-; 
--\... "'"T-S"rAClbl-O:,L,; NT-NTAGl: l-3.5 
' 
' II "r-STAGJ:-1-:;,.,-;-:;, 
" li 
:: 
1: 
l:i 
,,, 
1·1 "r-S"rACH:-~-4.,-; 
II:; 
1':! 
/11' -r-sTAGJ: ~-'"'-'"' 
11,',/ 
,llli 
DI.:AO 
~------:1 01::-AD 
'----------J DJ:AD 
"r-STAGI:-:>.-4.~ 
~------:_:;\.. "r-N"rAGI:-Z-~." 
'----------o: OJ;AO 
'IIi ~~GJ:.:;,~··":.__::-,' ~------:::\ ... "r-S"rAOt:-:>-7.,-; 
IIi ,, '--------:1 OJiAD 
T-s-rAGI.-1.:>..5-Z 
··, T-N"rAOJ:-1-:<.!> 
-, T·STAGI>2-4.~ 
0, T·STA0I>2-~.~ 
"r-N"rAGL-2-6.~ 
1',i:"""""''"''"''-~(======: c__::TO-,'<TO:AOCO"Lo-To-'0:·0'-:J T-STAGJ:-;<.7.!> 
11
1 
-r.s-rACW-:>-7.,. - "- T-STAGJ:-:t-><." -~ T-STAGr-:-3-><.s 
II/ ::l DI:.AD 
1,/ /------~ce--:T~-S~T~A~G~-~-~0~-·~·':--- ; T-STACli:-3-1<,5 
\.. T·NTAGJ: :<-9.,-; 
I T-STACli:-:<.1<._~-_-;:cl 
'I '------------- OIOAD 
lnwn~~n•~f--T"-c'cToA>ac•~--~"-~"·c'--
DLAD 
OCAO 
1 ' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
' 
NT-STAOI---1-Z." NT-S"rAGC-1-:Z.~ 
NT·STAGC.l-:;1.5 
'----------: OJ,;AD 
NT-STAGI:-1-:<.~ NT-STACli>l-:<,,-; 
~-----~-'-.. NT-NTAGL-:>-4.,-; 
,., 
'',\., 
'----------~ DI:.AD 
1
1
1 \ NT-NTAClt>:Z-4.~ 
,, 
II'', 
,., 
'---------~ Dl-'AD 
N"r-S"rAC;l--:;!.,..~ 
II'•. 
II' ~'- N"r~'-'.T __ AG_•.' __ ·.:;-_".'·--' .·1 "T·'•''TAG,.·.,•.•,T 
1
1
1
,
11 
\!:~::!:~o";_~C'~l.3.:_~-_,~ ~------::~ =-  " '" 
11,',,, NT STAGI>2-6.,-; 
Ill\ =:( "-'T STAClJ: :< 7.,-; I \N"r-S"rAGJO.:;!-<>,,_ ,, 
/1', 
II,' 
/1 \ NT-S"rAGI:-:<-7.,-; 
/,'', 
l1', 
II', 
l
1
1
1
1 
\NT-STACH:-~·"·" 
,, 
,•, 
,., 
--
DCAD 
('~-----~Tc:::N~T~-~ST~A~O~L=--:·T~··' ·--'-.. NT-STAGL-:t-1<.,-; 
'---------:1 DI:.A_D 
NT-NTAGI:-:<-N.,-; 
DI;AD 
11,·\,_~S"rAGI-:-:"·9~;::( DI:AD 
--""'"'----
N"r-S"rAGl_:-;<.9,,-; 
DI:AD 
\Df:AO 
"----- DLAD 
N"r-S"rAGJ_..:;:·<•." 
N"r-S"rAGC-:<-7.!> 
NT-S"rAOI:-:<-7.~ 
::1 N"r-STAOI:-~-9." 
1u~ual ~""" ·.::; [+) 
Cost-effectiveness analysis of interferon beta in multiple sclerosis 
The follow-up time (analytical horizon) used in the model was the remainder of the lifetime after 
diagnosis of RRMS. For this analysis we defmed mutually exclusive Markov states. Initially we 
defmed Markov health states corresponding with severity levels ofMS: 
• Stage I: EDSS :S 3.5 
• Stage II: EDSS 4 to 6.5 
• Stage III: EDSS 7 to 9.5 
• DEAD: EDSS ~ 10 
Because the primary outcome variable in most clinical trials was defined as deterioration from baseline 
by at least 1.0 point on the EDSS for at least three months, the health states indicated above have been 
further categorized to allow for the incorporation of clinical trial results in the model: Stage I-2.5 
corresponds with an average EDSS of2.5: Stage I-3.5 with an average EDSS = 3.5, etc. Finally DEAD 
corresponds with an EDSS of 10. 
In the model, all patients start in the health state "'Stage I-2.5'', which corresponds to the average 
EDSS of patients in the interferon beta clinical trial at inclusion. After one cycle of three years there 
are tv.ro possibilities: a patient will stay in ''Stage I-2.5'' if the EDSS score has not changed by more 
than 1~ a patient will move to "'Stage I-3.5"after a worsening of the EDSS score of more than 1. 
In addition, there will be a number of patients on preventive treatment who drop out during the first 
cycle period due to adverse events. which means that they will receive no treatment for the remainder 
of the follow-up period in the model. Stage I-2.5 has been divided in Stage I-2.5-1 and Stage I-2.5-2 to 
reflect non-compliance during the first cycle (Stage I-2.5-1) and full compliance during subsequent 
cycles (Stage I-2.5-2). 
Therefore the health states were further categorized into Treatment (T) or No Treatment (NT). as 
shown in figure 1. 
Key Model Assumptions 
There are a number of key assumptions upon which the model is based. A three-year cycle time was 
used, because this interval closely approximates the follow-up period of the interferon beta clinical 
trials for preventive treatment in RRMS and secondary progressive MS. 
Follow-Up 
A study by Runmarker et aJ..3S showed that only 20% of the patients progressed to SP after 25 years. 
Therefore, we decided to construct a lifetime model. which allowed us to simulate the reduction in 
disease progression by interferon beta in real life more realistically. 
In the model, all patients start in the health state Stage I-2.5 with an average EDSS of 2.5, which 
corresponds with the average EDSS of the patients in the beta interferon clinical trial in RRMS (IFNJ3-
1b 2.4, placebo 2.3). Hence, the model is based on a hypothetical patient with an EDSS-score of2.5. 
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The model was based on an analysis of high-dose interferon beta. as prospective clinical studies have 
been performed in RKMS as well as in SP. 
Follow-up for estimating the effect of preventive treatment with interferon beta in RRlvfS and 
secondary progressive MS are available for up to three years. Follow-up data for the no preventive 
treatment arm came from follow-up data for the placebo arms of interferon clinical trials. Disease 
progression is based on the definitions which are used in the clinical trials: worse = change in 
EDSS> 1: stable= no change in EDSS. 
Disease Progression 
• Stage I. EDSS < 4.5. Disease progression was based on the IFN~-lb clinical trial in RRMS (mean 
EDSS at inclusion= 2.4): 
• Stage II. EDSS 4.5 to 7.5. Disease progression was based on the IFN~-lb clinical trial in 
secondary progressive MS (mean EDDS at inclusion= 5.2): 
• Stage III. EDSS 7.5 to 9.5. We assumed that beyond the actual follow-up period for the trial of 
IFN~-lb in secondary progressive MS, all treatment strategies have the same rate of disease 
progression and use the disease progression for placebo from clinical trials as a state transition 
matrix in the Markov process. Hence. although the disease progression can differ during the actual 
follow-up period of the clinical trials as a result of the treatment. progression beyond this period is 
assumed to be the same whether patients received preventive treatment or not. although this may 
be an underestimation of the effectiveness ofiFN~-1 b. 
• EDSS 9.5 until death. We assumed that there was no difference in mortality betv.reen patients with 
or without preventive treatment. 
Noncompliance was derived from the IFN~-lb trial in RRMS only. We assumed that noncompliance 
occurred only during the first cycle of our model and was due only to adverse events. Consequently, 
noncompliance data from the interferon beta clinical trial in SP was not used as patients in the IFN~­
lb clinical trial in SP started treatment with IFN~-lb which does not correspond with patients in our 
model who had already proven to be compliant. 
Acute Exacerbations 
• Stage I= EDSS < 4.5. The incidence of acute exacerbations was based on the IFN~-lb clinical 
trial in RRMS. 
• Stage II= EDSS 4.5 to 7.5. The incidence of acute exacerbations was based on the IFN~-lb 
clinical trial in SP. 
• Stage III = EDSS 7.5 to 9.5. We assumed that SP patients in stage III did not experience 
exacerbations anymore, and consequently assumed no benefit in terms of preventing acute 
exacerbations with IFN~-lb beyond the actual follow-up period of the interferon beta clinical 
trials. 
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The initial cohort in the model consisted of 30--year~old women. based on literature data. The mean 
age of onset forMS is during the late 20's and early 30's. and females are more susceptible by a factor 
2:1.1 
Age-specific population mortality rates for women were used. assuming that MS did not alter life 
expectancy. Literature did not yield evidence for an increased mortality risk due to MS. 
Clinical and Economic Outcomes 
Effectiveness 
The effectiveness measurement was based on the concept of utility, which measures the QAL Y 
(Quality Adjusted Life Years).3940 
Cost Assessment 
The cost assessment was based on the assignment of costs to the health states associated with a cycle 
time of three years. The costs of each health state were determined by the resource utilization 
associated with each health state: medical resource utilization (e.g .. medication. consultations) and 
non-medical resource utilization. Non-medical resource utilization included workdays lost, 
transportation, community assistance and home modifications. 
DATA SOURCES 
Three different types of data can be distinguished in modelling studies: 
• Probabilities of clinical events. which generally are out of the control of the physician. e.g .. 
probability of an acute exacerbation, disease progression; 
• Utilities of different Markov health states; 
• Costing information derived from estimates of the units of resource utilization and their 
prices/tariffs (product of unit and price). 
The probabilities of clinical events were based on interferon beta clinical trial data. while the utilities 
and costs were derived from two cross-sectional srudies. The prices and tariffs were derived from 
official lists. 
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Table 1. Clinical data and sources. 
RRMS 
From EDSS- 2.5 to EDSS- 4.5 
Continuation after first cycle INFB 8 :MIU 
Progression placebo 
Progression INFB 8 MIU 
Progression interferons 
minimum* 
maximum* 
SP 
From EDSS- 4.5 to EDSS"" 7.5 
Progression placebo 
Progression interferon INFB 8:MIU 
From EDSS"" 8.5 to death 
EXACERBATIONS 
From EDDS 2.5 to EDSS 4.5 
Placebo 
Interferon 
Difference 
From EDDS = 4.5 to EDSS = 7.5 
Placebo 
Interferon 
Difference 
From EDDS = 8.5 to Death 
Probabilities 
Probability per cycle Reference 
0.920 
0.28 
0.20 
0.193 
0.219 
Probability per cycle 
0.50 
0.39 
0.31 
Annual frequency 
1.21 
0.84 
0.37 
0.64 
0.44 
0.20 
0 
P. Duqette et al. Neurology 1993 
43; 655-661 [29] 
Idem 
Idem 
PRIMS Study Group. Lancet 
1998;352:1498-504 [20] 
Idem 
European Study Group (mean 5.2) 
[30] 
Idem 
Wcinshcnker BG et al. Neurology. 
1996:46;1613-19 [3]. 
P. Duqctte ct al. Neurology 
1993;43o655-61 [29] 
Idem 
European Study Group (NB (mean 
5.2) [30] 
Assumption 
Probabilities were derived from published literature (Table I). 
• Stage I: EDSS = 2.5 to 4.5: probabilities of disease progression and incidence of acute 
exacerbations derived from the interferon beta clinical trial in RRMS. 
• Stage II: EDSS = 4.5 to 7.5: probabilities of disease progression and incidence of acute 
exacerbations derived from the interferon beta clinical trial in secondary progressive MS. 
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Stage III: EDSS 8.5 to death: probabilities of disease progression derived from a meta-analysis of 
the placebo-treated groups in clinical trials in progressive Ms.17 
Age-specific population mortality rates for women derived from national statistics dara.22 
Utilities 
The QAL Ys for the different health states were derived from a cross-sectional study, and are shown in 
Table II.25 The classification of disease severity in this study corresponds with semi-Markov health 
states in our model. We also incorporated a temporary utility loss per relapse, which was derived from 
the same study- a reduction of 0.5 utility over a period of one month. 
Table II. Utilities for health states. fHealth Technologv Assessment 1998 (25)1 
Health state Utility 
EDDS utilities Stage Fixed input value 
EDDS-3 0.71 
EDDS-4 II 0.66 
EDDS-5 II 0.52 
EDDS-6 II 0.49 
EDDS-7 III 0.35 
EDDS-S* III 0.17 
EDDS-9" Ill 0.08 
DEAD 0.00 
Utility loss 
Relapse 0.5 
Costs 
Data on costs were derived from another cross-sectional study (Table III).16 This study used a 
retrospective approach, in which resource utilization and clinical data were collected at a single time-
point and covered the three months period prior to the dates of inclusion. 
The cost of care ofMS was calculated for patients in current clinical practice in the UK in 1996. which 
did not include costs of preventive treatments like interferons. Therefore the cost of interferon beta 
was added to health states corresponding to preventive treatment ("T -health states'"). 
The costs due to relapses were not separately presented in the cost of care study. Therefore we 
subtracted the costs of avoided exacerbations from the costs of health states that included preventive 
treatment with interferon beta. The direct medical costs due to an exacerbation were derived from the 
cost-effectiveness study in initial RRMS.25 
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Table III. Costs for health states. excluding cost of interferon. rMurphv et al .• 1998 05)1 
Health state Costs (£) 
Perspective mean 
Societal 
-Stage I 3500 
-Stage II 4,612 
- Stage III 9,989 
Health insurance 
-Stage I 535 
-Stage II 616 
-Stage lii 2020 
Cost per relapse 2.115 
Annual costs INFB 10500 
median 
2,829 
3.266 
6,906 
361 
348 
682 
Reference 
Murphy 1998 
Health Technology Assessment 
1998 
The friction cost method was applied to the evaluation of workdays lost by active patients. According 
to this method. the value of productivity loss was assumed to be 80% of the average value of a 
worker's productivity during the "friction period". Thereafter. it was assumed that sick employees 
could be replaced. Time lost by inactive patients was considered as leisure time lost and was valued at 
40% of the average wage in the UK.41 The replacement salary method (i.e. estimation of the wage that 
would be paid to a home-helper to perform the work that the patient was unfit to do) was applied to the 
valuation of care-giving time.42 We assumed that the number of working days lost associated with a 
relapse corresponded with relapse length, which was derived from the same study. 
ANALYSES 
The base-case analysis represents the expected average effectiveness and costs per patient discounted 
at 6%, while undiscounted costs were also included. An incremental cost-effectiveness analysis 
representing the additional cost and effectiveness obtained when a preventive treatment with interferon 
beta is compared to no treatment was also performed. 
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Univariate sensitivity analyses were based on the modification of the basic clinical and economic 
assumptions in the clinical outcome model to test the stability of the conclusions of the analysis over a 
range of assumptions, probability estimates and value judgments. Sensitivity analyses were performed 
only for the primary perspective of this study, that of the NHS. 
The first sensitivity analysis was performed to assess the impact of relapses on the analysis by 
excluding the clinical and economic consequences of relapses. We performed a second analysis to 
assess the sensitivity of the analysis to the annual costs of interferon beta. The bounds for this analysis 
were based on annual costs of other interferon treatments. A third sensitivity analysis was performed 
for the cost of a relapse. The costs per relapse in the study by Health Technology Assessment included 
both ambulatory treatment and hospitalization. As this input variable had a wide range of values. the 
model was potentially highly sensitive to if25 A fourth sensitivity analysis was performed on the costs 
of the health stages derived from the study by Murphy 16 (Table II) by using median costs of all three 
health stages instead of the mean costs. The fifth sensitivity analysis involved constructing an interval 
around the rate of disease progression. The bounds for this analysis were based on the rates of disease 
progression in RRMS. which have been published for other interferons. The rates were adjusted to 
transition probabilities corresponding to a three-year cycle time. 
The three previous sensitivity analyses were performed from the NHS perspective only. We also 
performed a sensitivity analysis on a 3% discount rate from the societal perspective according to VH's 
guidelines. 
RESULTS 
Based on the probabilities. utilities and the costs of the direct health-care utilization described in 
Tables I. II and III a base case-analysis was performed to obtain an expected value for the average 
total costs and the average QAL Y. Tables IV and V show the economic and effectiveness outcomes of 
the base case analysis for preventive treatment with interferon beta and no preventive treatment in MS 
from the third-party payer and societal perspectives respectively. The total average discounted cost per 
patient for the preventive treatment of an MS patient starting from RRMS was £221.436 for the 
interferon beta group versus £51.214 for the no treatment group (discounted at an annual rate of 6% ). 
A break do\VU of the costs shows that the higher costs of the interferon group are attributed to the cost 
of interferons (£179,367). while the other costs were £51.214 and £42.069 for the no treatment group 
and interferon group respectively. Based on the modeL the average QAL Y of the interferon group was 
28.2 years vs. 24.9 years for the no treatment group (Table IV). a gain in QAL Ys of 3.3 years. The 
differences in cost and effectiveness resulted in an incremental cost-effectiveness for interferon beta of 
£51582 per QAL Y gained. 
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Table IV. Results of cost-effectiveness: health insurance. 
INFBCE, Usual care CEM Difference 
Undiscounted Costs(£) 
INFB 498505 0 
Other 161.475 210.824 
Total 659,980 210.824 449,156 
Discounted Costs(£)* 
INFB 179,367 0 
Other 42,069 51.214 
Total 221.436 51.214 170.222 
Effectiveness 
QALYs 28.2 24.9 3.3 
Cost per QAL Y gained: 
Discounted costs and QAL Y s 51.582 
Table V shows the results of an analysis from the societal perspective. The total average discounted 
cost per patient for preventive treatment of an MS patient was higher in the interferon beta group at 
£473.115 versus £322.499 for the no treatment group, discounted at 6% per annum. The use of 
interferons substantially reduced the other costs from £322.499 to £293,748. 
Table V. Results of cost-effectiveness analvsis from societal perspective. 
INFBCEF Usual care CEM Difference 
Undiscountcd Costs(£)* 
INFB 498505 0 
Other 1.032.212 L209A09 
Total 1.530.717 1,209,409 321.308 
Discounted Costs(£)* 
JNFB 179367 0 
Other 293,748 322.499 
Total 473.115 322.499 150,616 
Effectiveness 
QALYs 28.2 24.9 3.3 
Sensitivity Analysis 
Sensitivity analyses were performed on the main probabilities and cost assumptions to test the 
robustness of the cost-effectiveness results. Table VI shows the results of the sensitivity analyses. The 
first two sensitivity analyses were performed to assess the impact of discounting. They show that the 
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incremental cost-effectiveness ratio is quite sensitive to discounting of both economic and clinical 
outcomes. A sensitivity analysis was also performed to assess the impact of relapses on the 
incremental cost-effectiveness ratio. When the cost of relapse and the utility loss due to relapse were 
excluded. the incremental cost-effectiveness of interferon beta was £38.222 compared to the base case 
result of£51582, which shows that the model is moderately sensitive to the inclusion of relapses. A 
sensitivity analysis was also performed on the annual cost ofiFN~-lb. When the annual cost is varied 
from £ 6000 to £ 12.000. the incremental cost-effectiveness ratio changes substantially from £28.280 
to £59,348. When the medical cost of a relapse is varied between its lower and higher range (£1.000 to 
£3,000). the incremental cost-effectiveness ratio changes only from £47.028 to £50.275. We also 
performed a sensitivity analysis on the disease progression v.rith interferon beta. When this was varied 
between minimum and maximum values. the incremental cost-effectiveness ratio increased from 
£43.520 to £56,756. Finally a sensitivity analysis was performed on a 3% discount rate for both costs 
and effectiveness. which shows that the use of interferon beta increased the costs from £510,940 to 
£701.410, while the QALYs increased from 24.98 to 28,12. 
Table Vl. Results of sensitivitv analvsis. 
Variable 
Health insurance pcn.-pective 
Basis 
No discounting of costs 
Discounting of effectiveness (2%) 
Excluding relapses 
Annual costs INFB (£) 
Medical relapse cost 
Disease progression 
Society perspective 
Discounting of costs and effectiveness at 3% 
DISCUSSION 
Rang-e of values 
6.000-12.000 
1.000-3.000 
RMMS: 0.193- 0.219SP: 
0.351-0.429 
Extra costs(£) 
199.470 
Cost per QALY gained 
Discounted 
5L582 
136.108 
113,]08 
38.222 
28,280---59348 
47,028~50275 
43.520~56.756 
QAL Y s gained 
3.14 
This study examined the cost-effectiveness of preventive treatment with interferon beta compared to 
no preventive treatment of patients with MS in a British setting. The analysis revealed that interferons 
were much more cost-effective compared with the results of a previous cost-effectiveness study. which 
was performed in patients with RRMS only.25 The incremental cost-effectiveness ratio in our study 
was £5L582 per QALY. while the outcomes in the other study were £328.300 and £228.300 per 
QALY over a period of 5 and 10 years respectively. This substantial reduction in the cost-
effectiveness ratio of interferon beta may be due to a longer follow-up period in our study, including 
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continuation of treatment with interferon beta in SP. Sensitivity analysis showed that our model was 
especially sensitive to discounting, the cost of interferon beta and disease progression. The results of 
this study showed that cost-effectiveness of a preventive treatment with interferon beta in MS 
substantially improves. when the use in SP is incorporated in the health economic analysis. 
The results of any modelling exercise need to be treated with some degree of caution. We have used 
various data sources for our model. which all have their pros and cons from a health economic 
perspective.21 Among them is the fact that our literature review does not necessarily represent real 
clinical practice. as much of the literature examined was based on data from clinical trials. Data from 
clinical trials do not necessarily have a high degree of external validity. as the results are often 
contingent upon protocol adherence, a situation that may not be easily reproduced outside the trial 
setting. The utilities in our model were derived from a cross-sectional study based on clinical 
treatment practice without the use of preventive treatment with interferon beta. The utility of a health 
state is a function of both underlying disease (e.g. severity) and adverse events associated with 
treatment. In our model we valued the health states only according to severity levels corresponding to 
the EDSS severity scale regardless of the usc of preventive treannent with beta interferon. Hence. the 
assumption in our model was that treatment with interferons did not affect the utility of the health 
states. Consequently the utilities did not take into account a potential lower utility of health states 
associated with interferon trcannent due to adverse events. Finally we did not include the costs 
associated with treatment of adverse events resulting from treatment with interferon beta, which may 
have underestimated the total costs for preventive treatment. 
Modelling of disease progression was constrained by published clinical trial data. Those data were 
presented as the percentage of patients staying at the same EDSS level or moving to a worse EDSS 
leveL which may have involved more than one transition. However the published data did not show 
more detailed data.. which may be due to statistical constraints: interferon may indeed reduce the 
number of patients progressing more than one EDSS leveL but the statistical significance of this effect 
may be more difficult to prove. 
Finally the study focused mainly on the cost-effectiveness of IFN~-lb 8 MIU only. demonstrating 
robustness of the outcomes of the model when using clinical trial data from other interferons. A meta-
analysis based on pooled results of the various interferon trials may have lead to more reliable input 
data for the model. However this approach was not feasible for a number of reasons: there was only 
one trial in SP that showed that interferon beta reduces disease progression: dose relationships did not 
allow us to cluster the different interferons and determine average rates: clinical trials did not have 
similar follow-up. The IFN~-1 b trial had a follow-up period of three years. while other trials had a 
follow-up of only two years: populations in the trials in RRMS were not similar, which is shown by 
different placebo outcomes as well as initial EDSS scores. 
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Comparing the modeled disease progression for no preventive treatment with real life data from a 
study by Runmarker et aL.38 quantitatively validated our model, which did not include preventive 
treatment with interferons. After 24 years. approximately 18% of the patients in our model progressed 
to SP. This outcome corresponds with findings in the study by Runmarker et aL3s. where 20% 
progressed to SP after 25 years. A limitation in the study by Runmarker may be the small number of 
patients and the inclusion of patients with progressive MS, which may explain the slower disease 
progression in our modeL 
CONCLUSION 
In conclusion. the study showed that preventive treatment with interferon beta in patients with 
multiple sclerosis may not be fully justified from a health-economic perspective. although interferon 
beta is associated with an improved effectiveness compared with no preventive treatment. 
Development of clinical guidelines may be used to optimize the cost-effectiveness outcomes and 
budgetary constraints. A suitable approach is the prospective collection of health economic data and 
utilities in a naturalistic setting to validate the preliminary fmdings of this model and generate 
guidelines based on real life data. 
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The Incorporation of Potential Confounding 
Variables in Markov Models 
SUMMARY 
The data in modelling studies may come from a variety of sources and are subject to varying degrees 
of uncertainty. A main concern is the use of a panel of experts to gather data, which may be replaced 
by information on costs and utilities from a cross-sectional study for the various health states in a 
Markov model. However the costs and utilities may not be only a function of the defined health states. 
but also of other explanatory variables, which may act as confounding variables when they are not 
taken into account. Hence the external validity of Markov models may be limited. and consequently 
the results of the model are not an accurate reflection of reality. In this manuscript we presented a 
strategy to improve the quality of the methods used in Markov modelling studies by increasing the 
external validity. This strategy consists of an incorporation of an extra explanatory variable in the 
Markov health states by means of health state specific relationships between this explanatory variable 
and costs as well as time-dependent values of the extra explanatory variable. In addition we 
determined the relevance of the incorporation of an extra explanatory variable by means of various 
sensitivity analyses. The concepts were illustrated using a hypothetical Markov model for Parkinson's 
disease. The results showed that the outcomes of a health economic model may be severely biased. 
when a confounding effect of an extra explanatory variable is not taken into account, whic~ proves the 
need for the incorporation of other explanatory variables in a health economic model. 
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INTRODUCTION 
A recent paper showed that there is growing evidence that health economic data is beginning to be 
used more widely by decision makers in the decision- making process for reimbursement of drugs. 1 
Because in practice it is not always possible to derive information from scientifically sound 
prospective studies, health economic models are increasingly used to provide the necessary cost-
effectiveness information.2 This especially applies to chronic conditions such as Parkinson's disease. 
which otherv.rise might require prospective studies over periods varying from 5 to 10 years. In these 
cases models can be used to extrapolate clinical outcomes beyond the duration of the trial.3 
If economic modelling is to play a fundamental role in healthcare decision-making. it is vital that the 
methods and data sources used in modelling studies are carefully scrutinised and refined. The data 
may come from a variety of sources and are subject to varying degrees of uncertainty. Data sources for 
the variables being used in a model may be clinical trials. literature (e.g. meta-analysis). databases, 
medical records, Delphi panels and official tariff lists (for healthcare utilisation). In a previous paper, 
we extensively discussed the advantages and disadvantages of the different kinds of data sources.2 A 
main concern was the use of a panel of experts to gather data. which cannot be derived from the 
literature. There is no guarantee that such an assessment of resource utilisation and utilities accurately 
reflects reality. Considering that results from modelling smdies are of interest to many parties with 
different responsibilities and diverging interests, it is obvious that potential bias due to the use of 
Delphi panels should be minimised. In a subsequent paper we described a strategy for substantially 
reducing the amount of data. which needs to be derived from a Delphi panel. 4 This may substantially 
improve the quality of the input data in a model, and consequently the outcomes on costs and 
effectiveness. An alternative data source for a modelling study was presented, namely a cross-
sectional study. which can be used to yield costs and utilities for Markov health states. The overall 
combined design may be considered a hybrid between a naturalistic prospective study and a modelling 
study by ma'Cimising the pros and minimising the cons of both types of design. This hybrid design is 
based on bridging the probabilities derived from literature and clinical trials v..rith information on costs 
and utilities from a cross-sectional study. 
In our previous study. the health states in our Markov model for Parkinson's disease corresponded 
with severity levels according to the existence of motor fluctuations: "no fluctuations" and 
'"fluctuations". However costs and utilities may not be only a function of the defined Markov health 
states, but also of other variables. Studies by Dodel and Lepen showed that costs are also a function of 
severity according the Hoehn&Yahr scale, a different clinical scale that combines clinical signs and 
functional disability.5 6 The study by Dodel also showed that utilities of the health states also depend 
on the Hoehn& Y ahr scale. Hence costs and utilities may not be only a function of the defined Markov 
health states. but also of other explanatory variables. which may act as confounding variables when 
they are not taken into account. 
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The objective of this manuscript is to present a strategy to incorporate another explanatory variable in 
a Markov model in order to increase the external validity and to detennine the relevance of the 
incorporation of another explanatory variable. 
METHODOLOGY 
Types of Confounding Effect by Other Explanatory Variables 
The confounding effect of other explanatory variables may affect the costs and utilities of health states 
as well as the transition probabilities. 
Health States 
We may distinguish three types of contradictions with external validity, when another explanatory 
variable is not taken into account. 
The first limitation is that assigning a fixed cost to each health state over the follow-up period assumes 
a static distribution of explanatory variables for each health state, while a dynamic distribution should 
reflect the reality. Although some explanatory variables may not change over time (e.g. gender). there 
may be other explanatory variables. which are time dependent (e.g. disease progression). 
A second limitation is that in our original modeL the distribution of the patients over the various health 
states was based on the distribution of the sample of the cross-sectional study, which may not 
correspond with the population distribution in the clinical triaL A related limitation is that the trial 
population may not be representative of the target patient population that is going to use the drug due 
to its restriction on external validity. Consequently the average health-specific costs/utilities derived 
from the sample may differ from reality. when the distribution of an explanatory variable is not taken 
into account. 
Transition Probabilities 
The model structure and stratification of Markov health states are based on the primary clinical 
outcome of the clinical trial and the initial transitions in a model usually are derived from those 
efficacy measures. In this example the efficacy measure of the trial was the reduction of the 
development of fluctuations. and the health states were ''no fluctuations" and "fluctuations". However. 
disease progression in PD may be also measured by the Hoehn&Yahr scale. which takes into account 
a much broader range offactors.7 It is conceivable that progression according to Hoehn&Yahr may 
depend on existence of fluctuations and consequently may be different for patients with and without 
fluctuations. This type of covariance should be taken into account by balancing the treatment anns for 
all potential confounding variables: in this example the distribution according to Hoehn&Yahr stage 
should be similar bet\veen the treatment anns. Since clinical trials are only powered to prove 
differences in efficacy between the study drug and the comparator, it is difficult to identify other 
explanatory variables and detennine a statistically significant relationship on the basis of the clinical 
97 
Chapter 7 
trial data, for example a regression equation where efficacy is a function of the study drug and the 
other explanatory variable. 
Finally covariance may also exist between the efficacy of study drug and the explanatory variable. In 
this example the new study drug may not only reduce the development of fluctuations. but may also 
reduce disease progression according to Hoehn& Y ahr stage. 
Figure 1. Markov model for Parkinson's disease 
_no~ucmalions __ ~] 
, 1-Pprogression 
-.:__n:u.c.t]..l._~Jj.Qns, ___ ..-1 
us_ual_G_ai:_e_r'f - ---._1 
L Pprogression fluc_tuati_pns __ -,_fl:!!_CJ}J._~lions,__ _ / 
stratell)' I ~o~uctuations__ I 
_no.:_fluctuations_ l-Pprogress10n AP 
~_fluctuations - c] 
Table I. The fixed input values for the Markov model. 
Stage Costs (€) Utility 
(3 months) 
No fluctuations 
Fluctuations 
Mean 
972 
2.138 
Mean 
0.73 
0.49 
Disease 
progression 
(3 months) 
0.0252 
As in the previous paper. concepts are illustrated for a hypothetical Markov model for Parkinson's 
disease. which will be used to model the cost-effectiveness of a hypothetical new anti-Parkinson drug 
(AP) in Gennany.4 Published real data were used. whenever possible. but we had to rely on 
extrapolation methods in absence of real data in order to illustrate the relevant issues. This new drug is 
supposed to be used as add-on therapy to usual care. The perspective is that of the health insurance. 
Figure 1 shows the overall structure of this model and the clinical and economic data used to construct 
the model summarised in Table I. The stratification of the Markov health states is based on the 
primary clinical efficacy measure of the phase III clinical triaL which was the existence or absence of 
motor fluctuations. Our model is based on the follovring assumptions: 
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• The Markov health states in this model correspond with severity levels according to the existence 
of motor fluctuations: ''no fluctuations" and ··fluctuations". 
• Disease progression corresponds with the development of fluctuations. We assume that AP will 
reduce the probability of development of fluctuations annually by 10%. The probability of 
fluctuations for usual care was based on a study by Rinne (Table 1).8 
• We assume that beyond the actual follow-up period of the trial (1 year) the delay in disease 
progression due to treatment with AP will continue at the same rate beyond the clinical trial 
period. 
• The severity according to Hoehn&Yabr scale is the only other explanatory variable. 
• The model has a follow-up period of 5 years: the cycle time is 3 months, which is based on the 
follow-up period of the cross-sectional study. We assume that there is no mortality during this 
study period. 
• In our model a hypothetical cohort of persons with no fluctuations will receive AP or usual care. 
After the first cycle patients may have remained without fluctuations or have become fluctuators. 
Patients will continue the treatment with AP for the remainder of the study period. also when they 
have become fluctuators. 
• Costs and utilities are discounted at 5%. 
Incorporation of Other Explanatory Variables 
An option is a further stratification of the Markov states by incorporating severity according to the 
Hoehn&Yabr scale. Figure 2 shows the Markov model after incorporating the severity according to 
the Hoehn&Yabr scale. This approach has several methodological consequences. Figure 2 shows that 
the incorporation of only one explanatory variable substantially increases the complexity of the modeL 
which will decrease the transparency of the model. There is general consensus to limit the complexity 
of models for purposes of transparency. Bu.'{ton offered a number of recommendations for good 
practice in modelling. The first recommendation is that the model should be kept as simple as possible 
to aid understanding by decision makers.9 The incorporation of more than one extra explanatory 
variable would further increase the complexity of the model. 
The stratification of the model is also constrained by the availability of data sources to be used in the 
model yielding data on: transition probabilities. units ofhealthcare utilisation and utilities. 
• Transition probabilities: The probabilities for the initial transitions in a model usually correspond 
with the efficacy measures derived from a clinical trial. However the clinical trial for a new drug is 
only powered to show a statistical significant difference betv.reen the study drug and comparator 
for the broad indication. Therefore the trial will not have enough power to detennine statistically 
significant transition probabilities for subpopulations based on the stratification according to other 
explanatory variables. 
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Figure 2. Markov model for Hoehn& Y ahr stage. 
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• Healthcare utilisation and utilities: When the cross-sectional study is used to determine costs and 
utilities for Markov health states. the stratification of health states according to the other 
explanatory variables will result in a substantial increase of subpopulations and consequently a 
larger total sample size is required, which may not be feasible, especially when more explanatory 
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variables are included."- In the initial model for Parkinson's disease the data collection was 
performed only for two health states: "no fluctuations" and "fluctuations". 
The incorporation of other explanatory variables in a Markov model consists of the follo-wing steps: 
Step1: Development of health state-specific linear models 
This strategy consists of an extension of the hybrid design by combining Markov modelling and 
regression models using a cross-sectional study design. We described in the previous paper in detail 
the execution of a cross-sectional study. and consequently will focus here only on relevant issues 
related v.rith the incorporation of explanatory variables. The mean values of all units of costs and 
utility were initially determined for each severity level (''"no fluctuations" and "fluctuations"), which 
were incorporated in the corresponding health states in the Markov model. An extension of the 
previous strategy is to determine relationships between the costs/utilities and the explanatory variable 
"Within each health state. We will focus on costs only. but the approach for utilities may be considered 
to be largely similar. 
In the existing Markov model the costs per health state are only a constant function of the defined 
health state: ··no fluctuations" and ••fluctuations". 
C-NF~ f(state-NF) 
C-F~ f(state-F) 
(Eq. 1) 
"Where C-NF represents the mean costs of the health state "no fluctuations" (NF) and C-F the mean 
costs of the health state .. fluctuations" (F) in Euro (€). 
The first step consists of the development of a relationship between the health states and the other 
explanatory variable (Hoehn&Yahr score). We develop two separate health-specific linear models for 
"no fluctuations" and .. no fluctuations··. because covariance may exist between the Hoehn&Yahr stage 
and the existence of motor fluctuations. Consequently we defmed the following relations: 
C-NF~ C1NF. whenHoehn&Yahris1: (Eq.2) 
C2NF. when Hoehn&Yahr is 2: 
C3NF. when Hoehn&Yahr is 3: 
C4Nf. when Hoehn&Yahr is 4: 
CSNF. when Hoehn&Yahr is 5: 
C-F~ C1p. whenHoehn&Yahris 1: 
C2f. when Hoehn&Yahr is 2: 
C3f. when Hoebn&Yahr is 3: 
C4p. when Hoehn&Yahr is 4: 
C5p. when Hoehn&Yahr is 5: 
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The weighted costs of each health state at cycle t are based on the distribution of the five Hoehn& Y ahr 
at cycle t: 
C-F1~ Fln Cl p+ F2p1. C2p+ F3n C3p+ F4p1. C4p+ F5p1. C5p 
Where FlNFt· F2NFt, F3NFt· F4NFt· F5NFt are frequency distributions of the five Hoehn&Yahr 
stages in the health state '"no fluctuations"' at cycle t: and Fl Ft· F2p,. F3p,, F4p,. F5pt are frequency 
distributions of the five Hoehn& Y ahr stages in the health state '"fluctuations" at cycle t. 
Step 2: Incorporation of health state-specific linear models in a Markov model: determination 
of time-dependent values of an explanatory variable 
In the model. all patients start in the Markov health state corresponding with the indication of the drug 
(Hoehn&Yabr 1) and subsequently progress to higher severity levels. The values F (FlNFt· F2Nft, 
... F5Nft and Flft· F2ft. ... F5pt) in the above-mentioned equations reflect the disease progression 
from Hoehn&Yahr 1 to Hoehn&Yahr 5: the distribution will be skewed to the left in early PD. but 
skewed to the right in advanced PD. Hence they are time-dependent variables. because they are a 
function of the time spent in the model. 
Analysis 
We performed various analyses in order to assess the impact of the above- mentioned contradictions 
with external validity. when an explanatory variable is not taken into account. 
Initial Distribution 
The distribution of the patients in the health state NF in the initial model at t=O was based on the 
sample of the cross-sectional study, which did not correspond with the clinical trial population 
consisting only of patients in Hoehn&Yahr stage I (FlNFJ=l). Consequently the average health-
specific costs derived from the sample may differ from the reality, when the cost of the health state NF 
at t=O is only based on patients in Hoehn&Yahr I. 
The new anti-Parkinson drug AP is indicated for patients with initial symptoms of PD: state=NF and 
FlNf=l corresponding with the clinical trial population. However the trial population may not be 
representative of the patient population who is going to use the drug in daily practise. We used in our 
model the frequency distribution of the AP clinical trial and performed a sensitivity analysis on the 
initial frequency distribution in order to test the impact of this type of error. 
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Table II. The fn.:ed input values for the Markov model. 
Stage Transition Costs 
Probability (€) 
(3 months) 
NF F 
H&Yl 0.195 121 633 
H&Y2 0,095 848 1.036 
H&Y3 0,090 917 US! 
H&Y4 0,055 1.223 1,601 
H&Y5 LOOO 2,137 5,956 
Subsequent Distributions 
The study by Davey provided data on the time-dependent relationship for disease progression 
according to Hoehn&Yahr (Table II). 10 A Markov model was constructed. which consisted of five 
Markov health states corresponding with five Hoehn&Yahr stages (Figure 3): the cycle time and 
follow-up corresponded with original model: 3 months and 5 years respectively. The Markov model 
was used to determine a frequency distribution for the Hoehn&Yahr stages at every cycle. In the base 
case analysis we assumed that disease progression according to the Hoehn& Y ahr scale is independent 
of the existence of fluctuations and that AP will not influence the disease progression according to the 
Hoehn& Y ahr scale. Therefore extra sensitivity analyses were performed to determined on: 1) The 
existence of covariance between efficacy of study drug and explanatory variable and 2) The existence 
of covariance between health states and the explanatory variable. 
Figure 3. Markov model for Hoehn& Yahr stage. 
~ H&Yl H&Yl ~ 0 
fl H&Y2 
pl2 
<l H&Y2 H&Y2 # 
~ £! H&Y3 p23 ~ H&Y3 H&Y3 ~ 0 # 
t3 H&Y4 
p34 
H&Y4 H&Y4 # 
# : H&YS p45 H&Y5 ~ ~ H&YS 
f5 
RESULTS 
The base case analysis is based on a 10% improvement for AP. The adjustment for the explanatory 
variable is based on 1) a correction for the distribution of the patient population. 2) the stratified costs 
for each health state according to the Hoehn&Yahr s and 3) the incorporation of the disease 
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progression for the Hoebn&Yabr. The frrst column of Table III shows the outcomes. when the analysis 
is based on fixed values for the health states without incorporating the explanatory variable 
Hoebn&Yabr stage. The other column shows the results of analysis, when adjusting for the 
Hoebn&Yabr stage. 
Table ill. Results: base case comearison and sensitivitv on imerovcment AP. 
Base-case AP:ZO% 
comparison improvement 
(AP: 10% 
imJ!rovement} 
Fixed Adjusted Fixed Adjusted 
Value value 
Costs (€) 
Usual care 22,007 9.358 22.007 9.358 
AP 25,000 12,620 24,619 12.514 
Difference 2.993 3.262 2.612 3,156 
269 544 
Change (9.0%) (20.8 %) 
Utilities 
Usual care 3.12 3.12 3.12 3.12 
AP 3.14 3.14 3.16 3.16 
Difference 0.02 0.02 0.04 0.04 
ICR 149,650 163,100 65,300 78,900 
Change 13.450 13,600 
(9.0%) (20.8%) 
The absolute costs for both usual care and AP decrease substantially from respectively €22,007 to 
€9.358 and from €25,000 to €12.620. On the other band. the increase in costs by using AP increases 
from €2,993 to €3.262, which is a 9.0% increase. The utilities do not change, because we did not 
adjust utilities for the explanatory variable. The incremental cost-effectiveness ratio (ICR) increases 
from 149,650 to 163.100 €/QALY. which is also an increase of9.0%, because the utility difference 
does not change. This table also shows that a 20% improvement for AP further decreases the costs and 
ICR for AP in analyses with and without adjustment for the explanatory variable. However the 
difference increases from 9.0% to 20.8%. Hence the incorporation of an explanatory variable 
substantially changed the outcomes, which is sensitive to the extra clinical benefit of the study drug. 
Table N shows the results of a sensitivity analysis for AP. when the distribution of the cost of care 
patient population is used. which differs from the clinical trial population (external validity). H&Y 1: 
20%. H&Y 2: 30%, H&Y 3: 20%, H&Y 4: 20%, H&Y 5: 10%. The results show that the costs for 
usual care and AP are very sensitive to the distribution of the initial population: an increase from 
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€9,358 to €22,738 and from €12.620 to €25.811 for respectively usual care and AP. However the ICR 
only changes from €163.!00 to €153,650. 
Table IV. Results: patient distribution based on the cost-of-care study. 
Base-case New 
outcomes 
Costs (€) 
Usual care 9.358 22.738 
AP 12.620 25.811 
Difference 3.262 3,073 
ICR 163,100 153.650 
Table V shows results of a sensitivity analysis for AP, when the clinical trial population is not 
representative of the patient population who is going to use the drug in daily practise. We assumed that 
not only non-fluctuating patients in H&Y stage I are going to use the drug. we assumed following 
distribution H&Y 1: 80%. H&Y 2:20%. H&Y 3: 0%. H&Y 4: 0%. H&Y 5: 0%. The results show that 
the model is not very sensitive to the discrepancy between clinical trial population and the .. real" 
patient population. 
Table V. Results: external validity 
(clinical trial versus real population). 
Base-case New outcomes 
Costs (€) 
Usual care 9358 10,867 
AP 12.620 14J34 
Difference 3,262 3.267 
ICR 16300 163350 
Table VI shows the outcomes. when we assume covariance between efficacy of the study drug (AP) 
and the explanatory variable (H&Y): AP reduces disease progression according to H&Y by 10%. The 
costs for 1\P decrease from €12.620 to €12,190. while the costs difference with usual care decreases 
by €430. The incremental cost-effectiveness ratio (ICR) changes from 163100 to 1.416,000 €/QALY. 
Hence the existence of covariance betv.reen efficacy of study drug (1\P) and explanatory variable 
(H& Y) may also influence the outcomes of the model. 
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Table VI. Results: covariance AP and H&Yprogression. 
Base-case New outcomes 
Costs (€) 
Usual care 9.358 9.358 
AP 12.620 12.190 
Difference 3.262 2.832 
ICR 163.100 141.600 
Table VII shows the outcomes. when we assume covariance between health state and explanatory 
variable (H&Y): disease progression according to H&Y is 10% lower in patients without fluctuations 
and 10% higher in patients with fluctuations. This analysis also affects the outcomes for usual care. 
The costs for usual care decrease from €9358 to €7,338: the costs for AP decrease from €12,620 to 
€10,066. The costs difference with usual care changes from €3,262 to €2,728 and the incremental cost-
effectiveness ratio (ICR) changes from €163.100 to 136.400 €/QAL Y. Hence the existence of 
covariance between health state and the explanatory variable (H&Y) may substantially influence the 
outcomes, and in this example especially the ICR. 
Table VII. Results: covariance fluctuations and H&Y 
(H&Y progression depends on fluctuations). 
AP Base-case New outcomes 
Costs (€) 
Usual care 9,358 7.338 
AP 12.620 10.066 
Difference 3.262 2.728 
ICR 163.100 136.400 
Table VIII shows the results of a probabilistic sensitivity analysis, which was based on the 
distributions of the costs. This analysis shows that the total uncertainty associated with outcomes of 
the model substantially decreases after the adjustment for the Hoehn&Yahr classification: The 
standard deviation after incorporation of the Hoehn& Y ahr state is only approximately 10% of the 
standard deviation of the initial model for both treatment arms. 
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Table vn. Results of probabilistic sensitivity analysis. 
SD (€) Base-case New 
outcomes 
Usual care 14,614 L947 
AP 14,862 L960 
DISCUSSION 
In this manuscript we presented a strategy to improve the quality of the methods used in Markov 
modelling studies by increasing the external validity. This strategy consisted of an incorporation of an 
explanatory variable in the Markov health states by means of health state specific relationships 
between the explanatory variable and costs as well as time-dependent values of the explanatory 
variable. In addition we further explored the consequences of incorporating an explanatory variable by 
means of various sensitivity analyses. The strategy was applied to a hypothetical Markov model for a 
new product AP in Parkinson's disease. The results showed that the outcomes of a health economic 
model can be severely biased, when other explanatory variables are not taken into account. 
In addition we showed that this discrepancy is due to three different types of contradictions with 
external validity: 1) fixed costs for each health state over time versus time-dependence of costs of each 
health state over time due to other time-dependent explanatory variables~ 2) initial model population 
distribution corresponding with the cost of care study versus initial model population distribution 
adjusted to the clinical trial population and 3) the discrepancy between the trial population and the 
actual population. In addition we showed the sensitivity of the outcomes of the model to: 1) 
covariance for time-relationship between health state and the other explanatory variable and 2) 
covariance between efficacy of study drug and the other explanatory variable. The sensitivity analyses 
showed that the bias may vary for each type of error and may differ for the various outcomes (costs, 
ICR) of the model. For example, in this study the error due to inappropriate patient distribution mainly 
changed the economic outcomes. while the cost-effectiveness remained similar. 
There are a number of limitations in this study. The current strategy is based on a number of 
assumptions, which may often not hold, and may be in conflict with reality. An assumption was that 
the Hoehn&Yahr scale was the only confounding variable. Literature showed also the existence of 
other confounding variables, for example age and ADL.6 Incorporation of a higher number of 
confounding variables may increase the external validity of the Markov model, but the feasibility 
depends on the statistical power of underlying cost-of-care data and may consequently substantially 
increase the necessary sample size for a cross-sectional study. An alternative is the use oflongitudinal 
observational databases, which are designed to measure the clinical and economic impact of a 
particular disease in a large number of patients without any intervention with real practice. Another 
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limitation was that this study only considered the impact of other explanatory variables on costs, while 
ignoring the consequences on utility outcomes. 
Although the incorporation of other explanatory variables in the model introduces the extra 
uncertainty associated with those variables, the sensitivity analysis for this model in PD showed that 
this extra uncertainty is more than offset by the reduction of the overall uncertainty of the model. The 
Markov states ""F" and '"NF" are heterogeneous populations, when taken into account the 
Hoehn&Yahr stage and consequently the costs show a large variance. The additional stratification 
according to the Hoehn& Y ahr stage within each Markov state yields more homogenous 
subpopulations, which consequently will show less variance in costs. This reduction in variance may 
be counterbalanced by lack of statistical power, when the sample sizes for the subpopulations become 
too small. 
From the perspective that results from modelling studies are of interest to many parties vvith different 
responsibilities and diverging interests, it is obvious that recognising the relevance of explanatory 
variables and appropriately dealing with explanatory variables is required for obtaining unbiased 
results from health economic modelling studies. especially when those data are being used for 
reimbursement decisions. Although this study clearly showed the relevance of the confounding 
variable using a specific example. we recommend development of more general methodologies, which 
can be applied for dealing with confounding variables taking into account all types of error. which 
were identified in this study. For example. the impact of an explanatory variable on utilities should 
also be incorporated in the modeL and subsequently the modelling of the interaction of costs/utilities 
and measures of disease progression needs to be considered. 
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Measuring Sensitivity in Pharmacoeconomic 
Studies: 
An Integration of Point-sensitivity and Range-
sensitivity 
SUMMARY 
The level of uncertainty v.rith regard to the outcomes of pharmacoeconomic studies cannot be 
completely covered by the statistical methods routinely employed to handle uncertainty in clinical 
research. Sensitivity analysis is the most common methodology to deal with the extra uncertainty 
associated with pharmacoeconomics, and has also been incorporated in recent guidelines on healthcare 
evaluation. However, the execution of a sensitivity analysis and the interpretation of its results have 
not yet been standardised, which may lead to subjectivity and consequently weaken the value of 
economic evaluations. This article presents a method of dealing more systematically with uncertainty 
and eliminating potential bias in sensitivity analysis, with regard to the measurement of sensitivity and 
the comparison of the degree of sensitivity between variables. An assessment of the disadvantages of 
using slope as a measure of sensitivity leads to 2 types of sensitivity analyses (point-sensitivity and 
range-sensitivity), which are integrated into one method for the measurement of sensitivity. 
ChapterS 
INTRODUCTION 
Escalating costs have become a major concern for healthcare professionals. decision-makers and the 
public. prompting the increasing use of economic evaluations of healthcare alternatives. Health care 
economic research identifies measures and compares the costs and clinical outcomes of different 
treatment strategies. In the process. inputs (in the form of costs of resources consumed) are compared 
with outputs (such as the benefits to the patient resulting from a specific treatment). Healthcare 
economic evaluation is a science using epidemiological. economic and clinical methodologies that 
studies the appropriate use of medical interventions and is a tool that can give guidance to efficient 
resource allocation in health care. 
Economic evaluation is beginning to be used widely to support decision makers in health services for 
allocation of scarce health care resources, and guidelines for evaluations have been developed in 
Australia and Canada. L.Z Because economic evaluation is used for pricing and reimbursement issues by 
authorities or third-party payers. it is vital that these analysis are performed according to generally 
accepted and standardized methods. This increases the transparency of pharmacoeconomic studies. 
allowing a more rational interpretation of results and a better comparison of different studies. 
The importance of dealing systematically and comprehensively with uncertainty is often overlooked 
by many analysts. Udverhelayi et al note that although authors frequently mentioned the limitations in 
their underlying assumptions. only 30% of the studies used sensitivity analysis to explore the effects 
of changes in those assumptions. 3 
Sensitivity analysis is currently the most widely applied method of dealing with uncertainty in 
economic evaluations. A sensitivity analysis is based on the modification of the basic clinical and 
economic estimates of parameters over a plausible range of values, in order to judge the effect on 
study results of alternative assumptions for the range of potential values for uncertain parameters.4 
Most recent pharmacoeconomic publications contain sensitivity analyses on several parameters. 
However. a sensitivity analysis is often perfonned on only a limited number of variables. without 
justification of the choice of selected variables or the chosen range of each variable. In addition. the 
interpretation of the results of a sensitivity analysis remains subjective as there is no scale for 
measurement of sensitivity and consequently there is no threshold value for discriminating between 
"sensitive" and "not sensitive". 
A recent publication of by Briggs recommends standardization of the methodology of sensitivity 
analysis in order to increase the reliability of economic evaluations.5 Although the current guidelines 
recommend sensitivity analyses. they do not contain any particular requirements regarding how to 
perfonn such an analysis.6 7 The Australian guidelines. for example. suggest determining the 
sensitivity of the overall analysis by substitution of the upper and lower confidence limits of the 
variable parameters. In addition to this one-way sensitivity analysis. the Canadian guidelines 
encourage more sophisticated approaches. such as Monte Carlo simulation. which permits the analyst 
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to assign ranges and distributions to uncenain variables that are being modelled using decision-
s 
analytical techniques. 
The present study describes a mathematical approach to measuring sensitivity, and defines 2 types of 
sensitivity (point-sensitivity and range-sensitivity): a general strategy is described incorporating both 
types of analysis. The concept is illustrated by application of the process to an economic evaluation 
based on decision analytic techniques, since such analyses are widely used in pharmacoeconomic 
studies and the results are becoming generally accepted by regulatory authorities.12 6 In addition. since 
sensitivity analysis is already being applied in decision analysis provides a useful tool for illustration 
of the refmed concept described here.9 
METHODS 
Model Description 
Decision analysis a well-recognized method for analysing the consequences of decisions that are made 
under uncertainty.9 It is an explicit. quantitative, prescriptive approach to medical decision making and 
allows both clinical and economic consequences of medical actions and attitudes to be analysed under 
conditions of uncertainty. 
From treatment algorithms, a decision tree model can be constructed. which considers the timings of 
actions and their consequences over time. A decision tree consists of a series of branches. each 
representing different options (decisions or events). which arise at different points. referred to as nodes 
(e.g. decision node and chance nodes). In effect. the decision tree provides a therapeutic model. 
showing the consequences and complications of different therapeutic interventions. 
The model resulting from the decision analysis must correspond. as much as possible. to the real life 
situation of the disease and should reflect actual treatment patterns. with input values (probabilities 
and items of health care utilization) deviating as little as possible from population values. Data sources 
for the variables being used in a model may be meta-analysis. databases, clinical trials and/or Delphi 
panels. and for each variable a fixed input value and a range can be derived. 
The analysis. being based on a fixed input value for all variables, will yield the basic average outcome 
per patient (e.g. average number life years. average costs per patient). The fe<ed input value can be the 
mean in the case of a large sample size (for example a database), whereas the median is recommended 
for smaller sample sizes. The range of each variable is then used to determine the sensitivity of the 
outcome to the analysis. when the input value is varied within its range. 
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Figure 1. The Markov state model for depression. 
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To illustrate the application of the sensitivity analysis technique described here, a Markov model is 
used and applied to the economic outcomes of maintenance treatment with selective serotinin reuptake 
inhibitors (SSRls) as the first choice therapy for depression over a 1-year follow up period. The 
general structural details of the Markov depression model have already been described in a previous 
paper and the specific details of the model with respect to depression are shovm in figure 1. 10 
The model in figure 1 defines 4 mutually exclusive states: no depression. mild depression, severe 
depression and chronic depression and the patient's progression through these states is divided into 6 
cycles of 2 months each. which closely approximates the time of the sequential therapeutic stages. 
Chronic depression represents an absorption state, and after entering this state, a patient remains there. 
The transition probabilities bet\Veen the states are based on response rates to treatment and relapse 
rates after termination of treatment; Table 1 shows the probabilities for each transition in the model. 
This information was obtained from published literature values and current clinical practice.10 The cost 
assessment was based on the assignment of a fixed cost to each health state. which depends on the 
choice of therapy: Table 1 lists these costs. together v.rith the source material for the valuation. Further 
details of the sources for the clinical and economic data. with respect to depression. have been given in 
a previous article. 10 
In the present srudy, the depression model is being used only to illustrate the concept of sensitivity. 
The range of variables has been chosen to show the relevant issues involved in sensitivity analysis 
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without considering their external clinical relevance. The input values have been varied to illustrate 
the concepts of point sensitivity as applied to the model for depression. 
Table I. Point-sensitivitv analvsis at fixed input values for variables in the depression model. 
Variable Fixed Input Point 
Clinical probabilities 
Response rate to frrst-linc treatment 
with an SSRI (p 1) 
Response rate to TCA after SSRI 
treatment failure (p2) 
Response rate to another TCA after 
earlier TCA treatment failure (p3) 
Response rate to hospitalisation (p4) 
Relapse rate during maintenance 
treatment with SSRI (rl) 
Relapse rate during no treatment after 
response to a TCA (r2) 
Economic ($US):I.·* 
Daily treatment cost of SSRI 
(DTC-SSRI) 
values Sensitivitv 
0.60 -1.23 
0.30 -0.39 
0.30 0.40 
0.50 0.45 
0.04 0.06 
0.10 0.01 
2 0.03 
Daily treatment cost ofTCA 0.19 0.00 
(DTC-TCA) 
Consultation tariff(CT) 50 0.02 
Per diem tariff (pd)* 500 0.94 
Abbreviations: SSRI - selective scrotonine reuptake inhibitor: TCA - tricyclic 
antidepressant 
* From NuijtcnlO 
**From TLG Costing Database. 1995 
RESULTS 
Measurement of Sensitivity 
The most common graphical result of a sensitivity analysis for a decision-analytic model is a linear 
relationship bet\Veen an input variable and an outcome. Figure 2 shows the relationship between the 
per diem tariff and the average total direct medical costs per patient over a 1-year period. when the 
former is varied from $US200 to $US800 within the depression model. The basic average cost per 
patient is $13,813 for a fixed input value for the per diem of$US500. 
The slope of the line in figure 2 provides a measure of the sensitivity of the outcome to a variation in 
the per diem tariff and is directly proportional to the outcome. However, the slope of a sensitivity line 
is a limited measure of responsiveness of the outcome to a change in a variable because it does not 
take into account the fixed input value and the range associated with that variable. Instead the slope 
depends only on the structure of the model and the fixed input variables of the other variables. 
Point-sensitivity 
In the sensitivity analysis for the per diem. which is shown in figure 2, the slope of the line is identical 
for every range of input values. However, an increase in the per diem of. say. SUS200 is a large 
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increase for a fixed input value of $US200 and a less significant increase for a fixed input value for the 
per diem of $US800. In addition. by an analogous argument. knowing the difference in outcome is 
not very revealing. unless compared with the basic average outcome. An increase of $US 100 is quite a 
significant reaction to the value of the per diem, if the foldback outcome (average total direct medical 
costs) is $US200. but it is less significant if the foldback outcome is SUSI.OOO. 
To take account of the fixed input value. sensitivity is best calculated by comparing the percentage 
change in input value to the percentage change in outcome value. 
In many respects. measuring the responsiveness of the demand for a quantity of a particular 
commodity to changes in its price is similar to a sensitivity analysis in the present context. in which 
the extent of responsiveness of an outcome to changes in an input variable over a range are quantified. 
Figure 2. Sensitivity analysis for the per diem tariff. Using the model for depression. the outcome (average 
total direct medical cost over a 1-year period) was determined for different input values for the per diem 
tariff. ranging from $US200 to SUS800. 
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In economics, the price elasticity of demand ( Tt) is a measure of the responsiveness of quantity of a 
commodity to a change in market price and is defmed as: the percentage change in quantity demanded 
divided by the percentage change in price. 11 The changes in price. and the resulting changes in 
quantity, are expressed as a percentage change. with respect to the average price or quantity. 
Therefore. this equation provides a measure of the responsiveness, or elasticity. of one item \Vith 
respect to the other. The more responsive the quantity demanded to changes in price. the greater the 
elasticity and the higher the absolute value of 11· The direction of the relationship betvveen the price 
and quantity determines the sign of TJ. Measuring the extent of responsiveness of quantities to changes 
in price is similar to the concept of sensitivity analysis. in which the extent of responsiveness of an 
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outcome to changes in an input variable over a range is detennined. Hence, sensitivity may be defmed 
according to the formula of elasticity. as: 
Sensitivity=(~ outcome/~ input) x (average input/average outcome). (Eq. 1) 
where··~ outcome" represents the change in outcome resulting from a change in input( .. ~ input"). 
This definition for sensitivity (11,), may be written symbolically in the following form. in which Y and 
X represent outcome and input values respectively: 
11, = (~Y/6X.) x (average X/average Y) (Eq. 2) 
where the averages over the arc of the sensitivity curve are being considered (fig 2). The 
responsiveness of outcome to an input value at a particular point on a sensitivity curve can also be 
determined. a concept referred to as point-elasticity. The precise definition of point-elasticity uses the 
concept of a derivative, and is given by: 
11, ~dY /dX X XN (Eq. 3) 
where 1Js in this case refers to point-elasticity. and X and Yrepresent the fixed input value and the fold 
back outcome. respectively. 
Point-elasticity in sensitivity analysis measures the responsiveness of the outcome to the input value at 
a fixed point and does not include any associated range of the input. In the case of a linear sensitivity 
relationship. the formula for point-elasticity can be simplified in he following manner. IfY=outcome 
and X=input then the equation of the sensitivity line is: 
Y~(axX)+b (Eq. 4) 
The slope a of the line may be given by: 
a=dY/dX (Eq. 5) 
Hence, by substitution in equation 3: 
lls =ax XIY (Eq. 6) 
or: 
11, ~(a X X)/[(a X X)+ b)] (Eq. 7) 
This equation for point-elasticity permits the determination of the sensitivity of outcome to input. an 
analysis that in the present study. is referred to as point-sensitivity. From equation 7. it is clear that 
the determination of point-sensitivity is dependent on the slope of the line and the fixed input value. 
but is not related to the range of a variable. 
For example, if the point-sensitivities are determined for per diem tariffs of $US200 and SUSSOO. 
using the equation derived above. the respective values are 0.87 (relatively inelastic) and 0.96 (nearly 
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elastic) for a=26 and b=795. These values show that the outcome in the depression model is more 
point-sensitive to a per diem of SUS800 than for of $US200. The point-sensitivity shows how critical 
a variable is for the model and it allows a comparison between all variables, which is not confounded 
by the range of each variable. The overall relationship between a range of per diem values and point-
sensitivity is shown in figure 3. and similar calculations can be made for all the variables in the 
depression modeL In Table L point-sensitivity values. together with the respective sign of the value, 
have been calculated for all the variables in the modeL According to the terminology of economic 
elasticity, the higher the absolute value for point-sensitivity. the more sensitive the model is to this 
particular variable_ I! The most critical parameter for the model is the response rate to first-line 
treatment v.rith an SSRI (pi)~ the outcome of the model is perfectly point-sensitive to this variable, in 
that lls (pi) is larger than one. whereas the per diem tariff (pd) yields a moderate point-sensitivity, v.rith 
a 11" (pd) value of 0.94. The negative sign of the point sensitivity of pi means that an increase in 
response rate to first-line treatment leads to a reduction in direct medical costs. In contrast, the 
outcome of the model is not point-sensitive (i.e. inelastic) to the other variables since '7s is smaller than 
one. Nevertheless, there is a substantial difference in point-sensitivity between the response rate to 
hospitalisation (0.45) and the daily treatment cost of an SSRI (0.03). 
Range-sensitivity 
The slope of a sensitivity analysis (fig. 2) does not take into account the responsiveness of outcome to 
the range of an input value. For example. using the data in figure 2. the sensitivity. as determined by 
the slope. for a fixed input value of $US500 (slope = 26) is identical for a small range ($US400 to 
$US600) and a large range ($US200 to SUS800), However. a sensitivity analysis based on an input 
value with a large range clearly leads to a larger difference in outcome than an input value with a small 
range and. hence the response of the outcome is very much dependent on the range of the input value. 
Therefore. the difference in outcome between a fixed input value of $US500 with a small range 
($US400 to $US600) and a large range ($US200 to $USSOO) is $US5.207 and $US15,62l. 
respectively (fig. 2). 
The most common currently used method of measuring sensitivity is based on determination of the 
difference in outcome when an input value is varied within its range. This type of sensitivity analysis. 
defined for the remainder in this article as range-sensitivity, does not depend on the fixed input value, 
but instead depends only on the range of the variable. Therefore, the range-sensitivity for a per diem 
ranging from $US200 to $US300 would be identical to that of a per diem varying from $US400 to 
SUS500. As range-sensitivity depends only on the range of a variable, the change in outcome v.rith 
respect to a variable input can be expressed as: 
.6.0utcome = slope x .6.Input 
or: 
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where the slope a is derived from the appropriate sensitivity curve (fig 2). Table II shows a range-
sensitivity analysis for all the variables in the depression modeL in which range-sensitivity is 
expressed as the absolute difference in outcome between the minimum and maximum input values. It 
is clear that the per diem tariff is the most critical variable when this value ranges from SUS200 to 
SUSSOO. leading to an absolute difference in outcome of $US15.621. However. if the data source 
used provides a per diem with a much smaller range in values. the absolute difference in outcome 
would clearly be considerably less. 
Table II. Range-sensitivity analysis. Range-sensitivity is expressed as the absolute difference in outcome 
between the minimum and maximum input values. 
Variable Input values 
Clinical probabilities* 
Response rate to first-line treatment 
with an SSRI (p 1) 
Response rate to TCA after SSRI 
treatment failure (p2) 
Response rate to another TCA after 
earlier TCA treatment failure (p3) 
Response rate to hospitalisation (p4) 
Relapse rate during maintenance 
treatment with SSRI (rl) 
Relapse rate during no treatment after 
response to a TCA (r2) 
Economic ($US)** 
Daily treatment cost of SSRI 
(DTC-SSRI) 
Daily treatment cost of TCA 
(DTC-TCA) 
Consultation tariff (CT) 
Per diem tariff (pd)* 
min.-max. 
0.50-0.70 
0.15-0.20 
0.10-0.50 
0.10-0.90 
0.02-0.10 
0-0.50 
Fixed 
FLxed 
10-90 
200-800 
Absolute change 
in outcome ($) 
5.650 
891 
7,436 
9.850 
1.661 
932 
0 
0 
526 
15.621 
Relative 
range-sensitivitv 
0.41 
0.06 
0.54 
0.71 
0.12 
0.07 
0 
0 
0.04 
1.13 
Abbreviations: SSRI selective scrotoninc rcuptakc inhibitor: TCA tricyclic antidepressant 
* From Nuijten10 
** From TLG Costing Database, 1995 
Another disadvantage of the absolute difference in outcome as a measure of range-sensitivity is that it 
does not take into account the basic average outcome: the model for depression discussed in the 
present study with an outcome of $US13,813 is less sensitive to an absolute difference of SUS15.621 
than a model v.rith a 10-fold lower outcome ofSUS1.381. The relative-range-sensitivity. determined by 
dividing the absolute difference in outcome by the basic average outcome. permits direct comparison 
of different pharmacoeconomic studies, provided they have similar outcomes. 
Overall Sensitivity 
In the examples shown in Table II, the per diem tariff is the most range-sensitive variable. However. 
as discussed above. the degree of range sensitivity of the per diem tariff depends on the range of the 
input and the same principle applies to any variable used to assess sensitivity. In order to determine 
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which variable has the most impact on a modeL point-sensitivity and range-sensitivity can be 
integrated into an overall measure of sensitivity. The combination is achieved using the concept of an 
integral of point-sensitivity betv.reen the lower and upper limits of the range of an input variable. For 
the per diem tariff, this would correspond to the area under the point-sensitivity/per diem curve (AU C) 
[fig. 3] between the upper and lower limits of the range of the variable. 
Figure 3. The relationship between point~sensitivity and per diem tariff for the depression model. Point-
sensitivity was determined for different per diem values (US$200 to US$800) using the methods described 
in the text. 
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However, a severe limitation of this approach is that the area under the curve for one variable cannot 
be compared to another, as each measurement has its own units. based on the units of the input 
variable. For example, for the per diem tariff the unit of the overall measurement is $US. while the 
measurement for the response to hospitalisation is a value without a unit of measurement. 
On the other hand. a relationship bemreen point-sensitivity (determined according to the range of an 
input variable) and the corresponding outcome allows the determination of an overall measure of 
sensitivity. based on the units of the outcome (in this case. $US). Consequently. the measurement of 
sensitivity has the same units for all variables in the model. In figure 4. point~sensitivity has been 
determined for a range of the per diem tariff and plotted against the outcome for each per diem tariff. 
liS 
integration of point-sensitivity and range-sensitivity 
Figure 4. The relationship between point-sensitivity and outcome (direct medical cost in $US). 
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The AUC in this case gives a measure of overall sensitivity, which can also be calculated by 
integration. 
From equation 3: 
l]" ~ (dY/dX) x (X/Y) 
l]" ~(a X X)/[( ax X)+b] 
Y~(ax X)+b 
x~(Y-b)/a 
Therefore, by substitution: 
l]" ~ (Y -b )/Y ~ 1-b/Y 
By integration of this last equation, the following expressions for the measurement of overall 
sensitivity can be obtained: 
upper limit 
overall sensitivity= [Y -b x Ln(Y)] 
lower limit 
The advantages of this approach are demonstrated in figure 5, in which the sensitivity of the 
depression model has been detennined for per diem input (pd) and response rate to first-line treatment 
with a SSRl (pi). The variable inputs can be directly compared. in terms of their effect on outcome. 
even though they themselves have different units. in this case US$ (per diem tariff) and a probability 
of response rate. This graph shows that the overall sensitivity of the per diem (pd) is largely 
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determined by its range-sensitivity, while the overall sensitivity of the response rate (pi) mainly 
depends on the point-sensitivity. 
Figure 5. Overall sensitivity analyses for 2 variables of the depression model in. Point~sensitivity and 
outcome (average total direct medical cost per patient over a l~year period) were determined for a range 
of input values for the per~diem tariff (pd) and the response rate to first~line treatment with an SSRI (pl). 
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The advantage of the concept of overall sensitivity is that all variables can be ranked, incorporating 
both types of sensitivity as shown in Table III. In addition to the absolute value. a relative overall 
sensitivity can be determined. This measure is determined by dividing the value for overall sensitivity 
by the basic average outcome of the model. Relative overall sensitivity allows a comparison of 
sensitivity of variables betvveen different studies with similar end-points (e.g. costs). 
Perhaps the greatest advantage of the measurement of overall sensitivity is the ability to directly 
compare the impact of all the variables on the model for depression. Table III shows that the per diem 
tariff is the most sensitive parameter for this model while other parameters. such as the relapse rate 
during maintenance treatment with an SSRI. have little or no effect. 
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Table III. Overall sensitivitv for all variables in the model for depression. 
Variable Overall absolute Overall relative 
Clinical probabilities* 
Response rate to frrst-line treatment with an SSRI (pi) 
Response rate to TCA after SSRI treatment failure 
(p2) 
Response rate to another TCA after earlier TCA 
treatment failure (p3) 
Response rate to hospitalisation (p4) 
Relapse rate during maintenance treatment with SSRI 
(r1) 
Relapse rate during no treatment after response to TCA 
(r2) 
Economic (SUS)** 
Daily treatment cost of SSRI 
(DTC-SSRI) 
Daily treatment cost ofTCA 
(DTC-TCA) 
Consultation tariff (CT) 
Per diem tariff(pd)* 
sensitivity sensitivity 
($US) 
7.114 
173 
3..266 
5.045 
144 
30 
0 
0 
12 
14.602 
0.52 
0.01 
0.24 
0.37 
0.01 
0 
0 
0 
0 
1.06 
Abbreviations: SSRI selective scrotoninc reuptakc inhibitor. TCA tricyclic antidepressant 
* From Nuijten10 
**From TLG Costing Database. 1995 
A measure of the total level of uncertainty of the model associated with input values may be 
determined by measurement of the cumulative relative overall sensitivity, being a summation of all 
relative overall sensitivity values for all variables. which are shovro. in Table III. In the current model. 
the total relative sensitivity was 2.20. This measure of total relative sensitivity may also be used to 
compare different sru.dies. 
DISCUSSION 
A method of dealing v.rith uncertainty is presented in this paper. The concept has been illustrated for a 
modelling study. but may also be applied to other designs of economic evaluations. In most 
pharmacoeconomic studies. however, the uncertainties created by sampling error are minuscule 
compared to those created by assumptions and therefore sensitivity analyses are indispensable for 
modelling studies, like the one presented. 
The overall sensitivity measurement is based on combining point-sensitivity and range-sensitivity. 
This method allows an objective judgment to be made of the sensitivity of all variables of the model, 
which subsequently may be ranked according to degree of sensitivity. This approach avoids the 
subjective selection of variables for the sensitivity analysis and the potential bias in judging the degree 
of sensitivity in most current economic studies. Additionally, the relative overall sensitivity enables 
an objective comparison between the impact of a variable in 2 different studies. Finally, the total level 
of uncertainty of a model may be detennined by summation of the relative overall sensitivity of all 
variables. 
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Measuring Sensitivity in Pharmacoeconomic 
Studies: Refining Point-Sensitivity and Range-
Sensitivity by Incorporating Probability 
Distributions 
SUMMARY 
OBJECTIVE: The aim of the present study is to describe a refinement of a previously presented 
method. based on the concept of point-sensitivity. to deal with uncertainty in economic studies. 
DESIGN: The original method was refined by the incorporation of probability distributions which 
allow a more accurate assessment of the level of uncertainty in the model. In addition. a bootstrap 
method was used to create a probability distribution for a fixed input variable based on a limited 
number of data points. The original method was limited in that the sensitivity measurement was based 
on a uniform distribution of the variables and that the overall sensitivity measure was based on a 
subjectively chosen range which excludes the impact of values outside the range on the overall 
sensitivity. PATIENTS AND PARTICIPANTS: The concepts of the refined method were illustrated 
using a Markov model of depression. MAIN OUTCOME MEASURES AND RESULTS: The 
application of the refined method substantially changed the ranking of the most sensitive variables 
compared with the original method. The response rate became the most sensitive variable instead of 
the 'per diem' for hospitalisation. CONCLUSIONS: The refinement of the original method yields 
sensitivity outcomes, which greater reflect the real uncertainty in economic studies. 
Chapter9 
INTRODUCTION 
Sensitivity analysis is currently the most widely used method to deal with uncertainty in economic 
evaluations. A sensitivity analysis is based on modification of the basic clinical and economic 
estimates of parameters to judge the effect on study results of alternative assumptions for the range of 
potential values for uncertain paramcters. 1 Most recent pharmacocconomic publications contain 
sensitivity analyses on only a limited number of variables, v.rithout justification of the choice of 
selected variables or the chosen range of each variable. In addition, the interpretation of the results of a 
sensitivity analysis remains subjective, as there is no scale for measurement of sensitivity and. 
consequently. there is no threshold value for discriminating between "sensitive" and "non sensitive" 
variables. 
In a previous study, we described an objective method we developed for usc in sensitivity analyses 
which minimizes the amount of potential subjectivity.2 This new procedure. employing point-
sensitivity and range-sensitivity. allows an objective judgment of the sensitivity of all variables of a 
model. permitting the variables to be ranked according to the degree of sensitivity. This approach 
avoids the subjective selection of variables for the sensitivity analysis and the potential bias in judging 
the degree of sensitivity in most current economic studies. Additionally, the determination of relative 
overall sensitivity enables an objective comparison between the impact of a variable in 2 different 
studies. Finally. the total level of uncertainty of a model may be determined by summation of the 
relative overall sensitivity of all variables. 
Figure 1. The Markov state model for depression. 
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Overall sensitivity: incorporation of probability distributions 
The aim of the present study is to describe a refinement of the strategy by the incorporation of 
probability distributions in the original study. As in the previous study, concepts are illustrated using a 
Markov model which determines the economic outcomes of a maintenance treatment with selective 
serotinin reuptake inhibitors (SSRis) as first choice short term treatment, then continued as a 
maintenance treatment in responders over a 1-year follow up period. Figure 1 shows the overall 
structure of this model. and the clinical and economic data used to construct the model are summarised 
in Table I. Further details on the structure of the model and the sources of the clinical and economic 
data as well as the fixed input values for the model. are given in a previous paper.2 However. in the 
present study the distribution of variables are not based on real data, but rather have been chosen to 
illustrate the relevant issues associated \Vith the incorporation of probability distributions. 
MEASUREMENT OF SENSITIVITY 
Summary of Concepts 
Point-sensitivity analysis measures the responsiveness of the outcome to the input value at a fixed 
point and does not include any associated range of the input In the original study. the definition of 
point-sensitivity was based on the concept of point-elasticity (equation 1) where l]s refers to point-
elasticity and X and Y represent the fixed input value and the outcome, respectively. 
~,~dY/dXX/Y (Eq. 1) 
In the case of a linear sensitivity relationship (Eq. 2) a more simple formula (Eq. 3) can be used: 
(Eq. 2) 
~,~a ·X/(a·X+b) (Eq. 3) 
where a and b are constants 
Range-sensitivity analysis measures the difference in outcome when an input value is varied \Vithin its 
range; this difference depends on the range of a variable and the slope. This can be expressed as: 
(Eq. 4) 
where the slope a is derived from the appropriate sensitivity curve. In this equation M represent the 
range of the input value. 
Point-sensitivity and range-sensitivity were integrated in the previous study into an overall measure of 
sensitivity by using the concept of an integral of point -sensitivity between the lower and upper limit of 
the range of the output. This can be expressed as: 
upper limit 
AOS~ [Y-b x Ln(Y)J 
lower limit 
(Eq. 5) 
where AOS is the absolute overall sensitivity of an input variable and Ln is the natural logarithm. 
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Table I. Clinical and economical data: input values and range. 
Variable* _,I,n..,p.;u;ct v.:ca~l"u"'cs'-----;-:-----------.,-
fixed lower range upper range 
Clinical probabilities 
Response rate to first-line treatment 
with an SSRI (pI) 
Response rate to TCA after SSRI 
treatment failure (p2) 
Response rate to another TCA after 
earlier TCA treatment failure (p3) 
Response rate to hospitalisation (p4) 
Relapse rate during maintenance 
treatment with SSRI (rl) 
Relapse rate during no treatment after 
response to a TCA (r2) 
Economic ($US) 
0.60 
0.30 
0.30 
0.50 
0.04 
0.10 
0.49 
0.25 
0.10 
0.10 
0.02 
0.00 
0.70 
0.35 
0.50 
0.90 
0.10 
0.50 
Daily treatment cost of SSRI 2 N .A.** N .A. 
(DTC-SSRI) 
Daily treatment cost ofTCA 0.19 N.A. N.A. 
(DTC-TCA) 
Consultation tariff(CT) 50 10 90 
Per diem tariff(pd) 500 200 800 
Abbreviations: SSRI selective serotoninc reuptakc inhibitor: TCA - tricyclic antidepresssant 
* Further detail on data sources is given in a previous article (Nuijten 1997)2. 
**: N.A.: not a licable. 
Rationale for Adjustment of the Original Method 
The formula (Eq. 5) for the determination of the AOS shows that this measure of sensitivity assumes a 
uniform distribution for the outcome (Y). This relationship holds if the input value (X) of a variable has 
a uniform distribution according to the relationship defined in the Eq. 2: 
(Eq. 2) 
However the real distribution of the input variable may correspond with a variety of probability 
distributions. Table II shows the real distribution and the rational behind the determination of the fixed 
input value and the range for each variable: these were the values used for the determination of overall 
sensitivity in the previous study.2 The impact of the assumption of uniform distributions of the 
outcome ( Y) on the overall sensitivity is shown in figure 2. where outcome is total direct medical costs 
associated with treatment of depression over a period of 1 year following initial medication SSRis. 
The distribution of the outcome (Y) corresponding to a real distribution of pi (the response rate to a 
first choice treatment with an SSRI) and that corresponding to a uniform distribution and range of pi 
(on which the measurement of the overall sensitivity was previously based) arc depicted. On this basis. 
the assumption of a uniform distribution will lead to an underestimation of the point-sensitivity for 
values near the mean {pi=0.6: Y=l3.813). whereas this assumption will lead to an overestimation of 
the point-sensitivity near the lower (pJ~0.5; Y~!6.637) and upper value (pl~0.7; Y~!0.987) of the 
range. Hence the original method for the determination of the overall sensitivity should be adjusted to 
the real probability distribution by weighting the different intervals. 
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The second limitation of AOS (Eq. 5) was that the overall sensitivity measure was based on a 
subjectively chosen range. which excludes the impact of values outside the range on the AOS. In the 
original analysis. the range for pi was based on a 900/o confidence interval (CI). where the lower limit 
was >5% and upper limit was <95%. while the range for the per diem hospitalisation values (pel) was 
based on the absolute minimum and maximum values of a sample of per diem values (n=200). In the 
original analysis. pd was a more sensitive variable than pi: the AOS of pd and pi was 14.602 and 
7J 14. respectively. However. an extension of the range of pi from a 90% to a 98% CI more than 
doubles the AOS from 7J 14 to 17.073. and consequently pi becomes a more sensitive variable than 
pd (7.1 14>14,602). Hence, in the case of a continuous distribution (e.g. normal distribution) without a 
real minimum and maximum. the AOS of a variable depends on the choice of the CI. In order to solve 
the impact of the subjectively chosen range. a correction for the weight of each interval should be 
applied. This can also be used to determine an appropriate CI (e.g. 99%. 99.9%). which approximates 
the hypothetical 1 00% interval. 
Table II. Clinical and economical input data for the model: determination offi.xed input values and range. 
data source and distribution. 
Variable Input values 
Fixed 
Clinical probabilities 
pi mean 
p2 mean 
p3* mean 
p4 median 
rl mean 
r2 mean 
Economic ($US) 
DTC-SSRI price 
DTC-TCA price 
CT mean 
pd 
* 
** 
mean 
C.I.: confidence interval 
Ql-Q3: first and third quartile 
1'\.A.: not applicable. 
TLG Costin):! Database. 
METHODS 
ranae 
5-95% C.l.* 
5-95% C.l. 
Ql-Q3'' 
Ql-Q3 
Minimum-maximum 
Minimum-maximum 
N.A.*** 
N.A. 
Minimum - maximum 
Minimum - maximum 
Data source 
meta-analysis 
meta-analysis 
meta-analysis 
Delphi 
clinical trial 
clinical trial 
TLG costing database**** 
price list (n=l) 
price list (n-1) 
tariff list (n=IO tariffs) 
per diem list (n=200 hospitals) 
Distribution 
Normal 
Normal 
not known 
not known 
Discrete 
Discrete 
N.A. 
N.A. 
Discrete 
Discrete 
The details of the refmement (incorporation of probability distributions) to the previously described 
method of reducing uncertainty in economic studies based on the concept of point-sensitivity (see 
Measurement of Sensitivity section) are described in this section. The concepts are illustrated by using 
the depression Markov model (figure 1). 
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Figure 2. The extrapolated distribution of the outcome (US$) for pl. 
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General Methodology for the Adjustment 
This section presents a mathematical method to correct for the real distribution of an input variable. A 
correction consists of the following steps: (i) the probability distribution of outcome Y is extrapolated 
from the real probability distribution for input value X, (ii) the total area under the point-
sensitivity/outcome curve is divided into a number of intervals~ (iii) the AOS is determined for each 
interval; (iv) a total weighted AOS is determffied by summation of the weighted AOSs of all intervals 
and; (v) the total weighted AOS is divided by the -width of the intervals. This correction is performed 
for each input variable. and subsequently the input variables can be ranked according to the adjusted 
absolute overall sensitivity. The remainder of this section describes the mathematical approach to 
determine the adjusted AOS based on the previous steps. 
Refined Mathematical Method for Determining the Adjusted Absolute Overall 
Sensitivity 
The formula for overall sensitivity (Eq. 5) was described above sensitivity (see Measurement of 
Sensitivity section). In order to divide the total area under the curve into a number of intervals, Eq. 5 is 
divided into the following parts: 
YO+d Y0+2d YO+nd 
AOS~[Y-b·Ln(Y)]+ [Y-b·Ln(Y)]+ .... [Y-b·Ln(Y)] (Eq. 6) 
YO YO+d YO+(n-l)d 
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Where YO and YO+nd correspond with respectively the lower and upper limit, d is width of each 
interval and n is number of intervals. Within each interval. we assume that there is a uniform 
distribution. 
In Eq. 6. the contribution of every part to the total AOS is similar. because of the assumption that the 
distribution of Yis uniform within its range. In Eq. 7 the AOS of each interval is weighted according to 
its relative frequency. 
YO+d Y0+2·d YO+n·d 
AOSoqJ/fu·[Y-b·Ln(Y)]+f2/fu·[Y-b·Ln(Y)]+ ........ £'fu·[Y-b·Ln(Y)]+ (Eq. 7) 
YOr YO+d YO+n·d 
Where fu is frequency of each interval according to a uniform distribution, which equals lin and 
where n is the number of intervals andfo,fl ... .fn correspond to the frequency of each interval derived 
by extrapolation from the real distribution ofinputXby using the formula. Y=a.X+ b. In the case of a 
uniform distribution all intervals have the same frequency. fu= 1/n and in this case Eq. 7 can be 
simplified to Eq. 6. and subsequently to Eq. 5. 
Eq. 7. shows that the AOS depends on the range of the distribution. which determines the number of 
intervals nand consequently. fu=l/n. A correction consists in dividing AOS by the range, which equals 
product of number of intervals and with of each interval (n-d), which is shovro in Eq.S. 
YO+d Y0+2·d YO+n·d 
AAOS~{fl·[Y-b-Ln(Y)]+f2.[y-b·Ln(Y)]+ ... f[Y -b·Ln(Y)]} nlnd (Eq. 8) 
YOr YO+d YO+n·d 
Subsequently Eq. 8 can be simplified to Eq.9. 
YO+d Y0+2·d YO+n·d 
AOS~ { fl·[Y -b-Ln(Y) ]+!2· [ Y -b· Ln(Y)]+ ....... f· [Y -b· Ln(Y)] }/d (Eq. 9) 
YOr YO+d YO+n·d 
Where AAOS is the adjusted AOS according to the refined method. In addition. an adjusted relative 
overall sensitivity (AROS) can be determined by dividing the AAOS by the basic average outcome of 
the model. The advantage is that this AROS allows comparison between different studies (as long as 
they have similar outcomes). Finally. an overall level of uncertainty of a model may be determined by 
summation of the AROS values for all variables. 
129 
Chapter 9 
In the original method 2 the upper and lower limit of each input variable were subjectively chosen. 
excluding the impact of values outside the range on the overall sensitivity. An adjustment to the real 
probability distribution will lead to an extension of the range for each input variable. In the case of a 
distribution with a real minimum and maximum. the upper and lower limit will be based on those 
values. In the case of a continuous distribution (e.g. nonnal distribution) without a real minimum and 
maximum. the upper and lower limit will be extended to areas of the probability distribution. which 
can be assumed not to contribute to the AAOS. In this refined method. the initial range was based on a 
98% CI. where the lower limit was > 1% and the upper limit was < 99%. An additional sensitivity 
analysis was perfonned by extending the range in order to test the appropriateness of the chosen CI. 
\Vhen an extension of the range only marginally increases the AAOS. we may assume that the 
calculated AA OS approximates the AA OS of the complete distribution. 
Table lli. The outcomes of the refined method for determination oftheAAOS for pl. 
(Y=a X+b~ Y. where a= -28250 and b=30762. d=848}. 
Interval X Interval Y Frequency AOS AAOS 
0.40-0.43 18615- 19462 0.002 522 
0.43-0.46 17767- 18615 0.007 586 4 
0.46-0.49 16920- 17767 0.024 656 16 
0.49-0.52 16072- 16920 0.059 733 43 
0.52-0.55 15225- 16072 0.104 819 85 
0.55-0.58 14377- 15225 0.161 914 147 
0.58-0.61 13530- 14377 0.191 1022 195 
0.61-0.64 12682- 13530 0.184 1142 210 
0.64-0.67 11835- 12682 0.131 1280 168 
0.67-0.70 10987-11835 0.072 1438 104 
0.70-0.73 10140- 10987 0.027 1622 44 
0.73-0.76 9292- 10140 0.009 1838 17 
0.76-0.79: 8444- 9292 0.004 2095 8 
0.79-0.82 7597- 8444 0.002 2406 5 
Sum 0.990 17073 1046.6 
Bootstrap Method 
The above mentioned method enables the assessment of the AOS for variables with a probability 
distribution. However. there may be variables in the model for which no probability distribution can 
be determined because of a limited amount of data. Table II contains a description of the real 
probability distribution of each input variable. except for the response rate to hospitalisation (p4). 
which was derived from a 20-member Delphi panel. Delphi panels generally consist of a limited 
number of members. varying from 5 to 20. the determination of a probability distribution and a CI 
using traditional statistical methods is not possible. The most common approach is to use the median 
as an input variable and use a range corresponding to the first and third quartile for the standard 
sensitivity analysis (range sensitivity). However. this method does not allow the creation of a 
probability distribution. which is required for the measurement of the adjusted overall sensitivity. 
based on the method described above. 
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The so-called bootstrap method allows the creation of an artificial probability distribution, which 
subsequently can be used to assess the adjusted overall sensitivity. This can be compared with the 
adjusted overall sensitivity of the other input variables. The bootstrap approach uses the original 
sample data to generate an empirical distribution. A sample is drawn from the original sample with 
replacement, where each observation has an equal probability of being dravm on any occasion. The 
size of the sample drawn is equal to the size of the original sample and may contain some duplicated 
observations, while other observations may be omitted altogether. This new bootstrapped sample is 
then used to calculate a mean. Another bootstrap sample is dravm from the original sample and 
another mean is calculated. Generally it is accepted that 50 to 200 samples should be sufficient for 
estimating the mean and standard deviation. 3 
Figure 3. The probability distribution for the input variable response rate to hospitalisation (p4) 
determined using the bootstrap method. 
0,30 
0,25 
0,20 
0,10. 
0,05-
0.00 ""'-----------------------------''" 
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RESULTS 
Specific Results 
0,51-(),55 
" 
0,56-0,60 0,61-0,65 0,66-0,70 0,70-0,74 
Table Ill shows the application of the refined method for input variable pl, the response rate to first 
choice treatment with an SSRL The probability distribution of pl, was extrapolated toY using the 
formula, Y=a·X+b. where a=-28.250 and b=30,762. The width of each interval for X and extrapolated 
Yare 0.003 and 847, respectively. The CI of the chosen range equals 98. which was based on a lower 
limit of> 1% and an upper limit of < 99%. The AA OS was determined for each interval by assuming 
that a uniform distribution exists within each interval due to its small width. Consequently Eq.9 was 
used to determine the AA OS: 
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AAOS~{0.002·522+0,007·586+0.024·656+0.059·733+0.1 04·819+0.161·914+0.191·1022+0.184·1142 
+0.131·1280+0.072-1438+0.027-1622+0.009·1838+0.004·2095+0.002-2406}/847~1 046.6 
The AROS was determined by dividing this value by the average outcome (Y), which leads to a value 
of 0.075772. Subsequently, a sensitivity analysis was performed on the CI by an extension of the CI 
from 98% to 99%. which showed that an adequate CI was chosen in the standard analysis: the AAOS 
only increased 3.2% from 1046.6 to 1079.8. Hence, the AAOS may be considered an approximation of 
the real AA OS of a hypothetical 100% CI. 
The bootstrap method was applied to input variable p4. which was based on Delphi panel estimations 
and consequently does not have a probability distribution. Figure 3 shows the probability distribution 
of p4. determined using a bootstrapping procedure. based on a sample of 20 estimations and 200 
rcsamplcs. 
Table IV. The overall absolute sensitivitv for all variables in the model for deJ.:!ression. 
Variable Point- Original AOS New Range 
sensitivi Range 
tv 
pl 1.23 C.I.:5-95% 7348 C.l.: 1-99% 
p4 0.45 Ql-Q2 5045 Ql-Q2 
pdicm 0.94 Min-max 14602 min-max 
p3 0.40 QI-Q3 3266 C.I.: 1-99% 
p2 0.39 C.L:5-95% 173 C.L 1-99% 
rl 0.06 min-max 144 min-rna" 
CT 0.02 min-rna" 12 min-rna" 
r2 0.01 min-rna" 30 min-max 
DTC-SSRI 0.03 NA 0 NA 
DTC-TCA 0.00 N.A. 0 NA 
Sum N.A. 30620 
* R:mking according to refined and original method. 
** Actual range corresponds with the chosen range. 
Overall Results 
AOS AAOS AROS 
17073 1,2342 0.00008935 
29063 0.9551 0.00006914 
14602 0.9363 0.00006778 
6183 0.4358 0.00003155 
1583 0.4084 0.00002957 
150 0.0600 0.00000434 
12 0,0227 0.00000165 
30 0.0134 0.00000097 
0 0 0 
0 0 0 
68696 4.0658 0,00029436 
Ranking* 
1-2 
2-3 
3-1 
4-4 
5-5 
6-6 
7-8 
8-7 
9-9 
10-10 
After application of the refmed method for all input variables. the variables can be ranked according to 
their AAOS and/or AROS (Table IV). The variables DTC-SSRI and DTC-TCA were ranked according 
to their point-sensitivity, because the overall sensitivity for fixed drug prices is zero. The total adjusted 
relative sensitivity of the model was 0.00029436, which can be considered a measure of the overall 
uncertainty of the model. Table IV shows that the use of the refmed method considerably changed the 
ranking of the variables. The most sensitive variable according to the original method. pd. became less 
sensitive than p4 and pl. which became the most sensitive variable of the model (pi). In addition, 
consultation tariff (CT) became more sensitive than the relapse rate during no treatment after response 
to a TCA (r2). 
DISCUSSION 
In a previous publication by me,1 an alternative method was presented to deal with uncertainty in 
economic studies. based on the concept of point-sensitivity. The concept was illustrated using a 
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modelling study, but may also be applied to other types of economic evaluations. The method allows a 
more objective judgment of robustness of a model by avoiding the subjective selection of variables for 
the sensitivity analysis and the potential bias in judging the degree of sensitivity in most current 
economic studies. However, the first limitation of this method was that the sensitivity measurement 
was based on a uniform distribution of the variables. which in reality may have different distributions. 
The second limitation was that the overall sensitivity measure was based on a subjectively chosen 
range, which excludes the impact of values outside the range on the overall sensitivity. 
The present study describes a refinement of the original method by the incorporation of probability 
distributions. which allow a more accurate assessment of the level of uncertainty in the model. In 
addition. the bootstrap method creates probability distributions for fixed input variables that are based 
on a limited quantity of data. A technical limitation is that determination of overall sensitivity for a 
variable is based on fixed input variables for all other input variables. Hence. the method may 
underestimate the real uncertainty. Finally, one needs to consider that there are currently no sensitivity 
data available, which are based on the discussed method in this paper. Hence, there is not yet a scale 
for grading the level of uncertainty. Hence, the interpretation of a total overall sensitivity outcome for 
a model or sensitivity outcomes for individuals variables may be difficult at the moment. Currently, 
the method can already be used to compare uncertainty between different variables in one study and 
total uncertainty between studies. 
CONCLUSION 
The application of this refmement substantially changed the ranking of the most sensitive variables. as 
illustrated using a depression model. Hence, the changes observed in the depression model show that 
the refinement of the procedure for estimating sensitivity may have important implications for the 
interpretation and analysis of health economic assessments 
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Inter-Variable Uncertainty in 
Modelling: The Concept 
Sensitivity 
SUMMARY 
Decision-Analytic 
of Second-Order 
The constraint of the current methods of sensitivity analysis in decision-analytic models is that those 
methods only show the sensitivity of the outcomes to a change through a range of potential values for 
one or more variables vvithout taken into account the existing relationships bet\veen those variables. 
The present study presents various methods. which considers this type of inter-variable uncertainty for 
economic evaluations based on modeling techniques. We presented initially a method assuming only 
uniform distributions. and subsequently various methods incorporating the real distributions. The 
results show that this second-order sensitivity of a dependent input variable depends very much on the 
distribution of the independent input variables. Overall our analysis showed that the most sensitive 
variables for the outcome of the model. were also the most sensitive for the 2-order sensitivity of the 
other input variables. Although a more general mathematical prove is required to support those 
conclusions, we ended with general recommendations for execution of a sensitivity analysis. including 
the results of a 2-order sensitivity analysis. 
Chapter 10 
INTRODUCTION 
There is growing evidence that health economic data is beginning to be used more widely to support 
decision makers in the health service for allocation of scare healthcare resources. 1 The most evident 
impact of health economic studies is expected for reimbursement audiences because of the elaboration 
of economic reporting requirements. If economic evaluation is to be used for pricing and 
reimbursement issues by authorities or third party payers. it becomes important for the different stake 
holders (industry. government. health insurance) that these analyses arc being performed according to 
generally accepted and standardised methods. The handling with uncertainty in economic evaluation is 
an important area that remains relatively underdeveloped. Sensitivity analysis is currently the most 
widely used method to deal with uncertainty in economic evaluations. A sensitivity analysis is based 
on modification of the basic clinical and economic estimates of parameters to judge the effect on study 
results of alternative assumptions for the range of potential values for uncertain parameters.1 The 
methods used. the choice of parameters and the range of these parameters must be stated and 
substantiated. If this procedure is followed for all the estimates in turn, then we refer to it as a 
'univariate sensitivity analysis". In a multivariate sensitivity analysis. the effect of simultaneous 
changes in different variables is examined on the outcomes of the study. Probabilistic sensitivity 
analysis is the most advanced method. which tries to obtain random distributions around each 
parameter and -- in conformity with the distributions -- then tries to arrive at a new estimate for each 
parameter. For each combination of estimates a new estimate of the costs. effects and cost-
effectiveness ratio is therefore obtained. By repeating this procedure many times a random distribution 
can then be presented based on the results of the study. 
Figure 1. Markov states and possible transitions used in the depression model. 
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No depression: 
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The concept of second order sensitivity 
Table I. Clinical and economical data: input values and range. 
Variable* Input values 
Fixed (SD) Range Distribution 
Clinical probabilities 
Response rate to frrst-line treatment with an SSRI (pi) 0.60 (0.05) 0.50-0.70 Normal 
Response rate to TCA after SSRI treatment failure (p2) 0.30 (0.03) 0.25-0.35 Normal 
Response rate to another TCA after TCA treatment failure (p3) 0.30 (0.03) 0.25-0.35 Normal 
Response rate to hospitalisation (p4) 0.50 (0.04) 0.41-0.58 Normal 
Relapse rate during maintenance treatment with SSRI (rl) 0.04 (0.015) 0.02-0.06 Normal 
Relapse rate during no treatment after response to a TCA (r2) 0.10 (0.033) 0.07-0.16 Normal 
Economic ($US) 
Daily treatment cost ofSSRI 2 (0) N.A.*"' N.A. 
(DTC.SSRI) 
Daily treatment cost ofTCA 0.19 (0) N.A. N.A. 
(DTC-TCA) 
Consultation tariff (consult) 50 (23.4) 10-90 Uniform 
Per diem tariff(dicm) 500 (173) 200-800 Uniform 
Abbreviations: SSRJ selective serotoninc rcuptake inhibitor. TCA tricyclic antidcpresssant 
"' Further detail on data sources is given in a previous article (Nuijten 1997). Distributions of p. r1 and r2 have been 
changed compared with previous paper. 
**: N.A.: not applicable. 
The constraint of the above-mentioned methods for sensitivity analysis in decision analytic models is 
that those methods only show the sensitivity of the outcomes to a change through a range of potential 
values for one or more variables without taken into account the existing relationships between those 
variables. The objective of this manuscript is to present various experimental methodologies. which 
considers this type of inter~variable uncertainty for economic evaluations based on decision analytic 
techniques. The concepts are illustrated using a Markov model. which compares the economic 
outcomes of a maintenance treatment with selective serotinin reuptake inhibitors (SSRis) as the first 
choice therapy for depression over a one year follow up period. Figure 1 shows the overall structure 
of this model and the clinical and economic data used to construct the model are summarised in 
Table I. Further details on the structure of the model and the sources of the clinical and economic data 
as well as the fixed input values for the model, are given in previous papers.3 4 
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MEASUREMENT OF SENSITIVITY 
Summary of Concepts 
Sensitivity analysis is based on the determination of the difference in a clinical or economic outcome 
when an input value is varied within its range and depends only on the range of a variable. This can be 
expressed as: 
(Eq. 1) 
where Sv1 is sensitivity of variable v1. the slope a is derived from the appropriate sensitivity curve. In 
this formula the outcome is either the effectiveness or the economic outcome associated with an initial 
treatment over a period of follow-up. In our example the outcome was the total medical costs over as 
period of 1 year. The assumption was that there is linear relationship between the outcome and the 
input values. which was true for the depression model. In this equation Ll.Y and L1V1 represent the 
range of respectively the output and input values. The per diem {pd) was the most sensitive variable 
using the presented method for sensitivity analysis. The sensitivity of an input variable in current 
sensitivity analyses only depends on the range of that input variable v 1· because the coefficient a 
seems a constant variable according to Eq. 1. However the coefficient a is actually dependent of all 
other variables in the modeL excluding v 1· 
(Eq. 2) 
Where coefficient a 1 of variable v 1 is a function of variables v2,v3 ... vn· 
Consequently: 
(Eq.3) 
Hence the sensitivity of v 1 depends on the range of v1 (dV1) and the fixed input values of all other 
variables in the model (v2, v2, .... vn)· Thus the constraint of the standard sensitivity analysis is that it 
shows the sensitivity of the outcomes to a change through a range of potential values for v 1 without 
taken into account the existing relationships between this measure of sensitivity and the other variables 
(v2,v2 .... .v11). The present study presents various methodologies. which considers this type of inter-
variable uncertainty for economic evaluations based on modeling techniques. 
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Table II. The uniform 2-order sensitivitv for all variables in the model for deeression. 
pi p2 p3 p4 consult diem rl r2 
8Sv 
pi 0 797 3298 4686 20 6927 554 466 
p2 797 0 1028 1408 6 2159 244 173 
p3 3298 1026 0 5628 3 8916 977 501 
p4 4687 1408 5628 0 2 11822 573 9 
consult 19 6 3 2 0 0 9 53 
diem 6927 2159 8927 11822 0 0 2048 1076 
rl 554 245 975 572 6 2111 0 3 
r2 467 174 501 s 53 1075 3 0 
till 
pi 0.0 3985.0 16490.0 23430.0 100.0 34635.0 2770.0 2330.0 
p2 7970.0 0.0 10280.0 14080.0 60.0 21590.0 2440.0 1730.0 
p3 32980.0 10260.0 0.0 56280.0 30.0 89160.0 9770.0 5010.0 
p4 27898.8 8381.0 33500.0 0.0 11.9 70369.0 3410.7 53.6 
consult 0.2 0.1 0.0 0.0 0.0 0.0 0.1 0.7 
diem 11.5 3.6 14.9 19.7 0.0 0.0 3.4 I.S 
rl 2359.5 1043.4 4152.5 2436.1 25.6 8990.6 0.0 12.8 
r2 3492.9 1301.4 3747.2 59.8 396.4 8040.4 22.4 0.0 
METHODS 
Uniform Distributions 
This section presents a mathematical method to determine the dependence of the sensitivity of a 
variable on other input variables. Initially we assume that all variables have a uniform distribution 
with an absolute lower and upper limit (Table I). The sensitivity of vI is determined at the lower value 
of another input variable V] (Svllmin) and subsequently at the upper limit ofv2 (Svllmw} A measure 
of the impact ofv2 on the sensitivity of vi is the absolute value of the difference (L1Sv12) between the 
sensitivity of vI at the lower limit of v2 and the sensitivity at the upper limit of v2: 
8Sv10~abs (Sv10 . - Sv10 . ) _ _max _mm (Eq. 4) 
Measures. which show the ··sensitivity of the sensitivity'". are defmed as second-order sensitivity for 
the remainder of this article. Consequently the traditional sensitivity of the outcome of a model to 
change of a variable is defined as a 1-order sensitivity. Figure 2 shows the outcomes for pl to the other 
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input values of the mode: this analysis shows that the sensitivity of pi is most sensitive to the per 
diem. The results for all variables are shown in Table II. 
Figure 2. The 2-order sensitivity of pl to the other variables in the modeL 
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A disadvantage of the above mentioned method is that the second-order sensitivity of variable VJ to v2 
depends not only on v2. but also on !JVJ. which is shown in the following equations: 
Sv12max =3max /:::,. V 1 
Sv12min =amin 6 V 1 
"-Sv 12 ~ ( "mmcaminl "-VI ~t.a "-VI 
(Eq. 5) 
(Eq. 6) 
(Eq. 7) 
Consequently. the second-order sensitivity ofvJ to v2 is better reflected by the following equation: 
(Eq. 8) 
\Vhere SSvJ2 is the unifonn second-order sensitivity ofv1 to v2. The results of this analysis are also 
shown in Table II, which shows that this adjustment does not change the relative impact of the other 
variables on the sensitivity of another variable (e.g .• pi). because all second-order sensitivity values 
are divided by the same value (e.g .. Lip I). An advantage of this measure of second order sensitivity is 
that it allows a comparison of the impact of one variable on the sensitivity of the other variables. 
Table II (Figures 3-a and 3-b) can be judged horizontally and vertically: 1) the rows show which 
variable has the highest impact on the sensitivity of a variable (e.g .. the per diem has the highest 
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impact onpl) and 2) the columns show the impact of a variable on the sensitivity of other variables 
(e.g., pdiem has the highest impact on p3). 
Figure 3-a.. The impact of the variables on the sensitivity for each variable. 
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Figure 3-b. The impact of each variable on the sensitivity of other variables. 
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The results of this analysis show that the 2-order sensitivity of consultation does not depend on the per 
diem. while the per diem heavily influences the sensitivity of the other variables. which can be 
explained using the following example: 
c~ c 1+c2+ .. ck 
Where Cis the total cost and C1. C2·-·Ckare the costs of kpathways in the modeL which are based on 
the following formulae: 
C1~P1 (kl·d+m1·cel+n1·ce2) 
C2= P2 (k2 ·d+m2 ·eel+ n2· ce2) 
Ck~ pk (kk·d+mk· CCI +nk · Ce2) 
Where ce 1 is the cost of consultation and ce2 is the cost of hospitalisation. which is based on the per 
diem. P 1· P 2 ... Pk are based on a multiplications of all probabilities alongside each pathway (k. m) 
and n correspond with number of respectively drug usage. consultations and hospitalisations along a 
pathway. Consequently: 
C~ P1 (kl d+m1 CC]+nl ce2)+ P2 (k2 d+m2 CCI+ n2 ce2) .. +Pk (kk+mk ce1+nk ce2) 
We now determine sensitivity for variable ce 1: 
Cmm~ PI (kl d+m1 ce11+n1 ce2)+ P2 (k2 d+m2 ce11+ n2 ce2) .. +Pk (kk+mk ce11+nk ce2) 
Cma,= Pl (kl d+m1 ce12+n1 ce2)+ P2 (k2 d+m2 ce12+ n2 ce2) .. +Pk (kk+mk ce12+nk ce2) 
~Svl2 =Cmax-Cmin 
~PI (m I cell- m I CC]2 + p2 (m2 cen-m2 CC]2) .. +Pk (mk ceu-mk cel2) 
Consequently the 2-order sensitivity of ce 1 does not depend on ce2. which is excluded from the last 
equation). while the difference between the two equations does not erase the other variables. because 
they are in multiplication relationship with consultation. Thus we may distinguish multiplication 
relationships and summation relationships in a modeL The second-order sensitivity of a variable only 
depends on variables. which are in a multiplication relationship: 1) relationships between probabilities 
and costs and 2) relationships between probabilities and probabilities. Summation relationships only 
relate to relationships between costs and costs (prices as well as resource utilization). Hence the 
second-order sensitivity of consultation does not depend on the per diem, which is excluded from the 
last equation), while the difference between the tv.ro equations does not erase the other variables. 
because they are in multiplication relationship with consultation. 
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Real Distributions 
A limitation of the above-mentioned equation 1 is that it only based on the range of variables without 
taken into account the distribution of v1: a is a function of the distribution of variable v2,3.4 ... k· 
Therefore the original method for the determination of the 2-order sensitivity will be adjusted to 
include the real probability distributions of all variables. We present various methods to measure the 
inter-variable relationships in the model for depression. 
Method 1 :Standard Deviation-Based Approach Using Linear Relationships 
The original equation (Eq. 1) is adjusted to: 
(Eq. 9) 
Sm is the sensitivity of variable Vm, which depends on the range of variable Vm, but also on the value 
of am. which is a function of all other variables. excluding V m· 
The follov.ring equation is determined: 
am=k·vn+l (Eq. 10) 
Where am is a function of variable vn: k and 1 are the coefficients. In this example when vm is pl and 
vn, is pdiem. kis -57.7 and m is -605. 
apr -57.7 · pdiem (Eq. 11) 
Consequently a at the fixed input value of pdiem of 500 equals -28245. Figure 4 shows that a linear 
relationship exists between the apl and pdiem, which we also proved for the other relationships 
between the a values and the input values: we also determined the corresponding values fork and l for 
all other variables. A measure of second-order sensitivity of vm to vn is the standard deviation of am 
resulting from Eq. 12. which is a function of the standard deviation ofvn (SD-vnJ. 
(Eq. 12) 
where SD-am is the second-order sensitivity of variable VJ to v2. 
An adjustment to our example leads to the follov.ring formula: 
SD-apl~ lkl SD-pdiem0~ 57.7 · ~ 173 
Thus the per diem leads to a standard deviation of 173. which reflects the second-order sensitivity of 
apl to pdiem. The standard deviations of the other variables are shown in Table III. which show that 
pdiem has the highest impact on the sensitivity of pl and all other variables. excluding consultation. 
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Those results also allow us to determine the impact of each variable on the sensitivity of the other 
variables~ in this example the per diem has highest impact onp3. 
Figure 4. The relationship between apl and pdiem. 
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Table m. The 2~order sensitivitv for all variables based on the standard deviation of a. 
pi p2 p3 p4 consult diem rl r2 
SD 
pi 0.05 0.03 0.03 0.04 23.4 173.0 0.015 0.033 
p2 0.01195.5 4947.0 5578.6 29.3 9986.4177.0 575.1 
p3 1992.5 0.0 3084.0 3352.4 17.6 6225.1 155.9 427.0 
p4 8245.0 3078.0 0.0 13400.0 8.8 25707.8 624.1 1236.6 
consult 6974.7 2514.3 10050.0 0.0 3.5 20289.7 217.9 13.2 
diem 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 
rl 2.9 Ll 4.5 4.7 0.0 0.0 0.2 0.4 
r2 589.9 313.0 1245.7 580.0 7.5 7785.0 0.0 3.2 
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Method 2: Standard Deviation-Based Approach by Applying Probabilistic Sensitivity Analysis 
The use of a probabilistic sensitivity analysis allows fue incorporation of the real distributions of all 
input variables. The assessment of the sensitivity of the model for v 1 is based on a probabilistic 
sensitivity analysis based on the distribution ofv1 only, while the values of the other variables are kept 
fixed at the input values. A measure of sensitivity of the model to v 1 is the standard deviation resulting 
from this probabilistic sensitivity analysis (SDv 1). Subsequently the 2-order sensitivity of v 1 to 
another variable v2 is assessed by another probabilistic sensitivity analysis based on the distributions 
of v 1 and v2, while the values of the other variables are kept fixed at the input values. This analysis 
will yield another standard deviation (SDv1 :/ which is different from the initial standard deviation 
(SDv 1) because of the incorporation of the extra uncertainty associated with variable v2- Hence a 
measure of the absolute second-order sensitivity of v 1 to v2 (ASSv 12) is the increase in the standard 
deviation due to v2: 
(Eq. 13) 
Subsequently the relative second-order sensitivity can be defined: 
(Eq. 14) 
Where RSSv 12 is the relative 2-order sensitivity of v 1 to v2. which is the proportion of change SSv 12 
compared to SDv r 
Figure 5 shows the absolute second-order sensitivity of pi to the other input variables. This figure 
shows that the sensitivity of p 1 is most sensitive to the per diem. which corresponds with the fmdings 
of the 2-order sensitivity analysis based on the previous methods. A main difference is that the other 
variables only have a minor impact on the sensitivity of pl compared with the previous methods. 
Tables IV and V contain respectively the absolute and relative 2-order sensitivity for all input 
variables in the model. Those tables show that the per diem has the most impact on the sensitivity of 
most variables. Those tables also that pl is the only variable. which somehow influences the 2-order 
sensitivity of the per diem. 
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Figure 5. The 2-order sensitivity of pl to the other variables in the model using probabilistic sensitivity 
analysis. 
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Table IV. The absolute 2-order sensitivity for all variables in the model for depression using probabilistic 
sensitivity analvses. 
AU• On< Two 
pi p2 p3 p4 consult diem <I 
pi 4831 1405 -1405 11i 101 65 II 3366 36 
p2 4831 533 989 -533 225 194 25 3991 101 
p3 4831 555 951 203 -555 181 18 3975 92 
p4 4831 488 982 239 248 -488 IS 4024 98 
consult 4831 !52 1264 406 421 354 -152 4381 201 
diem 4831 4490 281 34 40 22 43 4490 20 
<I 4831 318 1123 316 329 268 35 4192 -318 
<2 
2 
8 
6 
IS 
11 
15 
7 
d 4831 62 1345 479 499 444 101 4443 263 -62 
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Table V. The relative 2-order sensitivity for all variables in the model for depression using probabilistic 
sensitivitv analvses. 
Two 
pi p2 p3 p4 consult diem 'i d 
pi -1.00 0.08 0.07 0.05 0.01 2.40 0.03 0.00 
p2 1.86 0.42 0.36 0.05 7.49 0.19 0.02 
p3 1.71 0.37 0.33 0.03 7.16 0.17 0.01 
p4 2.01 0.49 051 -1.00 0.04 8.25 0.20 0.04 
consult 8 '" ~- 2.67 2.77 "" -.:>:> -1.00 28.82 1.32 0.07 
diem 0.06 0.01 0.01 0.00 0.01 -1.00 0.00 0.00 
'i 3.53 0.99 1.03 0.84 0.11 13.18 -1.00 0.02 
'2 21.69 7.73 8.05 7.16 1.63 71.66 4.24 -1.00 
Finally a total measure of sensitivity of all other input variables on vI is determined by the following 
equation: 
RSSvl234 ... n ~ SvliASSvl234 ... n (Eq. 15) 
Where RSS . .,.1234 __ .n is the relative second-order sensitivity of vi to all other input variables; SvJ is 
standard deviation for probabilistic sensitivity analysis for vi only and ASSvi234 ... n is standard 
deviation for probabilistic sensitivity analysis incorporating distributions of all input variables. 
Point-Sensitivity 
The above-mentioned methods for the determination of second-order sensitivity are based on the 
distribution of variables, which assess the simultaneously the impact of a fixed input value (mean) and 
its associated range on the sensitivity of another input variable. 
(Eq. 9) 
Eq. 9 states that sensitivity of variable V m depends on the range of V m and the mean fixed input value 
of am only. Consequently it is reasonable to perform a sensitivity analysis. which shows only the 
impact of the fixed input value of am without including the impact of its range. In a previous article, 
we introduced the concept of point-sensitivity analysis. which measures the responsiveness of the 
outcome to the input value at a fixed point and does not include any associated range of the input.3 
The defmition of point-sensitivity was based on the concept of point-elasticity (Eq. 16) where X and Y 
represent the fixed input value and the outcome respectively and Tis refers to point-elasticity, which 
describes the % change in the outcome. when the input variable changes 1%. 
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Tj,=odY/dX·XIY (Eq. 16) 
In the case of a linear sensitivity relationship (Eq. 17) a more simple formula (Eq. 18) can be used: 
~,~a ·X/(a·X+b) 
(Eq. 17) 
(Eq. 18) 
The concept of point sensitivity was in the previous studies3 4 applied to the first-order sensitivity of 
an input variable. but it can also be applied to determine the impact of the mean value of am on the 
second-order sensitivity of another input variable by adjusting the equations: 
(Eq. 19) 
\\There llm..n is the second-order point sensitivity of vm to vw Because of the linear sensitivity 
relationship (Eq. 20) a more simple formula (Eq. 21) can be used: 
(Eq. 20) 
'1~ ~k · vn /(k vn +I) (Eq. 21) 
In this example when vm is pi and vn. is pdiem, k is -57,7 and 1 is -607.7. the second-order point 
sensitivity is 1.021. Hence increasing the per diem by 1 %results only in a 1.201% increase of aplO. 
Figure 6 show the point-sensitivity ofpl to the other input variables. which shows thatp3 andp4 now 
have become more sensitive variables than the per diem. Table VI shows the results of the point-
sensitivity analyses for all variables in the model for depression, which show that p3 and p4 have 
become most sensitive variables for most of the other variables. while the impact of the per diem has 
become lower. 
Table VI. The (!Oint~sensitivitv outcomes. 
Two 
pi p2 p3 p4 Consult diem d d 
pi na 0.423 1.751 2.543 0.002 1.021 0.015 0.060 
p2 1.325 na 1.710 2.389 0.002 0.998 0.026 0.074 
p3 1.331 0.414 na 2.315 0.000 1.000 0.025 0.050 
p4 1.427 0.429 1.714 na 0.000 1.000 0.010 0.001 
consult 0.109 0.034 0.017 0.011 Na 0.000 0.003 0.074 
diem 1.330 0.415 1.714 2.315 0.000 na 0.025 0.051 
d 0.999 0.442 1.759 1.036 0.002 1.410 Na 0.001 
c2 1.501 0.566 1.610 0.025 0.035 0.961 0.001 na 
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Figure 6. The 2-order sensitivity ofpl to the other variables in the model using point-sensitivity analysis. 
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DISCUSSION 
The constraint of the standard methods for sensitivity analysis is that those methods only show the 
sensitivity of the outcomes to a change through a range of potential values for one or more variables 
without taken into account the existing relationships betv.reen those variables. The present study 
describes to present various experimental methodologies. which considers this type of inter-variable 
uncertainty for economic evaluations based on decision analytic techniques. We presented initially a 
method assuming only uniform distributions. and subsequently various methods incorporating the real 
distributions. The results show that this second-order sensitivity of a dependent input variable depends 
very much on the distribution of the independent input variables. Overall our analysis showed that the 
most sensitive variables for the outcome of the model (1-order sensitivity). were also the most 
sensitive for the 2-order sensitivity of the other input variables. Finally we presented a point-
sensitivity analysis. which shows only the impact of the fixed input value of 3m without including the 
impact of its range. The results from this type of 2-order sensitivity analysis resulted to a different 
ranking of all variables according to their impact on the sensitivity of other variables, which showed 
the impact of the distribution on the 2-order sensitivity. From a methodological point of view one may 
argue what is scientifically the most correct measure of second-order sensitivity: the 2-order 
sensitivity based on the distributions or on the fixed input value only. 
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The results from the 2-order sensitivity analyses show that the most sensitive variables in the model 
have also the most impact on the sensitivity of the other input variables. Consequently one can argue 
that the reduction of uncertainty associated with the most sensitive variables in a model, will lead to an 
overall reduction of uncertainty in the outcomes in the model because of a reduction in sensitivity of 
most variables. Hence it may be more important to investigate the uncertainty of the most sensitive 
variables of the model in more depth. e.g. by means of a meta-analysis. than to investigate the 
uncertainty associated with all variables. On the other hand. it may be worthwhile to reduce the 
sensitivity of the most sensitive variable by identifying the variables. which mostly influence its 
sensitivity by means of 2-order sensitivity analyses. Although a more general mathematical prove is 
required to support those conclusions. which are based on a depression model example. we may end 
with the following recommendations: 1) identify the most sensitive variables in the model by means of 
traditional sensitivity analysis (1-order sensitivity). 2) identify the variables. which have the most 
impact on the sensitivity of those most sensitive variables by means of 2-order sensitivity analysis, 3) 
reduce the uncertainty associated the variables. which were identified in the previous steps. 
Another approach to judge the benefit of further research to reduce uncertainty in a modeling study is 
based on the concept of Value of Information. Recently a Bayesian decision theoretic framework has 
been suggested for the evaluation of health technologies.5 6 This approach distinguishes the 
conceptually separate decision concerning efficient service provision given the level of information 
available. from the decision concerning to fund further information collection. The basic concept for a 
modeling study is to measure the uncertainty in cost-effectiveness outcomes and determine the worth 
of further data collection.5 Here the decision of further data collection is based upon the expected cost 
of uncertainty. which is determined by both the extent of the uncertainty surrounding the efficient 
service provision and the consequences of this uncertainty. The extent of the uncertainty is measured 
by the error probability associated with the decision and the consequences of uncertainty are measured 
in terms of health benefits foregone when this uncertainty causes the incorrect decision to be made 
concerning service provision. Where these health benefits are valued according to society's 
willingness to pay for certain health outcomes, the approach gives a monetary value for the amount 
that society is willing to pay to reduce the uncertainty surrounding the service provision. The primary 
objective of both the concept of 2-order sensitivity and the concept of Value of Infonnation is to 
identify the impact of input variables in a model on the level of uncertainty within a model and to 
explore the worth of further research to reduce uncertainty of an input variable. The Value of 
Information concept quantifies the costs of further research and relates it to reduction of uncertainty in 
the decision-making process. while the 2-order approach only helps the researcher in prioritizing 
further research by identifying the key input variables in the mode without incorporating the cost of 
extra research. The advantage of the 2-order approach is that it takes into account the inter-variable 
uncertainty based on the existing relationships betv.reen the input variables. Although the concept of 
Value of Information initially was applied to empirical data. it may also be applied to a health 
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economic model. \Vhen an input variable appears to be vexy sensitive because of its large range. the 
concept of Value of Information may be applied by assessing the cost of extra research for reducing 
the confidence interval of that input variable by means of using more data. For example a clinical 
response rate was initially based on one few studies leading to a large variance, which may be reduced 
by including the results of more published studies or by performing a formal meta-analysis. The 
concept of Value of Information in a health economic model may be extended by incorporating inter-
variable uncertainty. which may further reduce the extra costs for the reduction of the uncertainty 
associated with the healthcare decision. For example the 2-order sensitivity analysis may show that the 
uncertainty associated with the clinical response rate depends mainly on the hospitalization rate. 
Consequently the extra cost of exploring this rate may be less than the extra costs for reducing the 
range of the response rate. 
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Combining a Budgetary Impact Analysis and a 
Cost-Effectiveness Analysis Using Decision-
Analytic Modelling Techniques 
SUMMARY 
BACKGROUND: Reimbursement of new drugs is usually based on the budgetary impact of a new 
drug but there is also increasing demand for cost-effectiveness data on new drugs. OBJECTIVE: To 
present a modelling technique (methodology) for an appropriate assessment of the budgetary impact of 
a new drug, which can simultaneously be used for a traditional cost-effectiveness analysis. DESIGN 
AND PERSPECTIVE: To illustrate the methodology. a model was constructed for a new hypothetical 
drug in Parkinson's disease. which allowed us to detenninc the budgetary impact and the cost-
effectiveness of this new antiparkinsonian drug from a societal perspective. The methodology 
consisted of two steps: (i) a simple population model (Markov model) was constructed to validate the 
epidemiological data by proving the consistency between the prevalence and incidence of Parkinson's 
disease for the Dutch population: (ii) this model was extended to a more complex model (semi-
Markov model) by incorporation of disease progression for Parkinson's disease and all relevant 
economic and clinical measures. These included all drug utilisation associated with Parkinson's 
disease, as well as other resource utilisation patterns associated with outpatient and inpatient care for 
the treatment of Parkinson's disease. RESULTS: The study showed that the difference in 
epidemiological data between a simple model and a complex model are substantial. which justifies the 
development of a complex model with a higher external validity. The complex model allowed an 
assessment of all potential candidates for the new drug and simultaneously allowed the assessment of 
the cost-effectiveness of the new drug versus usual care. CONCLUSION: One model can be used for 
an appropriate assessment of the budgetary impact and the cost-effectiveness of a new drug. 
Chapter II 
INTRODUCTION 
In The Netherlands the main response to rising costs has been the introduction of an impressive 
number of cost containment policies over the last decade. This resulted in the Drug Reimbursement 
SystCIR based on the classification of drugs into groups of interchangeable drugs (GVS). There is a 
fixed refund price being based on the average list price for "therapeutically interchangeable drugs" 
belonging to the same group (cluster). Any new drug. which cannot be clustered, is not reimbursed, 
unless there is no treatment for the relevant pathology (e.g. Alzheimer). The use ofpharmacoeconomic 
data was considered for reimbursement of those drugs. which are cost effective. In July 1999, the 
Minister approved the guidelines ["Richtlijnen voor farmaco-economisch onderzoek" (Dutch 
guidelines for Pharmacoeconomic Research)]. 1 Currently the Ministry is considering to adjust the 
reimbursement legislation by implementing official requirements for submission of health economic 
data comparable with Australia and Canada.2 
Besides the cost-effectiveness of a new drug, reimbursement will also be based on the budgetary 
impact of a new drug on JOZ [Jaaroverzicht Zorg (Annual National Health Care Budget)]. especially 
the impact of a new drug on the drug budget. Therefore. the authorities require an assessment of the 
impact of a new drug on the annual health care budget, and especially the drug budget. For the 
financial analysis, data on the following subjects will be required: descriptive epidemiology (data on 
incidence and prevalence); the patient group that is indicated for the drug and the anticipated 
substitution effects (i.e. the extent to which the existing treatment will be replaced); the use of the drug 
(posology, length of the treatment, etc.), the price of the drug; and the total treatment costs. Especially. 
if reimbursement of pharmaceuticals is going to be based in part on data derived from a financial 
analysis, it is vital to carefully scrutinise and refme this type analysis. 
The primary objective of this manuscript was to demonstrate the concept of an appropriate assessment 
of the budgetary impact of a new second-line drug using modelling techniques. which simultaneously 
can be used for a traditional cost-effectiveness analysis. 
METHODS 
The financial analysis was based on data from a health economic study and descriptive epidemiology 
(data on incidence and prevalence). To illustrate the methodology, a model was constructed for a new 
hypothetical drug in Parkinson's disease, which allowed us to determine the budgetary impact and the 
cost-effe~tiveness of this new antiparkinsonian drug (AP) from the perspective of the society in The 
Netherlands. This new drug was proposed as an add-on therapy to usual care in patients who develop 
fluctuations. 
The methodology consisted of the following steps: 
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• Step 1: A simple population model (Markov model) was constructed. The objective of this model 
was to validate the epidemiological data by proving the consistency between prevalence and 
incidence of Parkinson's disease for the Dutch population. 
• Step 2; The simple population model was extended to a more complex model (semi-Markov 
model) by incorporation of disease progression for Parkinson's disease and all relevant economic 
and clinical measures. These included all drug utilisation associated with Parkinson· s disease as 
well as other resource utilisation patterns associated with outpatient and inpatient care for the 
treatment of Parkinson's disease. direct nonmedical costs and indirect costs (working days lost). 
The primary objective of this model was to estimate the potential number of candidates and the 
annual drug costs for a new drug in Parkinson's disease. Secondary objectives were (i) to compare 
the impact of this new drug versus usual care (standard therapy) on the total annual healthcare 
budget (health insurance perspective); (ii) to compare the impact on total costs from the 
perspective of society and the patient by including direct non-medical costs and indirect costs: and 
(iii) to perform a traditional cost-effectiveness analyses comparing the new drug versus usual care. 
Simple Population Model 
Literature Review 
A literature search on incidence, prevalence data and disease-specific mortality for Parkinson· s disease 
was performed on international. and especially Dutch, literature. Search parameters identified as 
keyv.rords included incidence. prevalence, Parkinson's disease. mortality, life expectancy. The 
prevalence estimates of idiopathic Parkinson's disease were in the range of 66 to 258 per 100.000. 
while the annual incidence varies from 4 to 24 per 100.000. Data on national Dutch population 
statistics were supplied by the Dutch national office of statistics (CBS: Central Bureau Statistics) 3 and 
included: annual mortality. annual birth rate and life expectancy. The DATA TOP study showed that 
after an average of 8.2 years of observation. the overall death rate was unaffected by type of treatment 
and was about that expected for an age- and gender matched US population without Parkinson· s 
disease.4 This study was initially designed to test outcomes in 800 previously untreated patients with 
Parkinson's disease, treated with deprenyl or tocopherol (vitamin E) over a period of 18 months; 
however. follow-up was extended to an average of 8.2 years yielding long-term death rates for 
Parkinson's disease. The results of the literature search are sho'N!l in Table L 
Model Structure 
A simple population model (Markov model) was constructed. The objective of this model was to 
validate literature data by proving the consistency between prevalence and incidence of Parkinson· s 
disease. A Markov process is a particular type of decision tree models and represents a convenient way 
of modelling the long-term evolution of health states over successive time periods: A Markov process 
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model describes several discrete states of health in which a person can be at time t=n as well as the 
states of health into which the person may move at time t=n+ 1. 
Figure 1. Simple Markov population model for Parkinson~s disease. 
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The progression from t=n to t=n+ 1 is called a cycle. Probabilities are associated with each change 
from one health state to another; these are tenned transition probabilities (P). A Markov model is 
deemed appropriate for use in situations where events reoccur (e.g. incidence) over time. and when 
individual persons of a population move among a finite number of health states (Parkinson· s disease 
or no Parkinson's disease) over the time period.5•6 Figure 1 shows the structure of the population 
Markov model for Parkinson's disease. The cycle time chosen for the model was 1 year. which 
corresponds with epidemiological data on annual incidence. prevalence and mortality and the 1-year 
horizon for the financial analysis. 
For this analysis we defined mutually exclusive Markov states. Initially we defined Markov health 
states corresponding with the existence of Parkinson's disease as follows: ""'P"': a person with 
Parkinson· s disease; "NP": a person without Parkinson· s disease. 
In the model all persons start in the health state "'NP"'. After one cycle of 1 year there are three 
possibilities: 
• A person will not develop Parkinson· s disease and will stay in health state "NP". 
• A person will develop Parkinson's disease and will move to health state ··p .. _ 
• A person will die and will move to health state "NP", which is based on assumption that the 
annual mortality equals the annual birth rate. 
During subsequent cycles. a persons with Parkinson· s disease will have tv.ro possibilities: 
• A person will not die and will stay in health state "P". 
• A person will die and will move to health state ""NP ... 
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Hence persons once entered in health state ••p" will not return to the health state "NP'", because 
Parkinson" s disease is a chronic disease without recovery. 
Key Model Assumptions 
There are a number of key assumptions upon which the model is based. These are: 
• The follow-up period was the minimal time period in which the proportion of patients with 
Parkinson's disease stabilises. 
• The population size is constant: the annual mortality equals the annual birth rate. 
• The population distribution with regards to age is constant. 
• Gender differences are not taken into account and consequently we assumed no differences in 
mortality rate. prevalence and incidence for Parkinson's disease benveen males and females. 
which is contrary to reality: males have a lower life expectancy. 
• Age is not incorporated in the model. Consequently. we did not consider that annual mortality 
will increase by age and that occurrence of Parkinson"s disease usually starts at an average age of 
62. This assumption is only allowed because of the previous assumptions with regards to constant 
population size (1) and constant population distribution with regards to age (2). 
• The model only incorporated the incidence and prevalence of Parkinson's disease. while other 
morbidities were only indirectly reflected in annual mortality rate. 
• Parkinson· s disease is not associated with a lower life expectancy. which was based on The 
DATA TOP study4 
Table I. Prevalence data. 
Source Prevalence 
per 100,000 
Surcliffe 1 66-258 
Dodel8 100-180 
De Pedro Cuesta9 100 
Range 66-258 
Ineidence 
(/100.000) 
Rajput 10 5-21 
Dodel (ReflS-21) 4-20 
Koller11 
5-24 
Range 4-24 
Source Population 
Statistics 
Annual mortality 0.012834 
rnte 
Population 
General 
General 
Population 
General 
General 
General 
General 
Population 
General 
157 
Chapter 11 
Figure 2. Complex Markov population model for Parkinson's disease. 
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Analysis 
The analysis determined at which prevalence and incidence data point the proportion of persons in the 
health state "P", representing the modelled prevalence ofParkinson·s disease. reaches an equilibrium 
after an ··infinite" number of cycles (n=lOOO). Hence the population model allows an assessment and 
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a validation of the incidence and prevalence data derived from international literature for the Dutch 
population by comparing the prevalence and incidence data. once the model has reached equilibrium.. 
with literature data (Table 1). 
Complex Population Model 
'While in a standard Markov process model transitions only depend on health state and time, the 
transitions in a semi-Markov model also depend on co-variates like clinical past history, the current 
treatment, age and gender, which allow a more realistic simulation of the disease. Figure 2 shows the 
structure of the semi-Markov population model for Parkinson's disease. which consists of two arms: 
an arm based on usual care only and an arm which includes the introduction of a new innovative 
hypothetical drug for Parkinson· s disease. The model structure for the usual care treatment arm is 
identicaL In our model a hypothetical cohort of persons v.;ith flucruations will receive AP or usual 
care. After the first cycle patients using AP may have improved by control of fluctuations: we assumed 
a response rate of 80%. Responders will continue the treatment with AP for the remainder of the srudy 
period even if they progress to experiencing fluctuations. while non-responders v.;ill terminate 
treatment with AP. 
In addition. the semi-Markov model was based on the following adjustments to the initial Markov 
model: 
• The cycle time chosen for this model was 6 months, which closely approximates the follow-up 
period of the clinical trials in Parkinson's" disease. which when doubled corresponds with a time 
horizon of annual financial budgets. 
• We stratified the existing "P" health state in the follov.ring states: "P-no fluctuations": a person 
v.rith no fluctuations: "'P-fluctuations .. : a person with flucruations. 
• We used the health state of the original Markov model: ·•NP": a person v.;ithout Parkinson's 
disease. 
• Age-specific mortality was incorporated in the model in order to reflect increasing mortality risk 
when a patient gets older: The population was stratified in following subpopulations: 
0.1.2.3,4, ...... 100. Because of difference in life expectancy between males and females, gender 
was also incorporated in the model by stratifying patients in to males and females. 
Our model was based on the following assumptions: 
• The Markov health states in this model correspond with severity levels according to the existence 
of motor fluctuations: ·no fluctuations ... ··fluctuations". 
• The follow-up period was the minimal time period which was necessary to stabilise (i) the 
proportion of patients with Parkinson's disease and (ii) the distribution bet\veen Parkinson's health 
states. 
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• A 6-month cycle was used because this interval closely approximated the follow-up period of the 
clinical trials for AP. 
• We assumed that AP will not reduce disease progression. 
• We assumed that the complete target population for AP will receive AP. Hence the analysis v.rill 
show the maximum budgetary impact of AP _ 
• We assumed that that the occurrence of Parkinson· s disease only starts in the subpopulation of 62, 
which is based on the average age of onset (62 years) in the literature.4 1 ~ 13 
• The population size is constant: the annual mortality equals the annual birth rate. 
• The model only incorporated the incidence and prevalence of Parkinson's disease. while other 
morbidities are only indirectly reflected in annual mortality rate. 
• Parkinson's disease is not associated with a lower life expectancy.4 
• A life-time model was constructed~ patients were followed until death. 
• We assumed no differences in prevalence and incidence for Parkinson· s disease between males 
and females. 
Data Sources 
The data sources and collection were based on the following: 
• The incidence and prevalence were derived from the simple Markov model. 
• The probabilities of disease progression to fluctuations and mortality were based on published 
literature and population statistics data (CBS).3 
• Utilities and units of resource utilisation were obtained from a cross-sectional study. 14 
• Direct medical costs. involving estimates of the units of healthcare utilisation and their 
prices/tariffs (product of unit and price), were derived from official lists. 15 
Probabilities 
The initial prevalence and incidence values were based on the simple Markov model and initially all 
patients with Parkinson· s disease started in the health state ""no fluctuations"'. The incidence was 
based on the general population and was adjusted to the assumption that the occurrence of Parkinson's 
disease only starts in the subpopulation of 62. The incidence of Parkinson· s disease in the general 
population (!pop) was calculated as (Eq. I) 
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Ipop=Iage-male x F age-male+Iage-femaleX Fage-female 
Where 
Ipop= incidence ofPD in the general population 
Iage-male =incidence ofPD in males at 62. 
Iage-female =incidence ofPD in females at 62. 
(Eq. I) 
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Fage-m.ale =Proportion of males at 62 in total population. 
Fage-female= Proportion of females at 62 in total population. 
We assumed that I age-male= Iage-female and 
!pop~ 4 per 100.000 
Fage-male = 0.044953 
Fage-female ~ 0.045083 
Consequently: 
Iage-male = Iage-female = Ipopf(Fage-m.ale+Fage-fem.ale)= 444.26 per 100,000. (Eq. 2) 
The transition probability between the different health states in our example was derived from a study 
by Nuijten. 14 The annual probability of0.147 was transformed to a 6-months probability of0.075. 
The probabilities of mortality were based on the annual age-specific mortality quotient for men and 
women derived from 1998 population data. which were transformed to 6-month probabilities.3 
Utilities 
The assessment of the utility was based on the assignment of fixed value to the health states associated 
with a 6-month cycle. The utilities for the different health states were derived from a cross-sectional 
study by Dodel.16 The health states "P-no fluctuations" and ""P-fluctuations"" had utilities of 
respectively 0.73 and 0.49. The classification of disease severity in this study corresponded with the 
health states in our model. The underlying assumption was that the function betv.reen severity and 
utility may be extrapolated from Germany to The Netherlands. when we assume that clinical outcomes 
are not country specific.17 
Resource Utilisation 
The resource utilisation for the different health states was based on a German cross-sectional study by 
Dodel, which was performed over a period of 3 months. 16 We used resource utilisation from the cross-
sectional study, to which we applied official Dutch tariffs and prices (Table II). We validated the 
assumption that the German and Dutch treatment patterns for Parkinson's disease are similar by 
comparing the distribution of antiparkinsonian drugs and referral patterns. 
Costing 
Costing was performed from the societal perspective according to the Dutch pharmacoeconomic 
research guidelines. The cost assessment was based on the assignment of fixed costs to the health 
states associated with a 6-month cycle. The costs of each health state were determined by the resource 
utilisation associated with a health state: medical resource utilisation (e.g. medication. consultations, 
laboratory and diagnostic tests and procedures, hospitalisations, nursing home). In addition, direct 
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non-medical costs were included. Examples are: equipment, transportation and home modifications. 
Indirect costs due to working days lost were not included. because the average age of patients with 
Parkinson"s disease is 60-64. while most people in The Netherlands are no longer actively working 
after 60 years.3 
Market prices. where available. were used to evaluate opportunity costs (i.e. costs of foregone 
opportunities as a result of investment in a specific healthcare strategy). In the absence of available 
costs. tariffs were used as an approximation. 
• Drug prices were derived from the Taxe (Dutch list of drug prices). 1s 
• Consultations, procedures and hospitalisation costs were derived from the College Tarieven 
Gezondheidszorg (COTG 1999).15 
• Nursing costs were derived from the COTG 1999.15 
• Transportation costs were valued according to the national allowance per Ian (CBS).3 
• Costs for home medications and other non-medical costs were based on market prices. 
Table II. Costs for Each Health State (in € per 3 months) 
Stage Direct medical 
costs 
Drugs Consul- Physio· Diagnostic Hospita- Total 
tations thcr::tp)· procedures lisation 
No-fluctuations 340 169 463 0 0 972 
Fluctuations 918 156 839 15 210 2138 
Stage Non-direct medical 
costs 
Social Trans- Home Other Total 
services port modif. 
No-fluctuations 0 116 1 0 117 
Fluctuations 405 115 120 10 650 
Analysis 
Financial and health economic analyses were executed, which were respectively performed at 
population and patient level. The analyses were performed after stabilisation of the model for usual 
care resulting in a static distribution between different health states and a subsequent switch to AP for 
fluctuators. 
We forecasted the impact of an add-on therapy with AP on the annual drug budget for each subsequent 
year after launch of AP until stabilisation of the annual costs of AP. This analysis shows for each year: 
1) the maximum number of patients using AP and 2) the annual costs of AP. The base case analysis 
was based on assumption that all potential candidates for AP will use the drug. A scenario analysis 
was performed assuming that only patients. who start developing fluctuations, are going to use AP. 
We also forecasted the impact of AP on the healthcare budget. This analysis was an extension of the 
previous one by including other direct medical costs. Finally we also included nonmedical resource 
utilisation in order to assess the impact on the national budget 
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Besides the fmancial analysis, a cost-effectiveness analysis was perfonned from the society 
perspective using the following outcomes: 
• The expected average effectiveness: time v.rithout severe fluctuations. QAL Y s. 
• The total costs per patient. including cost distribution: direct medical and non-medical costs. 
Clinical and economic outcomes were discounted because the time horizon of the model extended 
beyond a period of 1 year. The present values were calculated for the year 2000 and the discount rate 
was based on the recommended 4% according to the Dutch pharmacoeconomic guidelines. 1 
RESULTS 
Simple Population Model 
The initial prevalence and incidence values were the minimum values of the ranges 66 and 4 per 
100.000. Figure 3 shows the change in prevalence over an infmite period (1000 years). The model 
takes nearly 300 years to reach the equilibrium, because the initial population at t=O does not contain 
any patients with Parkinson's disease: these patients subsequently enter the model based on the 
incidence. The prevalence increases and stabilises when at 295 per 100,000. which slightly exceeds 
the upper range derived from literature. Thus we determined the appropriate prevalence and incidence 
data for the population model in The Netherlands. which was based on the listed key assumptions. 
including the assumption of constant population size. The results show that only at the minimum value 
for incidence the prevalence remains near the maximum value taking into account the ranges found in 
the literature. Hence. we validated the key input data of the population model: the incidence and 
prevalence of Parkinson's disease. This simple model confirms the relationship betv.reen prevalence 
and incidence data. but the representativeness of the model may be questioned. taking into account the 
low incidence and high prevalence at which the model stabilises. 
Figure 3. Results of population model for Parkinson's disease. 
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Figure 4. Results of population model for Parkinson~s disease. 
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Figure 5. Results of population model for Parkinson's disease: potential number of patients. 
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Complex Population Model 
Figure 4 shows the results of an analysis after stabilisation of the model. which was achieved after an 
··infmite"' number of cycles (n=1000): 5 years before the introduction of AP and the following 15 
years. The patient population before launch consisted of patients without fluctuations (NO-FLUC) and 
with fluctuations (FLU C) with a prevalence of 27 per 100.000 and 74 per 100.000. respectively. 
yielding a total prevalence of 100 per 100.000. Hence, the total number of patients with Parkinson's 
disease in The Netherlands is 15.865 based on a total population of 15.7 million, which consists of 
4.241 patients without fluctuations and 11.624 patients with fluctuations. Patients with fluctuations 
switch to AP at t=5 which corresponds with the time of launch. Subsequently. the patient population 
consisted of two additional patient groups: patients without fluctuations using AP (NO-FLUC-AP) and 
patients with fluctuations using AP (FLUC-AP). The model stabilises over a period of 20 years, 
leading to a new distribution of the prevalence. 
• NO-FLUC: 27 per 100.000 (unchanged). 
• FLUC: 14 per 100,000 (N~2J99). 
• NO-FLUC-AP: 14 per 100.000 (N~2.199). 
• FLUC-AP: 46 per 100.000 (N~7.223)_ 
Figure 5 shows the number of patients using AP after launch at t=5. which rapidly stabilises at 10.493. 
The initial drop was due to the 20% non-responders. 
Table III shows the development of the cumulative discounted costs after launch of AP compared with 
the total costs associated with usual care after respectively 1,5 and 10 years of introduction. AP 
reduces the total costs with €521,758. €2.221.224 and €3.609.027 after respectively 1. 5 and 10 years. 
AP substantially reduces medical costs. especially due hospitalisation and consultations. and also the 
non-medical costs. resulting in overall cost savings. In addition. AP also reduces costs within the drug 
budget. The cost saving of AP decreases the total drug costs from the first year by €115.072, which 
increased to €507 .321 and €786.154 after respectively year 5 and 10. 
Table III. Results of population model for Parkinson's disease for cumulative medical and other costs 
(discountin ). 
Year Costs (€) 
Dru~s Consul· Physio- Diagnostic Hospita- X on- Total 
tations therapy procedures lisation medical 
AP 455870 102207 393670 4262 35828 220141 1211977 
Usual care 570942 96851 521684 9613 130490 404154 1733735 
s AP 2135233 471298 1850075 20958 264776 1060873 5803213 
Usual care 2642554 448266 2414569 44492 603963 1870593 8024437 
10 AP 4014829 850949 3450614 41973 550916 2060459 10969741 
Usual care 4800983 814408 4386781 80833 1097277 3398486 14578768 
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Cost-Effectiveness analysis 
Table IV shows the outcomes of the cost-effectiveness study. The results of the baseline analysis show 
that the use of AP with a daily treatment cost (DTC) of €2. 7 (NLG 5) is less costly than usual care 
only with direct medical costs of €53329 versus €54654. respectively. and total costs of €69.917 
versus €71.268. AP increased the Time without fluctuations by 3.41 years and was associated "With a 
0.91 increase (11.77%) in QALYs (8.74 QALYs versus 7.82 QALYs). The use of AP results in an 
incremental cost-effectiveness ratio of 1,380 € per QAL Y, when only medical costs are included. The 
cost per year "Without fluctuations is €405, when only medical costs are included. The use of AP was 
dominant for both Time without fluctuations and QAL Ys, when all costs arc included. 
Table IV. Results of the Base Case Analvsis: Costs* and Effectiveness. 
Outcome Time QAJ;.Ys COsts(€) 
witllout 
AP 
Usual care 
Difference 
Cost per year 
without 
fluctuations 
Cost per QAL Y 
* discounted at 4% 
fluctuations 
3.41 
0.00 
3.41 
DISCUSSION 
Medical 
8.74 53329 
7.82 54654 
0.91 -1325 
405 
1380 
Non-medical 
16589 
16613 
-25 
N.A. 
N.A. 
Total 
69917 
71268 
-1350 
AP:dominant 
AP:dominant 
This study presented a methodology for an appropriate assessment of the budgetary impact of a new 
drug, which simultaneously can be used for traditional cost-effectiveness analysis. A model was 
constructed for a new hypothetical drug in Parkinson·s disease. which allowed us to determine the 
budgetary impact and the cost-effectiveness ofthis new drug (AP) from the perspective of the society 
in The Netherlands. 
The use of a Markov model allowed us to simulate a financial analysis and a cost-effectiveness 
analysis by extrapolating the clinical outcomes of AP beyond the duration of the AP clinical trial. 
There are also advantages to combining a budgetary impact analysis and a cost-effectiveness analysis. 
The analyses are based on the same underlying assumptions and data. which will increase the 
consistency between the outcomes of both analyses. 
Key data for the financial analysis are prevalence and incidence. A simple Markov model was 
constructed to validate the epidemiological data by testing the consistency between prevalence and 
incidence of Parkinson's disease for the Dutch population. The simple model can only be used to 
predict the potential number of patients who are candidates for a first-line treatment. at time of launch. 
However. the duration of treatment cannot be derived from this model: patients starting on a first line 
treatment will switch over time to another treatment due to disease progression and the initial 
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treatment of patients with Parkinson's disease will be adjusted after development of fluctuations. 
Therefore, the simple model cannot be used to determine the annual budgetary impact of a new first-
line drug. In addition. the model cannot be used to determine the annual budgetary impact for a new 
drug targeting subpopulations (e.g. patients with fluctuations), because the health state ·•p"" only 
considers patients with Parkinson's disease as a homogenous population without distinguishing 
betv.reen severity of the disease or other stratifications. 
Given the assumption of a stable population, the simple model should have been able to predict 
disease prevalence from incidence. However. it does it poorly, presumably because the data on 
incidence and prevalence derived from literature are very inaccurate. The literature data on prevalence 
and incidence vary from respectively 66 to 258 per 100.000 and 4 to 24 per 1000.000 (Table I), which 
strengthens this explanation. Another reason may be that the external validity of the simple model may 
be very limited and consequently is not an accurate reflection of reality. 
For example in the simple model we used an average mortality while Parkinson's disease is a 
condition. which occurs mostly in the elderly population and especially in males. Parkinson's disease 
usually starts at an average age of 62 and consequently patients with this disease will have substantial 
higher mortality. The incorporation of age may not be necessary for determining the potential number 
of candidates for a first-line treatment. but it is required for an appropriate estimation of duration of 
treatment. The more complex model appears to correct the problem by using age-specific and gender-
specific mortality rates, and as a result yield a closer relationship betv.reen modelled and observed 
prevalence rates using the observed incidence from the literature. Neither the presence of the various 
health states nor treatment affects in this model the relationship, because neither affects survival 
changing the equilibrium. 
If reimbursement of pharmaceuticals is going to be based mainly on economic data derived from 
modelling studies. it is vital to carefully scrutinise and refine this type design. The data being used in a 
modelling study may come from a variety of sources and are subject to varying degrees of uncertainty. 
In a previous manuscript. the limitations of the various types of data sources were extensively 
discussed. 17 The main drawback of all existing data sources is that they have not been developed for 
economic evaluations. but for either administrative or medicaVscientific purposes. Hence they may 
suffer from incompleteness (e.g. no information on either healthcare utilisation or clinical outcomes. 
especially QAL Y s ), sufficient external validity and appropriate format of the information, which does 
not fit the structure of the model. 
An extra concern about the financial analysis is the epidemiology data. When the model yields a 
discrepancy betv.reen the relationship between incidence and prevalence compared with literature data. 
we have to validate the model structure and epidemiological literature or identify other reasons. which 
may explain the difference. In particular, epidemiological data for other countries may not be 
applicable to the study country. When the discrepancy cannot be explained we recommend giving 
more weight to prevalence than to incidence data. Hence. incidence may be varied outside its range in 
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order to keep prevalence within an acceptable range. Prevalence has a higher impact on outcomes of 
fmancial analysis and accuracy of prevalence data is usually higher compared with incidence data. 
The model allowed various scenario analyses. In this example we only showed the impact of a 
scenario assuming that only patients who start developing fluctuations are going to use AP. Other 
scenarios are possible. Our analyses determined all potential candidates who are going to use the new 
drug, which assumed a 100% substitution. The current model also allows scenario analyses on the 
substitution effect. Another assumption is that population size is constant and that the population 
distribution with regards to age is constant, which is valid when predicting potential candidates of a 
drug within 10 years after launch. However, the model allowed the incorporation of aging of a 
population by changing the assumption that mortality rate equals birth rate. 
CONCLUSION 
Our conclusion is that one model can be used for an appropriate assessment of the budgetary impact 
and the cost-effectiveness of a new drug. The main methodological advantage is that the use of one 
model will increase the consistency between the fmancial analysis and the health economic analysis by 
using the same underlying model structure. its assumptions and data sources. 
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Chapter 12 
Reporting Format for Economic Evaluation: 
Focus on Modelling Studies 
SUMMARY 
This article presents the first version of a reporting fonnat for modelling studies which is based on a 
general reporting format by our taskforce, which was published in the previous issue of this journal. 
The use of decision-analytical models for economic evaluations is increasing because. in practice, it is 
not always possible to derive information from prospective studies. However, the acceptance of 
modelling studies is generally lower than prospective studies not only because of the use of secondary 
data. but also because the reports of modelling studies do not always have sufficient transparency. 
Hence, a standardised reporting format may improve the transparency and, consequently, the 
acceptance of modelling studies. This article presents an example of a reporting format for economic 
evaluation based on modelling studies. which may facilitate the development of future guidelines for 
modelling studies. The format consists of a number of headings, which are followed by a brief 
recommendation on the content. This format does not deal with methodology and data management, 
but especially addresses validation and quality assurance, which may increase the transparency of the 
report. 
Chapter 12 
INTRODUCTION 
Economic evaluation is beginning to be used widely to support decision makers in health services for 
allocation of scarce healthcare resources. Because economic evaluation is used for pricing and 
reimbursement issues by authorities or third party payers. it is vital that these analyses be performed 
according to generally accepted and standardized methods. In order to increase the scientific quality 
and integrity of pharmacoeconomic studies, national guidelines have been developed by various 
countries (Australia and Canada).1.:.3 However, in practice it is not always possible to derive 
information from scientifically sound prospective studies. In these cases decision-analytic models may 
be used to provide some of the missing information. Decision analysis is an explicit, quantitative. 
prescriptive approach to medical decision-making and allows both clinical and economic 
consequences of medical actions and attitudes to be analysed under conditions of uncertainty.4 The 
model resulting from the decision analysis must correspond, as much as possible. to the real life 
situation of the disease and should reflect actual treatment patterns with input values (probabilities and 
items ofhealthcare utilization) deviating as little as possible from population values. Models may take 
the form of simple decision-analytic trees or they may be very complex Markov models of underlying 
disease processes and treatments. 
The acceptance of modelling studies is generally lower than prospective studies because of the use of 
secondary data, but also because the reports of modelling studies do not always have sufficient 
transparency. Hence a standardised reporting format may improve the acceptance of modelling 
studies. A general reporting format for economic evaluation was described in a previous issue of this 
journaL5 Since, contrary to clinical trial data. there are no accepted methods for data collection and 
analysis for modelling studies. a more disaggregate reporting presentation is required for modelling 
studies. 
This paper presents an example of a reporting format for economic evaluation based on modelling 
studies (table I), which may facilitate the development of future guidelines for modelling studies. The 
format consists of a number of headings. which are followed by a brief recommendation on the 
content. The report is organised according to the ranking of the headings. If the structure of the report 
is different. markings made directly on the report indicate where in the report the content of each 
heading can be found. All headings are addressed in the report. If a heading is not relevant. it is not 
omitted. but a brief reason is given. 
REPORT INTRODUCTION 
The introduction of our report for a modelling study contains all the necessary relevant 
epidemiological, clinical and economic information, identical to what is already required for a 
standard prospective study. The purpose of any introduction is to describe the rationale of the study 
and to present the information on which the study hypothesis is based. However, for a modelling 
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study we also incorporate information on the reasons for choosing a modelling study and a 
justification for the design and methods employed in the study. Table II outlines the information used 
for each step in the decision-making process for a modelling study. 
Table I. ReportiO'g format for a modelling studv. 
REPORT INTRODUCTION 
• Epidemiology and treatment 
Prognosis 
Disease progression 
Local treatment pattern 
• Economic impact 
STUDY DRUG 
HYPOTHESIS 
OBJECTIVES 
DESIGN 
• Analytic framework 
• Patient population 
• Comp3IatOr 
Analytic horizon 
Perspective 
• Setting 
• Clinical measures 
• Effectiveness measures 
Economic measures 
METHODS 
• Hcalthcare system 
Model description 
Data sources 
Data collection 
Probabilities 
Healthcare utilisation 
• Data analysis 
• Sensitivity analysis 
• Discounting 
RESULTS 
• Intermediate results 
Final results 
CONCLUSION 
DISCUSSION 
VALIDATION AND QUALITY CONTROL 
• Validation 
• Quality control 
• Software 
RELATIONSHIPS 
APPENDICES 
REFERENCES 
Epidemiology and Treatment 
The introduction for a modelling study also contains, in addition to estimates on the prevalence and 
incidence of the particular disease, information on age. gender and risk factors. The clinical 
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information consists of a description of the pathology. including underlying pathophysiological 
mechanisms, and on the prognosis. disease progression. and existing treatment options. all of which 
are relevant to the design of the model. 
Prognosis 
A patient may fully recover without any higher risk for recurrence or other morbidity than the general 
population. On the other hand the patient may have a worse prognosis. a possibility which is discussed 
in the next section on disease progression. The information on patient prognosis is needed for the 
choice of the type of model (decision tree or Markov model) that will be employed in the modelling 
study. 
Disease Progression 
In many diseases, patient may not achieve a complete recovery. There may be: (i) an increased risk for 
a relapse (e.g. depression): (ii) incomplete recovery (e.g. stroke): or (iii) other morbidity (e.g. 
myocardial infarction due to angina pectoris). In addition. the disease progression may be 
characterised by: (i) episodes with intermittent symptom-free periods: (ii) exacerbations, from which 
there may be only partial recovery. leaving the patient in a worse health state after each episode (e.g. 
Multiple Sclerosis (MS): (iii) a more continuous chronic character (e.g .. Parkinson's Disease). There 
may also be risk factors that may act as triggers (e.g. fever in MS). This information is needed to 
decide on the characteristics of a Markov model (health states. cycle time. follow-up period) and 
effectiveness measure(s). 
Local Treatment Pattern 
The current treatment options (usual care) are discussed with their onset of action. efficacy, side-
effects. serious adverse events and compliance. Information from related clinical studies may be 
presented. In addition to drug therapy, other relevant treatment strategies (e.g. surgery). including no 
therapy. prevention. and screening are also presented. This information is needed to decide on the 
comparator(s) and clinical events which will be incorporated into the model structure. Information on 
the clinical events may also be used to decide on effectiveness measure(s). In addition to the first line 
therapy, treatment options for treatment failures are described, and this information may need to be 
incorporated into the modeL depending on local treatment patterns. This section also contains a 
description of relevant international or national guidelines, which may be used for the development of 
the model structure. The information on the local treatment patterns may be used to decide on Markov 
characteristics (Markov states and cycle time). Finally. information on the type of physician (GP or 
specialist) and setting (in-patient or out-patient) associated with each treatment option. may help to 
defme the perspective of the study and in the definition of economic outcomes. 
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Economic Impact 
The economic information refers to any previous related studies on the relevant pathology (cost-of-
care studies) and associated therapies (cost-effectiveness studies). Of special interest may be country 
specific studies. because results from studies in other healthcare settings may not be directly 
extrapolated to the study country. Information on direct medical costs, direct non-medical costs and 
indirect costs may permit a judgement as to the type of costs to be included and on the perspective(s) 
of the study. Previous studies may also yield information on main cost drivers and cost structure. 
STUDY DRUG 
This section contains a detailed description of the characteristics of the study drugs: indication, onset 
of action. efficacy, side-effects, serious adverse events. intermediate outcomes and compliance. The 
drug is also be compared with other therapies. A summary of the clinical trials is given. including 
information on the design. study population. follow-up period and clinical outcomes. The indication 
and onset of action will determine the study population. The information on clinical events associated 
with the study drug is needed for decisions on model structure and in defining the effectiveness 
measure(s). If the study drug is already on the market. information on market shares. niche and 
prescribers (e.g. GP or specialist) may be helpful in deciding on the perspective of the study and in 
defining economic outcomes. 
HYPOTHESIS 
The hypothesis for a modelling study will be based on information in the '"introduction .. and "study 
drug" sections. The rationale behind the hypothesis is described in detaiL This section does usually 
not contain any more information than that provided for a prospective pharmacoeconomic study. 
OBJECTIVES 
The description of the objectives of a modelling study will be based on the hypothesis and does not 
usually differ from the objectives of a prospective pharmacoeconomic study. Any limitation of the 
scope of the objective due to the availability of relevant data is mentioned. 
DESIGN 
The choice of a modelling study to prove the study hypothesis is justified. because the acceptance of 
modelling studies is lower than studies based on primary data. The reasons for doing a modelling 
study instead of a naturalistic study may be scientific (chronic disease) or purely practical. For 
example, pharmacoeconomic data may not have been required during the period of a clinical trial, but 
if such data have become required at submission, the only practical solution is a modelling study. 
After the decision has been made to use a modelling study. the choice of the type of model is justified: 
decision tree models or Markov models. Decision tree models are indicated for describing the 
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treatment pattern for an acute episode of illness leading to full recovery or death (e.g. community-
acquired pneumonia) while a Markov model represents a convenient way of modelling chronic 
diseases. In an ideal Markov model, a life-time follow-up is recommended. The choice of the type of 
model employed is justified, especially in cases where there are deviations from the above mentioned 
general rule. For example. when a study is performed from the hospital perspective. a decision tree 
model may be sufficient to determine the costs and effectiveness of a treatment during hospitalisation. 
Analytic Framework 
The main analytic framework of the study is described: cost-minimisation. cost-consequence. cost-
effectiveness, cost-utility or cost-benefit. The choice of the framework is justified. especially when it 
is has been determined by the limitations of a modelling study design. The data sources for 
development of the analytic framework are given and explained (e.g. clinical textbooks. other 
literature data and expert opinion). All assumptions are listed in a table, including the process of the 
creation of the assumptions and the validation process. 
Patient Population 
The hypothetical study population of the model is described, which will be based on the clinical 
trial(s) study population. Hence the most relevant inclusion and exclusion criteria of the clinical 
trial(s) are mentioned. The underlying assumptions for the selection of the hypothetical study 
population. and the validation process for these assumptions. are also described. Subsequently a 
judgement is made as to the dissimilarities between the hypothetical study population. which should 
have a high external validity. and the limited clinical trial population(s). Factors that can limit the 
application of the results are discussed (e.g. differences in resistance across countries in community-
acquired pneumonia). 
Comparator 
The choice of comparator is primarily based on the country-specific guidelines (e.g. most widely used. 
cheapest etc.) and this choice is justified. For example. there may only be clinical data available for 
one other drug. information which can be incorporated into the model. In the event that there are no 
local guidelines. a justification of the choice of the comparator is given. 
Analytic Horizon 
The general rule for the determination of the study period in a modelling study is that a decision tree 
model covers the period from treatment initiation until recovery or death, while in a Markov model. 
ideally a life-time follow-up is recommended. The choice for the study period is justified. especially 
in cases of deviation from the above mentioned general rule, when the main reasons are discussed. For 
instance, in chronic diseases. a study period from one to five years may be sufficient. especially when 
extrapolation of short-term clinical trial results may not be acceptable from a clinical perspective. 
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Perspective 
The choice of perspective ideally depends on the treatment pattern (type of physician, setting), the 
rules of reimbursement. and country specific pharmacoeconomic guidelines. Previous economic 
studies and market information may help in defining the perspective. For example. if another study 
showed that indirect costs have a high impact, the society perspective may not be abandoned. The 
choice of the perspective is justified, and the rationale is explained, which may be due to the 
limitations associated with modelling. For example, if reliable information on working days lost is not 
available in the literature or other data sources. a society perspective may have to be abandoned since 
the credibility of expert opinion for this type of data is limited. 
Setting 
The model will be developed for the healthcare setting of the study country. The setting will depend 
on the perspective of the study and the local treatment patterns. including the indications of the study 
drug and comparator. Previous economic studies and market information may help in identifYing the 
perspective. A justification is given for any deviation form this rule, that might arise because of 
limitations of the modelling design. For instance. patients with depression are usually treated by GPs 
and psychiatrists. However, when the database. which was used for the study only contains 
information from patients being treated by psychiatrists, then the setting may be limited to that of the 
psychiatrist. 
Clinical Measures 
The choice of clinical measures, which will be presented in the cost-of-consequences table. are 
explained and assessed on clinical events associated with local treatment, including the study drug 
(and comparator) and management of patients with a treatment failure. In addition. information on 
clinical measures which may have been used in previous pharmacoeconomic studies in the pathology 
under investigation, is also presented. Clinical events (e.g. adverse events) may be neglected.. when 
they not differ statistically bet\Veen study drug and comparator. 
Effectiveness Measures 
The choice of effectiveness measures is explained, and may be based on disease progression. clinical 
events associated with local treatment, including the study drug and comparator, and scales of 
measurement, used in previous clinical and pharmacoeconomic studies in the pathology under 
investigation. The preferred effectiveness measures are mentioned, which would have been chosen in 
a regular prospective study. When the model design does not allow the incorporation of preferred 
clinical measures, the reasons are explained in this section. For instance quality of life, which deals 
with subjective feelings and emotions, cannot always be incorporated into a model structure. In this 
situation, alternative effectiveness measures which can be used for a modelling study are described 
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[e.g. time without symptoms/toxicity (TWIST)]. Subsequently the choice of the effectiveness measure 
being used in the model is justified, including a description of the validation process. 
Economic Measures 
The choice of the relevant economic measures will be primarily be based on the pathology under 
investigation and the perspective of the study, and is ideally identical to the economic measures 
which would have been chosen in a prospective study. Previous economic studies and market 
information may support the choice. When the model design docs not allow the incorporation of the 
preferred economic measures, this is explained in this section as well as the steps taken to deal with 
this limitation. 
METHODS 
Healthcare System 
This section contains a general description of the healthcare system. The general and specific rules for 
reimbursement for the pathology under investigation are described. This section is not dependent on 
the design of the study (prospective or modelling). 
Model Description 
This section contains a complete description of the structure of the model. including a figure of the 
model. The description allows the reader to follow every patient from the initial treatment until the 
end of the study period. including patients with treatment failure. In the case of a Markov model, this 
section contains a description of the Markov states (e.g. disease severity only or combinations of 
severity and treatment) and a justification. For instance. the Markov states may need to be based on 
health states (disease severity) and treatment. when the transitions do not depend only on health state, 
but also on treatment and previous treatment failures. Definition of Markov states will depend on 
information on disease progression and local treatment patterns. which may be supported by previous 
modelling studies or treatment guidelines. Validation processes are also be added. The patients' 
progression through the Markov states will be divided into cycles. which is described and justified 
(e.g .. the cycle time corresponds to the time of the sequential therapeutic stages). In Markov models 
the duration of the cycle is justified. including the validation process. The choice of cycle time is 
usually based on infonnation on disease progression. and local treatment patterns (e.g. duration of a 
therapy). which may be supported by previous modelling studies or treatment guidelines. The data 
sources for model structure development are given and explained (e.g. clinical textbooks. other 
literature data and expert opinion). All assumptions that were used in structuring the model are listed 
in a table. including the process of the creation of the assumptions and the validation procedures. 
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Table II. Relationship between studv choices and information. 
Epidemiology 
and treatment 
Prognosis Disease 
progression 
HYPOTHESIS X X 
OBJECTIVES X X 
DESIGN X 
Analytic Framework 
• Patient Population 
• Comparator 
• Analytic horizon X 
Perspective 
• Setting 
• Clinical measures X 
Effectiveness X 
measures 
• Economic Measures 
METHODS 
• Choice for model X 
• Type of model X 
• Markov states X 
Cvcle time X 
Data Sources 
Reportingfonnatfor modelling studies 
Local 
treatment 
pattern 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Economic 
im act 
X 
X 
STUDY 
DRUG 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
The sources of model variables (probabilities, healthcare utilisation. therapeutic choices. costs/tariffs) 
are mentioned; clinical trials. literature (e.g. meta-analysis). databases. medical records. Delphi panels 
and/or official tariff lists. The data sources are described in sufficient detail. For example. the 
description of clinical trials contains the results of the trial and details of the design. such as the study 
population. follow-up period of patients. follow-up of drop-outs and treatment failures (intention-to-
treat). method of randomisation and primary and secondary clinical outcomes with confidence 
intervals. The strengths. weaknesses and possible sources of bias, that may be inherent in the data 
sources used in the analysis. are described. Selection criteria for studies and databases are discussed 
and an indication is given of the direction and magnitude of potential bias in the data sources which 
were used. The search strategy is described: Keywords. Journals. Language. Timefrarne (e.g. 1987 to 
date). databases (e.g. MEDLINE. HealthSTAR. HSRProj. HSTAT etc.). 
Because of criticism of Delphi panels. the use of this data source is justified by explaining that no 
other data sources were available. The use of Delphi panels does not follow a clear and consistent 
pattern; different researchers apply the terms Delphi. modified Delphi and expert panel in different 
ways. Moreover the basic methodology is often not followed. with both errors in the application of 
the techniques and in the justification for their use. Therefore this section contains a detailed 
description of the methodology (e.g. the inclusion criteria for the participating experts) and the 
process (e.g. number of rounds. interviews or mail). 
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Data Collection 
The methods and processes for data collection (e.g. for a Delphi panel) and data abstraction (e.g. for a 
database) is described and explained. The data collection forms which were used in the study are 
included in the appendix of the report (e.g. the questionnaire for the Delphi paneL or the abstraction 
protocol for the database). The rationale behind the data collection forms is explained by showing the 
relationship between the model (structure and variables) and the form. The procedures used in the 
creation of these tools and the validation process are described. For example, the structure of a 
questionnaire may have been developed with the help of one clinical opinion leader, and validated by 
an advisory board of experts. 
Probabilities 
The methods for the determination of the probabilities are described. In Markov models the 
adjustment of all probabilities to the cycle time of the model are explained (e.g. the actuarial method). 
Assumptions and methods used in extrapolation of short term results to the follow-period in the model 
are described and justified. including the validation process. 
In addition to determination of the above mentioned fixed input values for the model. the method used 
for determination of the range for each probability is described and justified (e.g. first and third 
quartile in the case oflimited data). 
The appendix contains a table shov.ring all probabilities, listing the fixed input plus method and 
assumption., minimum and maximum plus method, data source and assumptions. In addition, for a 
Markov model the methods and associated assumptions used for calculation of the transition 
probabilities are listed. Finally the quality process employed for data entry (e.g. double entry or single 
entry with visual control) and data processing (e.g. visual control of all formulae) is described. 
Healthcare Utilisation 
The methods used for the determination of the units of healthcare utilisation (units of direct non-
medical costs and working days lost) are described in detail. In Markov models the allocation of 
healthcare utilisation to Markov states and transitions is described and any assumptions. including 
validation processes, are mentioned. This section also contains a description of the costing 
information. including the data source, for each unit of healthcare utilisation. which v.rill depend on 
the perspective of the study .. The units ofhealthcare utilisation are defined in tables for each Markov 
state and transitions in a Markov model as well as for each branch in a decision tree model. The 
costing information may consist of actual costs. prices or tariffs. reimbursement percentages and co-
payment, and data sources. 
In addition to determination of the above mentioned fixed input values for the model. the method used 
for determination of the range for each unit of healthcare utilisation and price/tariff is described and 
justified (e.g. first and third quartile in cases oflinrited data). 
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The appendix contains a table showing all units of healthcare utilisation. listing the fixed input plus 
method and assumption. minimum and maximum plus method. data source and assumptions. A 
similar table is shov.rn for the costing information. Finally. the quality process is described for data 
entry (e.g. double entry or single entry with visual control) and data processing (e.g. visual control of 
all formulas). 
Data Analysis 
The standard analysis used is described. This will usually be a foldback analysis. which is an analysis 
based on the fixed input variables and yields the average effectiveness and costs for each treatment 
strategy. In situations where the study drug leads to a higher effectiveness and higher costs. an 
incremental analysis is performed (e.g. cost per life-year gained). 
Sensitivity Analysis 
The execution of a sensitivity analysis and the interpretation of the results is not yet standardised. and 
this may lead to a subjective interpretation of the results which may consequently weaken the value of 
the economic evaluation. Hence the choice of the variables on which a sensitivity analysis is 
performed is justified and the rationale for the interpretation of the results of such an analysis defmed. 
Sensitivity analyses are performed for the clinical variable on which the study hypothesis is based. 
and on the main cost driver. 
Discounting 
This section will usually not depend on the design of the study (prospective or modelling). and will 
therefore not differ from country-specific or international guidelines. 
RESUlTS 
Intermediate Results 
This section starts with a reference to the appendix. which contains all the intermediate results of the 
study. This may be spreadsheets of all data collection forms. including results of data processing. For 
example. the estimations of all individual opinion leaders may be given. together with the fixed input 
value and range. after determination of the median and the first and third quartile. Results from the 
literature search (e.g. meta-analysis) may be presented in a similar way. The appendix also includes a 
table with the prices (or tariffs) of units of health care utilisation from the society and study 
perspective. including the origin of the data source. 
Final Results 
The presentation of the fmal results may start with a description of the country-specific treatment 
patterns. based on the therapeutic choices after initial treatment with the study drug or the comparator. 
Subsequently. the average clinical and economic outcomes are listed in a cost-consequence table. in 
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which the economic measures are expressed.. both in units ofhealthcarc utilisation and costs. Another 
table presents the effectiveness and economic outcomes, including incremental cost-effectiveness 
outcomes, if appropriate. Also the total cost structure associated v.rith each treatment strategy is 
shown. The disease progression over time and the timing of the different costs over time are presented 
in a graph or table, which may be combined in one figure to show the relationship between clinical 
and economic outcomes for each initial treatment. The results of all sensitivity analyses are presented 
using graphs or tables. 
CONCLUSION 
This section describes the interpretation of the results and concludes if the study hypothesis has been 
proven by the results of the study. Secondary conclusions may also be addressed e.g. main cost driver, 
cost structure. The robustness of the conclusion may be addressed by discussing the results of the 
sensitivity analyses. 
DISCUSSION 
This section contains a validation of the results of the model by comparing results from other studies 
or expert opinion. The observed differences with other studies are addressed and explained, along 
with the impact of the limitations and level of uncertainty in the modelling study. The discussion may 
conclude with recommendations to solve any existing uncertainty with regards to the final conclusion 
(e.g. a future prospective study might be recommended). 
VALIDATION AND QUALITY CONTROL 
Validation 
If relevant the general validation methodology and processes arc described, in addition to the specific 
descriptions included under each heading. 
Quality Control 
The process of Quality Control is described, dealing with subjects such as quality control of data entry 
and data processing (e.g. calculation of transition probabilities). 
Software 
The software being used is listed.. together with a description of the activities for which it was used. 
(e.g. Data 5.1 for modelling, Excel 5.0 for determination transition probabilities, Word 6.0 for report 
'Nriting). It is also indicated if the sofrware was validated and, if so, by whom, and when. 
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RELATIONSHIP 
This section discloses relationships betv.reen the performer of the study and the sponsor. Actions taken 
to avoid any potential bias are described (e.g., using a Medical Advisory Board. or validation by 
independent experts). 
APPENDICES AND REFERENCES 
Especially in modelling studies the disclosure of relevant appendices to reports will increase the 
transparency of the results. The appendices may cover the following information. which has been 
mentioned in relevant headings: list of variables and data sources, list of assumptions. list of formulae. 
the names and addresses of participating experts. 
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INTRODUCTION 
The objective of this thesis was to identifY and explore various types of uncertainty in modelling 
studies. Also methodologies were introduced, which may reduce the level of uncertainty associated 
with modelling, and which may consequently increase the acceptance of modelling studies. The 
concepts were empirically illustrated using Markov models in chronic diseases: depression. 
Parkinson's disease and multiple sclerosis. 
The review by Buxton et al explored the role of modelling in economic evaluation and concluded that 
the concerns about models mainly relate to the trade-off bet\Veen internal and external validity. 1 In this 
thesis I explored various types of uncertainty associated v.rith the data used in the modeL which relate 
to the internal-external validity issue raised by Buxton. I also examined in depth the measurement of 
uncertainty by means of sensitivity analysis and the worth of collecting extra data. 
DATA SOURCES: INTERNAL VERSUS EXTERNAL VALIDITY 
Validity of Data Sources 
Chapter 4 contains an assessment of the validity of various data sources for the variables being used 
in a modeL In general most of the data sources (clinical trials, meta-analysis). which yield the clinical 
data for the model lack external validity. because those data are usually derived from. randomised 
clinical trials with a high internal validity. The data sources. which yield data on healthcare utilisation 
also suffer from lack of external validity. when those data are derived from randomised clinical trials 
or clinical databases. Alternative data sources for healthcare utilisation are administrative databases. 
which contain data on healthcare utilisation v.rith a high external validity. Those databases often suffer 
from several limitations, because they were not developed primarily for health economic evaluations. 
Consequently the format of the information may not always fit the structure of the model and the data 
set may not be complete. for example when inpatient data have not been collected for reasons of 
reimbursement. Also there is in general a lack of appropriate databases in Europe. contrary to the US. 
The use of medical records suffers from similar limitations and access may be complicated because of 
legislation associated with privacy protection. 
Chapter 4 also contains a number of recommendations for good practise. which operationalises the 
concept oftransparancy. This chapter proposes to include in the report a very detailed description of 
all data identified as potentially relevant for the model together with some critical appraisal of each 
item of data. finished with a formal justification of the choice of each item of data. Such an approach 
has been recently welcomed by other authors.1 
Use of Cross-Sectional Data 
In Chapter 4 the advantages and disadvantages of different sources of data are discussed. A main 
concern is the use of a panel of experts to gather data. which cannot be derived from the literature. 
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because there is no guarantee that such an assessment of resource utilisation and utilities accurately 
reflects reality. Many health economic modelling studies are still based on data derived from Delphi 
panel. especially in Europe due to lack of appropriate other data sources (e.g. databases). Considering 
that the results from modelling studies are increasingly used in reimbursement decisions for new 
drugs. it is obvious that potential bias due to the usc of Delphi panels should be minimised. Chapter 5 
describes a cross-sectional study as an alternative data source for a modelling study. This hybrid 
design is aimed at bridging the probabilities derived from literature and clinical trials with information 
on costs and utilities from a cross-sectional study. 
Chapter 7 shows that the use of a hybrid design introduces another type of uncertainty due to the 
impact of confounding variables: the costs and utilities derived from the cost-of-care study, may not 
only be a function of the defined health states in a Markov model. but also of other variables. which 
may act as confounding variables when they are not taken into account and consequently reduce the 
external validity of the model. A methodology was presented to increase the external validity of a 
Markov model by the incorporation of confounding variables in the model. This study showed that the 
inclusion of confounding variables substantially changed the outcome of the model. A severe potential 
limitation is that the incorporation of multiple variables necessitates an increase of the sample size of 
the cross-sectional study in order to obtain statistically significant results, which may limit the 
feasibility of this approach. 
The negligence of a confounding variable lead to uncertainty relating to generalisability of results as 
proposed by Buxton and Briggs. which deals with the extent to which the results of a model, as they 
apply to a particular population. hold true for another population. J 3 Chapter 7 showed that the 
distribution of confounding variables in patients in a clinical trials or cross-sectional study may not 
correspond with the actual distribution in the population. Consequently the cost-effectiveness results 
of a model. which is based on those data sources. may be severely biased. 
Finally the ignorance of a confounding variable can also be considered an oversimplification, which is 
according to Eddy the most common error in modelling and which occurs by omitting important 
variables.4 
Use of Registers before Launch 
The statistical constraints may be solved by the usc of registers instead of cross-sectional studies. A 
register and a cross-sectional study are both observational studies. but the register has a much larger 
sample size and the data collection in a register is more comprehensive. Registries use large 
longitudinaL observational studies designed to measure the impact of a particular disease or condition 
on clinical and patient-specific outcomes, and to document the outcomes associated with different 
treatments or settings of care. Patients arc followed prospectively and data are collected on disease 
severity and clinical outcomes as reported by clinicians, as well as resource use. functional status and 
quality of life as reported by the patient. Currently targeted longitudinal observational databases. or 
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patient registries. arc being designed, which reflect the current treatment patterns without influencing 
the treatments or interventions and consequently the observational study is fully naturalistic without 
any intervention 'With real practice (e.g. no randomisation) and has a high external validity. The use of 
a register suits perfectly with the concept of evidence-based medicine (EBM). which means that 
clinical encounters should be supported by scientific conclusions based on data as much as possible. 
The large size of a register allows the development of statistically solid multiple regression equations 
with high external validity, which can be incorporated in a health economic model. Summarising. the 
cost-effectiveness of a new product can be modelled by combining data on the probabilities derived 
from literature and clinical trials with information on costs and utilities from a register, which is 
primarily developed for the collection of health economic data in daily practice. Thus a register also 
yields data with a high external validity like the cross-sectional study. but its large sample size also 
reduces the statistical constraints of a cross-sectional study. 
Although the incorporation of healthcare utilisation data from a register into a model substantially 
increases the external validity and reduces the uncertainty of the input data, this methodology remains 
only a simulation of the cost-effectiveness of a new drug. The input transition probabilities for the new 
drug are still based on efficacy and safety data derived from the phase III clinical trial, which suffer 
from limited external validity. Another concern is that the srudy population in a trial is often not 
representative of the population under treatment. meaning that results of trials cannot necessarily be 
generalised to the population actually being treated. For example. until recently. women were 
underrepresented in many trials. Even today the elderly are frequently underrepresented and those with 
co-morbidities are often excluded. Although the guidelines accept modelling techniques to extrapolate 
efficacy to effectiveness outcomes, the extrapolation from cost-efficacy to cost-effectiveness outcomes 
introduces an extra type of uncertainty. In Chapter 6 we extrapolated the short-term clinical trial data 
on progression in the multiple sclerosis clinical trials to a life-time effectiveness outcome (QALY's). 
This method of extrapolation was validated by comparing the modelled life-expectancy with the life 
expectancy from an observational study, which was not used in the model construction. Eddy defined 
this type of validation as a 3-order validation.4 
Use of Registers after launch 
The register can yield real-life data for the comparator in the health economic model. which are based 
on data from daily practice. However the register usually does not contain any data on efficacy and 
safety of the new drug, when it is not yet reimbursed. Therefore reimbursement decisions for a new 
drug will always be constrained by this paradox. which requires effectiveness data before the new drug 
is used in daily practice. When decisions on reimbursement of pharmaceuticals will be based 
predominantly on health economic data, this paradox docs not allow a fmal decision for the 
reimbursement of the drug from a methodological point of view. especially because of the high 
consequences for the patient population. Therefore temporary acceptance of an innovative drug to the 
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reimbursement package might be considered. A conditional acceptance would permit initial decision-
making on reimbursement based on the cost-effectiveness of the new drug derived from modelling 
data. followed by validation through subsequent prospective data collection after reimbursement of the 
new drug by means of a naturalistic study. However such a study would require a much larger sample 
size than a Phase III trial in order to show statistically significant differences in health economic 
outcomes, because of the more heterogeneous patient population. Consequently the set-up of a 
naruralistic study would be constrained by logistical requirements. Alternatively the initial register 
may be used to yield real-life data for the new drug during the period of temporary reimbursement and 
continue data collection after launch of the new drug. The new data can replace the initial input data 
for the new drug in the health economic model. Consequently the model can be used to reassess the 
cost-effectiveness of the new drug based on real life data, which corresponds with a 4th order 
validation.4 However this approach is only meaningfuL when the conditions under which an 
intervention is actually implemented, closely reflect those assumed in the model. 
The register may also yield more statistically solid safety data with high external validity because of 
the large sample size of the register compared with the clinical trial. The large sample size of the 
register may also allow the identification of any type of covariance. which could not be incorporated 
in the initial model because of lack of power in the clinical trial and lack of sufficient real-life data on 
the new drug. The new study drug may not only show an improvement on the primary efficacy 
outcome in the clinical triaL but the new drug may also be superior (or inferior) on other clinical 
outcomes compared with standard therapy. Such other clinical outcome may act as a confounding 
variable, when it is not incorporated in the modeL because the transition probabilities and the 
costs/utilities of the health states may also be a function of this other clinical outcome. The impact of 
confounding variables has been illustrated in Chapter 7, which showed that the outcomes of a health 
economic model for Parkinson's disease are severely biased. when another measure of disease severity 
(Hoehn&Yahr scale) is not taken into account in addition to only the level of fluctuations. 
Observational data, however. may also have important limitations through the non-random decisions 
of clinicians that introduce bias. 5 In observational data, patients would often be treated differently 
based on the underlying condition. In such cases. comparing outcomes across patients would confound 
the effect the treatment with the effect of the underlying condition. This confounding. often referred to 
as a selection problem in the econometric literarure. certainly exists in the case of catherisation of 
patients with an acute myocardial infarction (AMI).6 By contrast, in a well-executed RCT, patient 
condition is independent of treatment. and one can therefore reasonably attribute observed effects to 
the particular variation in treatment being studied. In observational data the treatment is not allocated 
randomly. As a result, the characteristics of those obtaining the treatment will generally differ from the 
characteristics of those who do not get standard care (the controls). The differences may be observable 
characteristics such as age, in case a regression equation can potentially control for them.7 
Subsequently this regression equation can be incorporated in the health economic model for the 4th 
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order validation of the outcomes of the initial model. A more serious concern is that the differences 
may be unobservable (to the analyst) characteristics that affect patients under treatment. For example, 
patients who are more severely ill in ways known to their physicians but not to the analyst might not 
get the treatment. or vice versa. If so. the effect of the treatment on the outcome is confounded with 
the severity of illness. This effect is well understood by clinicians and epidemiologists and is a 
principal reason why RCTs are regarded as the gold standard in clinical research. The usc of 
observational data for health economic studies has also been questioned previously.8 
However new methodologies have been developed. that may reduce the need for a RCT. For example. 
Newhouse presented an econometric technique. instrument variables, that can be useful in estimating 
the effectiveness of clinical treatments in situations when a controlled trial cannot be done.6 This 
technique relies upon the existence of one or more variables that induce substantial variation in the 
treatment variable. but have no direct effect on the outcome variable of interest. The concept was 
illustrated with an application to aggressive treatment of acute myocardial infarction (AMI) in elderly. 
which showed that some of the differences in observed mortality between patients receiving 
catherisarion and no catherisation could result from differences in the capabilities of the hospitals and 
physicians treating the two groups of patients, independently of the procedures given to them. For 
example hospitals v.rith a cathererisation unit arc more likely to have other sophisticated treatments 
available to their patients. and their physicians and nurses may be more highly trained. There are other 
examples. where observational data have resulted in conclusions about the effectiveness of therapy. 
which have subsequently been shown to be wrong such as the prophylactic administration oflidocaine 
to patients v.rith AMI.9 
SENSITIVITY 
Sensitivity analysis aims at providing information on the degree of uncertainty in economic 
evaluations. A sensitivity analysis is based on the modification of the basic clinical and economic 
estimates of parameters to judge the effect on study results of alternative assumptions for the range of 
potential values for uncertain parameters. The methods used. the choice of parameters and the range of 
these parameters must be stated and substantiated. If this procedure is followed for all the estimates in 
tum, then we refer to it as a ·univariate sensitivity analysis' or one-way sensitivity analysis. The 
conventional approach is to vary one of the input variables from its baseline values and to observe the 
effect on the outcome of the model. A limitation of the univariate sensitivity analysis is that it does not 
incorporate the probability distribution of an input variable and docs not provide information about 
how likely the outcome will deviate from the base case values. 
Probabilistic sensitivity analysis (PBA) permits the analyst to assign a range and distribution to input 
variables. A multivariable PBA examines the effect of simultaneous changes in different variables on 
the outcomes of the study. which is based on generation of random distributions around each 
parameter and -- in conformity with the distributions -- then tries to arrive at a new estimate for each 
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parameter. For each combination of estimates a new estimate of the costs, effects and cost-
effectiveness ratio is therefore obtained. By repeating this procedure many times a random distribution 
can then be presented. In case of a monovariable PBA, the variation of only one input variable is 
incorporated.10 11 1::! 
Agro eta!. analysed the extent of reporting of sensitivity analysis in the health economic, medical and 
pharmacy literature.13 They found that in 59% sensitivity analysis was conducted and 39% of the 59% 
stated explicitly that a sensitivity analysis was being performed. It is interesting to notice the 
distribution: 80% of the health economic papers contained a sensitivity analysis; those figures are 
respectively 70% and 20% for the medical and pharmacy journals. The simple sensitivity analysis was 
employed most frequently. In health economic journals a simple sensitivity was performed in 50% of 
the cases. while a probabilistic sensitivity analysis was performed in only 10%. Other types of 
sensitivity analyses included threshold analysis and analysis of extremes. The authors also state that 
health economic guidelines contain limited information and recommendations regarding sensitivity 
analysis methods and that there is a large variability between the guidelines. Briggs also found that a 
disappointingly low percentage of studies adequately handled uncertainty. 14 Sheldon found that 
models often do not carry out sensitivity analysis thoroughly. Influential variables about which there 
really is uncertainty are often not varied as part of the sensitivity analysis. 1 ~ This could be because the 
authors endow it with false certainty or because the variables are hidden within the model. In those 
cases the sensitivity analysis is not only incomplete, but also it will underestimate the true uncertainty. 
In addition it is not sufficient to perform sensitivity analysis only on those variables. that are 
considered a priori very sensitive. There may also be variables, which appear to be sensitive after 
conducting the sensitivity analysis. Because of the complexity of the model a priori guesses of the 
sensitivity of input variables may lead to errors and consequently important variables may be excluded 
from the sensitivity analysis. A more important argument is that the selection of variables for the 
sensitivity analysis based on an a priori estimated sensitivity is in conflict with the objective of a 
sensitivity analysis. which is to identify the most sensitive variables. For example an antidepressant 
model did not vary critical assumptions on compliance. while the antidepressant model in Chapter 3 
showed the high impact of compliance on the outcomes of the model. 16 These fmding relate to a 
recommendation in Chapter 8 for univariate sensitivity analysis on every input variable of the model 
in order to avoid any bias and error in the selection of variables for the sensitivity analysis. In 
Chapter 8 a more objective method was presented for sensitivity analyses reducing the amount of 
potential subjectivity. This new procedure. integrating point-sensitivity and range-sensitivity in a 
measure of ··overall sensitivity"', allows an objective judgment of the sensitivity of all variables in a 
model. permitting the variables to be ranked according to the degree of overall sensitivity. \Vhen this 
method is compared with the existing methods for sensitivity analyses, this method can be considered 
a special type of univariate sensitivity analysis. because the sensitivity analysis is performed on each 
input variable separately. A difference is that the standard univariate sensitivity analysis is based on 
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the detennination of the difference in outcome (absolute univariate sensitivity) when an input value is 
varied within its range and depends only on the range of a variable, while the overall sensitivity also 
includes the responsiveness of the outcome to the input value at a fixed point (relative univariate 
sensitivity). Consequently the overall sensitivity yields more comprehensive infonnation for the 
interpretation of the sensitivity of the input variables. which may be helpful in prioritising further 
research for reducing the range of certain input variables. 
Another concern is the determination of the range to be used in the sensitivity analysis. In order to 
avoid bias in the selection of the range. the study should provide a source of explanation for the ranges 
used in a univariate sensitivity analysis instead of an arbitrary range. Therefore the range of an input 
variable may be derived from the stochastic variation of an input variable, for example the 5-95% 
confidence interval, where the 5% and 95% values are respectively the lower and upper limit for the 
sensitivity analysis. When the data do not allow the construction of a confidence intervaL the range 
can be based on the minimum and maximum values. In Chapter 8 this approach was used for the 
determination of the range of the input variables. 
A limitation of this method is that the overall sensitivity measure is based on a subjectively chosen 
range. which excludes the impact of values outside the range on the overall sensitivity. The 
uncertainty about the value of point estimates of parameters reflecting stochastic variation is best 
represented as a probability distribution. Chapter 9 presents a refinement of the initial method, as 
presented in Chapter 8, by the incorporation of the probability distribution. which allow a more 
accurate assessment of the level of uncertainty in the model. This method can be considered a special 
type of probabilistic sensitivity analysis (PEA). The refined method for the determination of the 
overall sensitivity can be considered a type of monovariable PEA. because it incorporates the 
probability distribution of one input variable, while the other input variables remain constant. On the 
other hand, there is a large difference in the outcomes. The level of sensitivity of a monovariable PBA 
is presented as an absolute statistical measure (SD. confidence interval). Contrary. the overall 
sensitivity is a relative measure, which includes the change of the input variable and consequently may 
be defined a relative monovariable probabilistic sensitivity analysis. 
A constraint of the above-mentioned and other methods for sensitivity analysis is that these methods 
only show the sensitivity of the outcomes to a change through a range of potential values for one or 
more variables without taking into account the existing relationships between these variables. 
Chapter 10 introduces the concept of 2-order sensitivity. which captures this inter-variable 
uncertainty and shows the practical implications of it for the execution of sensitivity analysis. We 
presented initially a method assuming only unifonn distributions, and subsequently various methods 
incorporating the real distributions. The fmdings from the 2-order sensitivity analyses can prioritise 
any subsequent prospective the data collection. 
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Application 
The results from sensitivity analyses can be used to judge the benefit of further research in order to 
reduce uncertainty in a modelling. The standard sensitivity analyses and the presented method of the 
overall sensitivity can be used to rank the input variables according to their level of uncertainty and 
prioritise further research for the most sensitive variables. The results from the 2-order sensitivity 
analyses show that the most sensitive variables in the model have also the most impact on the 
sensitivity of the other input variables. Consequently one can argue that the reduction of uncertainty 
associated with the most sensitive variables in a model, will lead to an overall reduction of uncertainty 
in the outcomes in the model because of a reduction in sensitivity of most variables. Hence it may be 
more important to investigate the uncertainty of the most sensitive variables of the model in more 
depth, e.g. by means of a meta-analysis. than to investigate the uncertainty associated with all 
variables. Oakly and Hagan investigated the relative importance of an input variable in driving the 
uncertainty of the outcome of the model.12 They compare the uncertainty of the outcome due to the 
variance of all input variables with the uncertainty due to the variance of all input variables. excluding 
the variable under investigation. Subsequently all variables can be ranked according to their relative 
impact. which will guide the efforts to reduce uncertainty. For example if it was possible learn the true 
value for two input variables and the cost for obtaining those values would be the same, the variable 
with the highest relative impact is chosen. An alternative approach to judge the benefit of further 
research to reduce uncertainty in a modelling study is based on the concept of Value of 
Information.17 18 This approach distinguishes the conceptually separate decision concerning efficient 
service provision given the level of information available, from the decision concerning funding 
further information collection. Here the decision of further data collection is based upon the expected 
cost of uncertainty, which is determined by both the extent of the uncertainty surrounding the efficient 
service provision and the consequences of this uncertainty. The extent of the uncertainty is measured 
by the error probability associated with the decision and the consequences of uncertainty are measured 
in terms of health benefits foregone when this uncertainty causes the incorrect decision to be made 
concerning service provision. Where these health benefits are valued according to society's 
willingness to pay for certain health outcomes, the approach gives a monetary value for the amount 
that society is willing to pay to reduce the uncertainty surrounding the service provision. Although the 
concept of Value of Information initially was applied to empirical data. it may also be applied to a 
health economic model. When an input variable appears to be very sensitive because of its large range. 
the concept of Value of Information may be applied by assessing the cost of extra research for 
reducing the confidence interval of that input variable by using more data. The primary objective of 
both the concept of 2-order sensitivity and the concept of Value of Information is to identify the 
impact of input variables in a model on the level of uncertainty within a model and to explore the 
worth of further research to reduce uncertainty of an input variable. The concept of Value of 
Information in a health economic model may be extended by incorporating inter-variable uncertainty, 
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which may further reduce the extra costs for the reduction of the uncertainty associated with the 
healthcare decision. For example the 2-order sensitivity analysis may show that the uncertainty 
associated v..rith the clinical response rate depends mainly on the hospitalization rate. Consequently the 
extra cost of exploring this rate may be less than the extra costs for reducing the range of the response 
rate. 
CONCLUSION 
Summarising, a model based on a hybrid design bridging clinical trial data and data from a register, 
seems to be the optimal design for yielding scientifically sound cost-effectiveness data at the time of 
reimbursement. I recommend a temporary reimbursement because of the above-mentioned potential 
sources of uncertainty, which can only be handled at the time of reimbursement by means of 
sensitivity analyses. The outcomes of the sensitivity analyses can guide the strategy for collecting real 
life data of the new drug, which can be used to replace the initial data in the model. Subsequently a 
final decision on reimbursement can be made based on the new cost-effectiveness outcome. This 
approach would minimise the logistical and methodological concerns related to current policy and it 
would also reduce the concern of industry that health economic evaluation guidelines would delay 
product launch, shortening the period of useful patent life and the return on R&D investment. New 
drugs would be made available more quickly if prospective data collection were not required prior to 
reimbursement. From the perspective that results from modelling studies are important for decision 
makers, it is obvious that recognising the relevance of uncertainty and appropriately dealing with it is 
required for obtaining unbiased results from health economic modelling studies. especially when those 
data are being used for reimbursement decisions. This thesis clearly showed the relevance of various 
types of uncertainty using specific examples. Another key research subject is the feasibility of the use 
of real-life data in the model by means of obsetvational data collection (e.g. registers). Considering the 
disadvantages of observational data. further research is required in order to provide scientifically 
sound methods and appropriate data sources for health economic modelling. 
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Summary/samenvatting 
In Search for More Confidence in Health 
Economic Modelling: Reducing Uncertainty 
Associated with Modelling Studies 
Summar!samenvatting 
Every government is eager to control the increase of expenses by the implementation of central cost 
containment policies particularly in relation to pharmaceuticals. For the most part. those measures 
have relied on budgeting or price controls. including negotiated prospective budgets for hospitals. 
centralized negotiated budgets for ambulatory physicians including drug prescriptions. and limitations 
on payments for particular medications. Because those traditional central cost containment measures 
were only partially successful. due to lack of incentives. the health authorities in Europe started to 
establish incentives for efficient healthcare delivery. Both traditional and recent containment measures 
focus especially on the pharmaceutical drugs sector in many countries. as these constitute a health 
technology that is relatively easy to introduce and implement compared to other forms of care. 
Financing prescription medicines in ambulatory care has been a central responsibility based on the 
traditional clinical trial outcomes used for registration: efficacy. safety and quality parameters. 
Although there is large variety between the various countries. there arc three related trends: 
decentralisation of the hcalthcare decision-making process. prescription restrictions. and extra data 
requirements. We can distinguish various extra data requirements all relating to the use of the drug in 
real daily practice. while the traditional clinical trial outcomes arc only derived from randomised 
clinical trials. At a central level the demand for cost-effectiveness and budgetary impact data is 
increasing. The requirement for health economic data has resulted in some countries already to formal 
reporting requirements (e.g. Canada, Australia. The Netherlands, The UK. Portugal and Finland). 
Although the most evident impact of health economic studies is expected for central reimbursement 
audiences. evidence for the usc of health economic studies by other audiences is expected to increase 
(e.g. patients. hospitals. insurers. formulary committees). 
Pricing and reimbursement have been based. until recently. on the traditional clinical trial outcomes 
(efficacy. safety and quality parameters) used for registration. which are called the first three hurdles. 
Consequently the growing burden on manufacturers to demonstrate the cost-effectiveness of their 
products is called the fourth hurdle in drug development. This fourth hurdle may have considerable 
consequences for all players involved. Health economic data may be collected alongside a Phase III 
clinical trial of a new drug. However data derived from this so-called .. piggy-back" trial suffer from 
external validity. because a clinical trial has strict inclusion and exclusion criteria and treatments are 
protocol driven. An alternative design is the naturalistic economic trial. which is a randomised trial 
with the primary objective of gathering ··real world" or representative cost and effectiveness data. 
However since study drugs are usually not approved for registration at the time of performing 
economic studies. the usc of prospective naturalistic trials is limited. making submission of data on 
effectiveness and expected costs at the time of reimbursement not feasible. On the other hand. 
projections about a drug's effectiveness and expected costs can be modelled using realistic and explicit 
assumptions based on data from clinical studies. In addition modelling often helps overcome the 
practical limitations of prospective studies. particularly for chronic conditions like Parkinson's disease 
that may require longer-term extrapolations of drug effects. In order to increase the scientific quality 
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and integrity of pharmacoeconomic studies. national guidelines have been developed by various 
countries. Although various groups have published recommendations on the good practice of 
economic evaluations 1 :': 3• those guidelines mainly focus on prospective studies and contain only a 
limited number of recommendations for the execution of modelling studies. This may partly explain 
why the acceptance of modelling studies has generally been lower than prospective studies. which is 
mainly due to the level of uncertainty associated v.rith modelling studies. If reimbursement of 
pharmaceuticals will be based predominantly on economic data derived from modelling studies, it is 
vital to scrutinise and refine the modelling approach carefully and especially the handling of 
uncertainty. 
Therefore the objective of this thesis was to identifY and explore various types of uncertainty in 
modelling studies. Methodologies are presented. which may reduce the level of uncertainty associated 
with modelling. and which may consequently increase the reliability of health economic outcomes of 
modelling studies. This may improve the acceptance of modelling studies. even in the absence of 
formal guidelines. The concepts are empirically illustrated using Markov models in chronic diseases: 
depression. Parkinson's disease and multiple sclerosis. Published real data are used. whenever 
possible. but extrapolation methods are used in absence of real data in order to illustrate the relevant 
issues. 
The following types of uncertainty in modelling studies are explored: 
• Uncertainty associated with the data sources providing the input data for the model. The reliability 
of the estimates depends on the choice of the data sources (selection criteria. external validity). 
The data may come from a variety of sources and are subject to varying degrees of uncertainty. 
The following issues relating to the selection of data sources were addressed: 1) Classification of 
data being used in modelling studies. 2) Assessment of the various data sources. including 
advantages and disadvantages. 3) General strategy on determining the appropriateness of a data 
source for a model. 4) Recommendations on a strategy for data source selection and a transparent 
reporting format for data source selection. A main concern in a modelling study is the use of a 
Delphi panel to gather data not available from actual existing data sources. There is no guarantee 
that the panel assessment of resource utilisation. utilities and patient preferences is an accurate 
reflection of reality. Therefore a cross-sectional study is presented as an alternative data source for 
a modelling study. It can be used to determine resource utilization and utilities for Markov health 
states. The overall design may be considered a hybrid between a naturalistic prospective study and 
a modelling study by maximising the pros and minimising the cons of both types of design. 
• Uncertainty reduction through sensitivity analysis: Sensitivity analyses are generally based on 
only a limited number of variables without justification of the choice of selected variables or the 
chosen range of each variable. which may lead to subjectivity in the execution of a sensitivity 
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analysis. An objective method is presented based on the integration of point-sensitivity and range-
sensitivity resulting in an ''overall sensitivity"". This approach avoids the subjective selection of 
variables for the sensitivity analysis and the potential bias in judging the degree of sensitivity in 
most current economic studies. 
• Inter-variable uncertainty: The constraint of standard sensitivity analyses is that those methods 
only show the sensitivity of the outcomes to a change through a range of potential values for one 
or more variables without taken into account the existing relationships between those variables. A 
methodology is presented. which considers this type of inter-variable uncertainty. which is defined 
as a 2-order sensitivity. The practical implications of this inter-variable uncertainty for the 
execution of sensitivity analysis are shov.rn. The results from the 2-order sensitivity analyses show 
that the most sensitive variables in the model have also the largest impact on the sensitivity of the 
other input variables. Consequently the reduction of uncertainty associated with the most sensitive 
variables in a model, will lead to an overall reduction of uncertainty in the outcomes of the model 
because of a reduction in sensitivity of most variables. On the other hand. it may be worthwhile to 
reduce the sensitivity of the most sensitive variable by using 2-order sensitivity analyses to 
identify the most influential variables. 
• Uncertainty about confounding variables: The costs and utilities may not only be a function of the 
defined health states in a Markov modeL but also of other variables. which may act as 
confounding variables when they are not taken into account. A strategy is presented for the 
incorporation of a confounding variable in Markov health states by means of health state specific 
relationships between the confounding variable and costs as well as time-dependent values of the 
confounding variable. Also the sensitivity of the outcomes of a model to the incorporation of a 
confounding variable is determined. The results show that the outcomes of a health economic 
model can be severely biased, when a confounding variable is not taken into account. This proves 
the need for incorporating confounding variables into a health economic model. 
• Uncertainty associated with epidemiological data: A methodology is presented for an appropriate 
assessment of the budgetary impact of a new drug. which simultaneously can be used for a 
traditional cost-effectiveness analysis. A Markov model is constructed to validate the 
epidemiological data by proving the consistency between prevalence and incidence of Parkinson"s 
disease. The analysis shows the substantial discrepancy ber--.veen the prevalence found in the 
literature and the prevalence derived from the model. which is based on the incidence data from 
the literature. Consequently a population-based model has an additional uncertainty in 
epidemiological data compared with the patient-based cost-effectiveness model. 
• Uncertainty associated with the reporting of a modelling study. Contrary to clinical trial data, there 
are no accepted methods for data collection and analysis for modelling studies. Therefore a more 
disaggregate reporting format is required for modelling studies. which addresses the various types 
of uncertainty in modelling studies and contains a justification of the choices in the selection of 
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data sources. model design and its assumptions, managing confounding variables and execution 
and interpretation of sensitivity analysis. 
The conclusion of this thesis is that various types of uncertainty can be distinguished in modelling 
studies. Until now the standard approach of dealing with uncertainty is the execution of sensitivity 
analyses, which only address the uncertainty associated with the range of the input variables 
(statistical uncertainty). This thesis explores in more detail the execution of a sensitivity analysis and 
identified other sources of uncertainty. An objective method for sensitivity analyses is presented, 
which minimises the amount of potential subjectivity. 
Uncertainty associated with sensitivity analysis: Sensitivity analyses are generally based on only a 
limited number of variables without justification of the choice of selected variables or the chosen 
range of each variable. which may lead to subjectivity in the execution of a sensitivity analyses. An 
objective method is presented integrating point-sensitivity and range-sensitivity, which allows an 
assessment of the ··overall sensitivity"'. In addition inter-variable uncertainty in sensitivity analysis is 
explored. This study shows the practical implications of this inter-variable uncertainty for the 
execution of sensitivity analysis. The results from the 2-order sensitivity analyses show that the most 
sensitive variables in the model have also the most impact on the sensitivity of the other input 
variables. Hence it may be more important to investigate the uncertainty of the most sensitive 
variables of the model in more depth, e.g. by means of a meta-analysis. than to investigate the 
uncertainty associated with all variables in order to reduce the total uncertainty of the model. 
Other sources of uncertainty: In addition to this statistical uncertainty other types of uncertainty in 
modelling studies are identified (data sources, confounding variables, epidemiological data) and 
strategies are presented how to deal v.rith them appropriately in the model. Finally a reporting format is 
presented, which addresses all types of uncertainty in a model and consequently increases the 
transparency of the model. Summarising this thesis shows that the moderate acceptability of modelling 
studies seems justified taken into consideration the various types of uncertainty associated with 
modelling studies. while the current methodologies only handle part of the total uncertainty being the 
uncertainty associated with the range of the input variables. 
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Op zoek naar grotere betrouwbaarheid in gezondheidseconomische modellen: 
de vermindering van onzekerheid inherent aan modelmatige studies 
Overheden zlen zlch steeds meer gedwongen de groei van kosten in de gezondheidszorg te bestrijden 
ondcrmcer door budgettering en prijsregulatie. Deze traditionele methodes van kostenbeheersing 
waren cchter slechts gedeeltelijk succesvol. vooral vanwege bet ontbrekcn van voldoende prikkels. 
Daarom zijn in verschillendc Europese landen van overheidswcge initiatieven op gang gekomen die 
moetcn lciden tot een doelmatigere gczondheidszorg. Daarbij richten de maatrcgelen voor 
kostenbehcersing zlch met name op de fannaccutische sector. 
Hocwel er grotc vcrschillen zijn tusscn de landcn ondcrling. zijn er drie met clkaar samenhangende 
ontwikkelingen te onderscheiden: decentralisatie van het besluitvormingsproces in de 
gezondheidszorg. bet oplcggen van beperkingen aan bet voorschrijven van geneesmiddelen en de cis 
extra gegcvcns in te dienen bij de aanvraag voor vergoeding van een nieuw geneesmiddel. De 
vergocding van geneesmiddelen is tot voor kort voomamelijk gebaseerd geweest op informatie die 
essentieel is voor de registratie van geneesmiddelen en toclating tot de marh.-t: werkzaamheid. 
veiligheid en 1..-waliteit. Deze uitkomsten staan bekend als "de drie hordes". De toenemende druk op de 
fabrikantcn om ook de doelmatigheid van hun produkten aan te tonen, wordt dan ook als cen extra en 
dus de "'vierde horde" beschouwd. die genomen moet worden. voordat het geneesmiddel vergocd kan 
worden. Terwijl werkzaamheid. veiligheid en kwaliteit afkomstig zijn uit gcrandomiscerdc klinischc 
studies (randomi=ed clinical trials) met cen hoge interne validiteit, is bij doelmatighcidsstudies vooral 
de extemc validiteit van belang: Een gezondheidseconomische studie moct inzicht gcven in de 
doelmatighcid van een nieuw gcneesmiddel op basis van bet te ve:rv.rachten gebruik in de dagelijkse 
pral."tijk. Naast de vraag naar gegevens over doelmatigheid van een nieuw geneesmiddeL is er ook en 
belangrijk rol voor financiele analyses die in kaart betrekking welk beslag cen nieuwe geneesmiddel 
zalleggcn op het gezondheidszorgbudget. 
Er zijn verschillende methodes om gegevcns voor gezondheidseconomische studies te verzamelen. Bij 
de z.g piggy-back trial worden gegevens over medische consumptie verzameld tijdens de fase III 
klinische studie, die echtcr primair voor registratic is opgezet. Een nadccl van deze methode is een 
gebrek aan externe validiteit omdat klinische studies strik."te inclusie- en exclusie criteria hanteren en 
omdat behandcling verloopt volgens een protocol. Een alternaticf is de natu.ralistische economische 
studie. Dit is, net als ecn klinische phase III triaL cen gerandomiseerde studie. maar een die primiar 
wordt opgzet om de doelmatigheid van een geneesmiddel tc bepalen door middel van het verzamelen 
van klinische en economische gegevens, die representatief zijn voor de dagelijke behandelprak:tijk. 
Hclaas is de bruikbaarheid van prospectieve natu.ralistische studies beperkt, omdat het verzoek tot 
vergocding in principe direct na rcgistratie wordt ingediend. waardoor er dus geen gegevens omtrent 
doelmatigheid voor handen zijn. Modelmatige studies vormen een altematief zonder de praktische 
beperkingen van prospccticve studies. in het bijzonder in het geval van chronische ziektcs zoals de 
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ziekte van Parkinson. waarbij extrapolatie van de effecten van geneesmiddelen naar de lange termijn 
nodig is. In verschillende landen zijn nationale richtlijnen opgesteld om de wetenschappelijke 
k:waliteit en betrouwbaarheid van farmacoeconomische studies te bevorderen. Hoewel verschillende 
groepen aanbevelingen hebben gepubliceerd voor bet volgens de regels der kunst uitvoeren van 
economische evaluaties. hebben zulke richtlijnen vooral betrekking op prospectieve studies en hebben 
slechts een gering aantal aanbevelingen betrekking op het uitvoeren van modelmatige studies. 
Wellicht ligt daarin een verklaring voor de lagere acceptatie van modelmatige studies vergeleken met 
prospectieve studies. wat verder wellicht samenhangt met de grote mate van onzekerheid in 
modelmatige studies. Omdat het in vcel gevallen onvermijdclijk is om modelmatige studies te 
gebruiken voor bet bepalen van de doelmatigheid van een nieuw gcneesmiddeL zal de vergoeding van 
geneesmiddelen in sterke mate gebaseerd worden op uitkomsten van modelmatige studies. Daarom is 
het van groot belang om de modclmatige benadering nauwkeurig te onderzoeken en te verfijnen: 
bovenal dient duidelijk te worden hoe om te gaan met onzekerhcid in modelmatige studies. 
Het doel van dit proefschrift was daarom om verschillende soorten onzekerheid die zich bij 
modelleren voordoen te identificcren en nader te onderzoeken. Methodes worden gepresenteerd die 
ontworpen zijn om de onzekerheid bij modelmatig studies te verminderen. en zo hun betrouwbaarheid 
te vergroten. Zo kan een bijdrage worden geleverd aan een grotere acceptatie van modelleren bij 
gezondheidseconomische evaluaties. ook al ontbreken er vooralsnog formele richtlijnen. De 
ontwikkelde concepten worden empirisch gelllustreerd aan de hand van Markov modellen voor 
chronische zieh.1:en: depressie. de ziekte van Parkinson. en multiple sclerose. Waar beschikbaar is 
gebruih."t gemaal1: van gepubliceerde "'echte"" data~ in andere gevallen is extrapolatie gebruikt om de 
relevante aspekten te kunnen illustreren. 
De volgende soorten onzekerheid werden onderzocht: 
• Onzekerheid die samenhangt met de databronnen die dienen als "input" van het model. De 
betrouwbaarheid van de schattingen hangt af van de keuze van de databronnen (selectiecriteria.. 
exteme validiteit). Gegevcns kunnen afkomstig zijn van een verschcidenheid aan bronnen en zijn 
onderhevig aan verschillende soortcn van onzekerheid. De volgende aspek:ten van het selecteren 
van databronnen wcrden besproken: 1) een classificatic van gegevens die voor modellering 
worden gebruil."t: 2) beoordeling van de vcrschillende databronnen en hun voordelen en nadelen: 
3) een algemene strategic om te beoordelen of een bepaalde databron geschik:t is voor bet 
betrcffende model: 4) aanbevelingen voor een strategic voor bet selecteren van databronnen en 
voor een transparante en uniforme wijze van rapportcren van databronselectie (verantwoording). 
Een emstig bezv..raar dat bijzondere aandacht verdient bij modelmatige studies is het gebruik van 
Delphi panels voor bet verlaijgen van data die niet aan bestaande databronnen ontleend k.Wlllen 
worden. Er bestaat geen garantie dat de schattingen door het panel van medische "consumptie", 
utiliteiten en patientenvoorkeuren de werkelijkheid op accurate wijze weergeven. Daarom wordt 
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in dit proefschrift (Hoofdstuk 4) een cross-sectional smdie voorgesteld als altematieve databron 
voor een modelmatige smdie. Gegevens over mediscbe consurnptie en utiliteiten k.'1lilllen door een 
dergelijke smdie geleverd worden voor de verschillende Markov gezondheidstoestanden. Een zo 
ont\vorpen smdie vormt een brug tussen enerzijds een naturalistiscbe prospectieve smdie en een 
zuivere modelmatige studie, zodanig dat de voordelen van beide types studie worden 
gecombineerd en de nadelen geminimaliseerd. 
• Verminderen van onzekerbeid met bebulp van een sensitiviteitsanalyse (gevoeligheidsanalyse). 
Sensitiviteitsanalyses richten zich over bet algemeen op slecbts een beperkt aantal variabelen, 
zonder dat de keuze van variabelen of de intervallen waarover ze worden gevarieerd verant\voord 
worden. Dit kan leiden tot een grote mate van subjectiviteit bij bet uirvoeren van een 
sensitiviteitsanalyse. In dit proefschrift (Hoofdstuk 8) wordt een objectieve methode gepresenteerd 
die gebaseerd is op integratie van punt-sensitiviteit (point-sensitivity) en interval-sensitiviteit 
(range-sensitivity) tot een '"totale sensitiviteif' (overall sensitivity). Deze benadering vermijdt de 
subjectieve keuze van variabelen bij senstitiviteitsanalyse en de mogelijke vertekening (bias) bij 
bet inscbatten van de "gevoeligheid" van variabelen die daarvan in de meeste huidige 
economische smdies bet gevolg kan zijn. 
• Onzekerbeid die bet gevolg is van samenhang mssen variabelen (inter-variable uncertainty). Een 
belangrijke beperking van sensitiviteitsanalyses zoals die standaard worden uitgevoerd.. is dat 
aileen het effect op de uitkomst wordt onderzocbt wanneer de waarde van een variabele wordt 
veranderd zonder dat daarbij rekening wordt gebouden met de mogelijke samenhang tussen 
variabelen. In hoofdstuk 10 van dit proefschrift wordt een methode gepresenteerd die de 
onzekerbeid die voortvloeit uit de onderlinge samenhang van variabelen onderzoekt. Dit 
verscbijnsel wordt gedefinieerd als 2dc-orde sensitiviteit. De prak."tiscbe gevolgen worden getoond 
wanneer bij sensitiviteitsanalsyses met dit type onzekerbeid rekening wordt gebouden. Resultaten 
verkregen met deze 2dc -orde sensitiviteitsanalsyses I a ten zien dat de meest "gevoelige" variabelen 
in een model ook de grootste invloed bebben op de gevoeligbeid van bet model voor andere 
variabelen. Daarom zal vermindering van de onzekerbeid in de meest gevoelige variabele de 
totale onzekerbeid in een model via tv.ree wegen terugdringen: zowel direct, als indirect door bet 
effect op andere variabelen. Anderzijds kan met bebulp van een 2dc-orde sensitiviteitsanalyse de 
sensitiviteit van de meest gevoelige variabelc verminderd worden door de variabclc(n) te 
identificeren. die de grootste invloed bebben op de sensitiviteit van de mccst gevoelige variabele. 
• Onzekerbeid ten gevolge van confounding variabelen. Kosten en utiliteiten bocven niet aileen een 
functie te zijn van de in een Markov model gedefinieerdc gezondheidstoestanden, maar ze 
kunnnen ook beYnvloed worden door andere variabelen die k.'11ID1en fungeren als confounding 
variabelen wanneer er geen rekening mee wordt gebouden. In Hoofdstuk 7 wordt een strategic 
gepresenteerd die bet mogelijk :rnaal--t zulke confounding variabelen '"in te bouwen" in een Markov 
model door bet bepalen van een relatie tussen de confounding variable en kosten voor elke 
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gezondheidstoestand. waarbij ook rekening gehouden wordt met de tijdsafhankelijkheid van een 
confounding variable. Ook werd de gevocligheid van de uitkomsten van bet model voor bet 
inbouwen van een confounding variabele bepaald. De resultaten laten zien dat de uitkomsten van 
gezondheidseconomische modellen sterk vertekend kunnen worden wanneer geen rekening wordt 
gehouden met confounding variabelen. Dit bev.rijst bet belang van bet incorporeren van 
confounding variabelen in gczondheidseconomische modellen. 
• Onzekerbeid die samenhangt met epidemiologische data. In Hoofstuk 11 wordt een methode 
gepresenteerd die bet mogelijk maakt om enerzijds een juiste scbatting te maken van de invloed 
van de introductie van een nieuw geneesmiddel op bet geneesmiddelenbudget (budgetary impact). 
terwijl andenijds tegelijkertijd een traditionele doelmatigheidsanalyse kan worden uitgevoerd. 
Een Markov model werd geconstrueerd om de epidemiologiscbe data te valideren door de 
consistentie tussen prevalentie en incidentie van de ziekte van Parkinson te testen. De analyse 
brengt een aanzienlijke discrcpantie aan bet licbt tussen de prevalentie zoals die gerapporteerd 
wordt in de literatuur en de prevalentie die volgt uit bet model en die berekend is op grond van de 
incidentie uit de literatuur. Hieruit kan geconcludeerd worden dat een populatie-model een extra 
bron van onzckerheid herbergt samenhangend met epidemiologische data in vergelijking met een 
doelmatigheidsmodel dat uitgaat van de individuele patient. 
• Onzekerheid die samenhangt met de v.rijze van rapporteren van modelmatige studies. In 
tegenstelling tot gegevens uit klinische studies. bestaan er geen algemeen geaccepteerde 
standaarden voor het verzamelen en analyseren van gegevens voor modelmatige studies. Er dient 
daarom gepleit te worden voor een meer gedetailleerde en gespecificeerde (gedisaggregeeerde) 
wijze van rapporteren van modelmatige studies. waarbij expliciet wordt ingegaan op de 
verschillende types van onzekerheid die inherent zijn aan modelmatige studies: de selectie van 
variabelen. bet ont\verp van bet model en aannames die er aan ten grondslag liggen. bet banteren 
van confounding variabelen en bet uitvoeren van senstitiviteitsanalyses en bet interpreteren van de 
resultaten daarvan. 
De conclusie van dit proefschrift is dat er verschillende types onzekerheid onderscbeiden kunnen 
worden in modelmatige studies. Tot op beden bestaat de gebruikelijke benadering van bet omgaan 
met onzekerheid uit bet uitvoeren van sensitiviteitsanalyses die aileen betrekking bebben op de 
onzekerbeid die samenhangt met bet interval waarbinnen de waarde van een input variabele kan liggen 
(statistiscbe onzekerbeid). Dit proefschrift gaat dieper in op bet uitvoeren van sensitiviteitsanalyses en 
identificeert andere brotlllen van onzekerbeid. Er wordt een objectieve methode gepresenteerd voor bet 
uitvoeren van sensiviteitsanalyses. die de mate van mogelijke subjectiviteit minimaliseert. 
De onzekerheid die samenhangt met sensitiviteitsanalyse: Over bet algemeen worden in 
sensitiviteitsanalyses slechts enkele variabelen onderzocht zonder dat de keuze van variabelen of bet 
interval waarover de variabelen worden gevarieerd verant\voord worden. Dit kan leiden tot 
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subjectiviteit bij bet uitvoeren van sensitiviteitsanalyses. De objectieve methode die in dit proefschrift 
werd gepresenteerd integreert punt-sensitiviteit en interval-sensitiviteit en ma.ak't bet zo mogelijk een 
oordeel te vormen over de "totale .. sensitiviteit. Voorts werd onzekerbeid die voortkomt uit de 
samenhang tussen variabelen onderzocbt. De resultaten van de daartoe ontv.rikkelde 2dc -orde 
sensitiviteitsanalyse laten zien dat de meest "gevoelige" variabelen in bet model. die op deze wijze 
geidenti:ficeerd kunnen worden. tevens de belangrijkste factor zijn die de gevoeligheid van de overige 
variabelen bepalen. Dit ma.ak't bet mogelijk om gericbt vooral aandacbt te besteden aan bet 
terugbrengen van de onzekerbeid in die variabelen. bijvoorbeeld door bet uitvoeren van meta-
analyses~ op die manier kan de totale onzekerheid in bet model sterker en op meer efficiente v.rijze 
worden verminderd dan door uitputtende analyses op elk van de overige variabelen afzondelijk. 
Overige bronnen van onzekerheid: Naast statistische onzekerheid werden andere soorten van 
onzekerheid in modelmatige studies geYdenti:ficeerd (databronnen. confounding variabelen. 
epidemiologiscbe gegevcns). en er werden methodes en strategieen gcpresenteerd om op de juiste 
wijze biermee om te gaan in een model. Tenslotte werd een gestandaardiseerde wijze van rapporteren 
voorgesteld die rekening houdt met aile types van onzekerheid in een model. waardoor de 
transparantie vergoot wordt. 
Samenvattend. laat dit proefschrift zien dat de matigc aeceptatie van modelmatige studies 
gerechtvaardigt lijk't.. wanneer rekening word gehouden met de verscbillende soorten onzekerbeid 
inherent aan modelmatige studies en bet feit dat in de buidige pral'tijk slecbts rekening wordt 
gebouden met een deel van de totale onzekcrheid en wei de statistische onzekerheid samcnbangend 
met bet interval van een variabele. 
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